TW200522950A - Hmg-Coa reductase inhibitors and method - Google Patents
Hmg-Coa reductase inhibitors and method Download PDFInfo
- Publication number
- TW200522950A TW200522950A TW093128908A TW93128908A TW200522950A TW 200522950 A TW200522950 A TW 200522950A TW 093128908 A TW093128908 A TW 093128908A TW 93128908 A TW93128908 A TW 93128908A TW 200522950 A TW200522950 A TW 200522950A
- Authority
- TW
- Taiwan
- Prior art keywords
- agents
- alkyl
- inhibitor
- inhibitors
- compound
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 18
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title claims abstract description 13
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title claims abstract description 11
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 title abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 203
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 68
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 35
- 201000010099 disease Diseases 0.000 claims abstract description 34
- 150000002632 lipids Chemical class 0.000 claims abstract description 28
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 23
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 21
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 8
- 208000032928 Dyslipidaemia Diseases 0.000 claims abstract description 6
- 208000017170 Lipid metabolism disease Diseases 0.000 claims abstract description 6
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 3
- 238000002657 hormone replacement therapy Methods 0.000 claims abstract description 3
- -1 Alkyl sulfur Chemical group 0.000 claims description 137
- 125000000217 alkyl group Chemical group 0.000 claims description 82
- 239000003112 inhibitor Substances 0.000 claims description 73
- 239000003795 chemical substances by application Substances 0.000 claims description 71
- 125000003118 aryl group Chemical group 0.000 claims description 59
- 239000008280 blood Substances 0.000 claims description 43
- 210000004369 blood Anatomy 0.000 claims description 43
- 239000000556 agonist Substances 0.000 claims description 37
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 35
- 239000003814 drug Substances 0.000 claims description 32
- 239000002253 acid Substances 0.000 claims description 29
- 125000001072 heteroaryl group Chemical group 0.000 claims description 29
- 239000003472 antidiabetic agent Substances 0.000 claims description 28
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 claims description 27
- 125000001424 substituent group Chemical group 0.000 claims description 26
- 230000002265 prevention Effects 0.000 claims description 25
- 239000003524 antilipemic agent Substances 0.000 claims description 24
- 229940125708 antidiabetic agent Drugs 0.000 claims description 22
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims description 20
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims description 20
- 125000003342 alkenyl group Chemical group 0.000 claims description 20
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 20
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 239000002585 base Substances 0.000 claims description 19
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 16
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 150000002367 halogens Chemical class 0.000 claims description 16
- 229940124597 therapeutic agent Drugs 0.000 claims description 16
- 102000007330 LDL Lipoproteins Human genes 0.000 claims description 14
- 108010007622 LDL Lipoproteins Proteins 0.000 claims description 14
- 150000002148 esters Chemical class 0.000 claims description 14
- 238000003786 synthesis reaction Methods 0.000 claims description 14
- 239000005557 antagonist Substances 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 239000005541 ACE inhibitor Substances 0.000 claims description 12
- 229910052783 alkali metal Inorganic materials 0.000 claims description 12
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 12
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 12
- 229910052708 sodium Inorganic materials 0.000 claims description 12
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 11
- 108010028924 PPAR alpha Proteins 0.000 claims description 11
- 102000023984 PPAR alpha Human genes 0.000 claims description 11
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 11
- 206010012601 diabetes mellitus Diseases 0.000 claims description 11
- 230000009467 reduction Effects 0.000 claims description 11
- 102000015779 HDL Lipoproteins Human genes 0.000 claims description 10
- 108010010234 HDL Lipoproteins Proteins 0.000 claims description 10
- 102000004877 Insulin Human genes 0.000 claims description 10
- 108090001061 Insulin Proteins 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 10
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 10
- 229940125396 insulin Drugs 0.000 claims description 10
- 150000003254 radicals Chemical class 0.000 claims description 10
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 9
- 125000004414 alkyl thio group Chemical group 0.000 claims description 9
- 229940024606 amino acid Drugs 0.000 claims description 9
- 239000000883 anti-obesity agent Substances 0.000 claims description 9
- 229940030600 antihypertensive agent Drugs 0.000 claims description 9
- 239000002220 antihypertensive agent Substances 0.000 claims description 9
- 239000002246 antineoplastic agent Substances 0.000 claims description 9
- 229940125710 antiobesity agent Drugs 0.000 claims description 9
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 9
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 8
- 229940127218 antiplatelet drug Drugs 0.000 claims description 8
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 claims description 8
- 208000024891 symptom Diseases 0.000 claims description 8
- 229940100389 Sulfonylurea Drugs 0.000 claims description 7
- 150000001340 alkali metals Chemical class 0.000 claims description 7
- 230000007131 anti Alzheimer effect Effects 0.000 claims description 7
- 230000000879 anti-atherosclerotic effect Effects 0.000 claims description 7
- 230000003262 anti-osteoporosis Effects 0.000 claims description 7
- 230000009977 dual effect Effects 0.000 claims description 7
- 125000001188 haloalkyl group Chemical group 0.000 claims description 7
- 235000001968 nicotinic acid Nutrition 0.000 claims description 7
- 239000011664 nicotinic acid Substances 0.000 claims description 7
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical group CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims description 7
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 239000004059 squalene synthase inhibitor Substances 0.000 claims description 7
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 7
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 6
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims description 6
- 229940034982 antineoplastic agent Drugs 0.000 claims description 6
- 239000003613 bile acid Substances 0.000 claims description 6
- 239000011575 calcium Substances 0.000 claims description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 6
- 229960003512 nicotinic acid Drugs 0.000 claims description 6
- 230000003647 oxidation Effects 0.000 claims description 6
- 238000007254 oxidation reaction Methods 0.000 claims description 6
- 229940044551 receptor antagonist Drugs 0.000 claims description 6
- 239000002464 receptor antagonist Substances 0.000 claims description 6
- 239000000849 selective androgen receptor modulator Substances 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 206010002383 Angina Pectoris Diseases 0.000 claims description 5
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 5
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims description 5
- 229940123208 Biguanide Drugs 0.000 claims description 5
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims description 5
- 102000004366 Glucosidases Human genes 0.000 claims description 5
- 108010056771 Glucosidases Proteins 0.000 claims description 5
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 claims description 5
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 claims description 5
- 102000000853 LDL receptors Human genes 0.000 claims description 5
- 108010001831 LDL receptors Proteins 0.000 claims description 5
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 5
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 5
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 5
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 208000029078 coronary artery disease Diseases 0.000 claims description 5
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 229940088597 hormone Drugs 0.000 claims description 5
- 239000005556 hormone Substances 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 230000003902 lesion Effects 0.000 claims description 5
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- 229960001243 orlistat Drugs 0.000 claims description 5
- 229940002612 prodrug Drugs 0.000 claims description 5
- 239000000651 prodrug Substances 0.000 claims description 5
- 239000003801 protein tyrosine phosphatase 1B inhibitor Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 5
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims description 4
- ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical class OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 claims description 4
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims description 4
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 4
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 229940122355 Insulin sensitizer Drugs 0.000 claims description 4
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 claims description 4
- IRLWJILLXJGJTD-UHFFFAOYSA-N Muraglitazar Chemical compound C1=CC(OC)=CC=C1OC(=O)N(CC(O)=O)CC(C=C1)=CC=C1OCCC1=C(C)OC(C=2C=CC=CC=2)=N1 IRLWJILLXJGJTD-UHFFFAOYSA-N 0.000 claims description 4
- 229940121773 Secretase inhibitor Drugs 0.000 claims description 4
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 claims description 4
- 125000003277 amino group Polymers 0.000 claims description 4
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims description 4
- 229960005475 antiinfective agent Drugs 0.000 claims description 4
- 239000004599 antimicrobial Substances 0.000 claims description 4
- 125000005100 aryl amino carbonyl group Chemical group 0.000 claims description 4
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 4
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 4
- 239000002327 cardiovascular agent Substances 0.000 claims description 4
- 229940125692 cardiovascular agent Drugs 0.000 claims description 4
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 4
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 239000002934 diuretic Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 229940125753 fibrate Drugs 0.000 claims description 4
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 claims description 4
- 229960001381 glipizide Drugs 0.000 claims description 4
- 125000005222 heteroarylaminocarbonyl group Chemical group 0.000 claims description 4
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 claims description 4
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 230000006371 metabolic abnormality Effects 0.000 claims description 4
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 4
- 229950001135 muraglitazar Drugs 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 229940043138 pentosan polysulfate Drugs 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 4
- 229940044601 receptor agonist Drugs 0.000 claims description 4
- 239000000018 receptor agonist Substances 0.000 claims description 4
- BSHDUMDXSRLRBI-JOYOIKCWSA-N rentiapril Chemical compound SCCC(=O)N1[C@H](C(=O)O)CS[C@@H]1C1=CC=CC=C1O BSHDUMDXSRLRBI-JOYOIKCWSA-N 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims description 4
- 229960001685 tacrine Drugs 0.000 claims description 4
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 claims description 4
- 108090000721 thyroid hormone receptors Proteins 0.000 claims description 4
- 102000004217 thyroid hormone receptors Human genes 0.000 claims description 4
- 230000002792 vascular Effects 0.000 claims description 4
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 claims description 3
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 claims description 3
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 3
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 3
- 101710095342 Apolipoprotein B Proteins 0.000 claims description 3
- 102100040202 Apolipoprotein B-100 Human genes 0.000 claims description 3
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims description 3
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims description 3
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 claims description 3
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 claims description 3
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 3
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical group C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 claims description 3
- 108010061435 Enalapril Proteins 0.000 claims description 3
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 claims description 3
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 claims description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 229940086609 Lipase inhibitor Drugs 0.000 claims description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 claims description 3
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 claims description 3
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 claims description 3
- 208000007718 Stable Angina Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 208000007814 Unstable Angina Diseases 0.000 claims description 3
- 229960000446 abciximab Drugs 0.000 claims description 3
- 230000005856 abnormality Effects 0.000 claims description 3
- 229960002632 acarbose Drugs 0.000 claims description 3
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 239000000048 adrenergic agonist Substances 0.000 claims description 3
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 claims description 3
- 229960004005 amlodipine besylate Drugs 0.000 claims description 3
- 239000004004 anti-anginal agent Substances 0.000 claims description 3
- 229940124345 antianginal agent Drugs 0.000 claims description 3
- 239000003416 antiarrhythmic agent Substances 0.000 claims description 3
- 229940125682 antidementia agent Drugs 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 235000006708 antioxidants Nutrition 0.000 claims description 3
- 239000002830 appetite depressant Substances 0.000 claims description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 239000000480 calcium channel blocker Substances 0.000 claims description 3
- 229960000830 captopril Drugs 0.000 claims description 3
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 3
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims description 3
- 229960001761 chlorpropamide Drugs 0.000 claims description 3
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 3
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims description 3
- 229960003009 clopidogrel Drugs 0.000 claims description 3
- 238000011161 development Methods 0.000 claims description 3
- 229940030606 diuretics Drugs 0.000 claims description 3
- 229960003638 dopamine Drugs 0.000 claims description 3
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims description 3
- 229960000873 enalapril Drugs 0.000 claims description 3
- 239000002532 enzyme inhibitor Substances 0.000 claims description 3
- 229960002297 fenofibrate Drugs 0.000 claims description 3
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims description 3
- 229960002490 fosinopril Drugs 0.000 claims description 3
- 229960003627 gemfibrozil Drugs 0.000 claims description 3
- YRSVDSQRGBYVIY-GJZGRUSLSA-N gemopatrilat Chemical compound O=C1N(CC(O)=O)C(C)(C)CCC[C@@H]1NC(=O)[C@@H](S)CC1=CC=CC=C1 YRSVDSQRGBYVIY-GJZGRUSLSA-N 0.000 claims description 3
- 229950006480 gemopatrilat Drugs 0.000 claims description 3
- 229960000346 gliclazide Drugs 0.000 claims description 3
- 229960002442 glucosamine Drugs 0.000 claims description 3
- 239000003324 growth hormone secretagogue Substances 0.000 claims description 3
- 229960002897 heparin Drugs 0.000 claims description 3
- 229920000669 heparin Polymers 0.000 claims description 3
- 125000005226 heteroaryloxycarbonyl group Chemical group 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 210000003405 ileum Anatomy 0.000 claims description 3
- 239000000411 inducer Substances 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims description 3
- 229960002198 irbesartan Drugs 0.000 claims description 3
- 229910021645 metal ion Inorganic materials 0.000 claims description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 3
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 claims description 3
- BAVYZALUXZFZLV-UHFFFAOYSA-N mono-methylamine Natural products NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 3
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 claims description 3
- 201000001119 neuropathy Diseases 0.000 claims description 3
- 230000007823 neuropathy Effects 0.000 claims description 3
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 3
- 229960001597 nifedipine Drugs 0.000 claims description 3
- 239000002664 nootropic agent Substances 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- LVRLSYPNFFBYCZ-VGWMRTNUSA-N omapatrilat Chemical compound C([C@H](S)C(=O)N[C@H]1CCS[C@H]2CCC[C@H](N2C1=O)C(=O)O)C1=CC=CC=C1 LVRLSYPNFFBYCZ-VGWMRTNUSA-N 0.000 claims description 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 3
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims description 3
- 229960002354 repaglinide Drugs 0.000 claims description 3
- 229960004586 rosiglitazone Drugs 0.000 claims description 3
- 230000009863 secondary prevention Effects 0.000 claims description 3
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 claims description 3
- 229960003425 tirofiban Drugs 0.000 claims description 3
- CMSGWTNRGKRWGS-NQIIRXRSSA-N torcetrapib Chemical compound COC(=O)N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CMSGWTNRGKRWGS-NQIIRXRSSA-N 0.000 claims description 3
- 229950004514 torcetrapib Drugs 0.000 claims description 3
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims description 3
- 229960001641 troglitazone Drugs 0.000 claims description 3
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 claims description 2
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 claims description 2
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 claims description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 2
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 claims description 2
- 102000004146 ATP citrate synthases Human genes 0.000 claims description 2
- 108090000662 ATP citrate synthases Proteins 0.000 claims description 2
- 229940118148 Aldose reductase inhibitor Drugs 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
- 102100034613 Annexin A2 Human genes 0.000 claims description 2
- 108090000668 Annexin A2 Proteins 0.000 claims description 2
- 200000000007 Arterial disease Diseases 0.000 claims description 2
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 claims description 2
- 229940122361 Bisphosphonate Drugs 0.000 claims description 2
- 239000002083 C09CA01 - Losartan Substances 0.000 claims description 2
- 229920002905 Colesevelam Polymers 0.000 claims description 2
- 102000034534 Cotransporters Human genes 0.000 claims description 2
- 108020003264 Cotransporters Proteins 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- 108010056764 Eptifibatide Proteins 0.000 claims description 2
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 claims description 2
- 108010049003 Fibrinogen Proteins 0.000 claims description 2
- 102000008946 Fibrinogen Human genes 0.000 claims description 2
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 108090000288 Glycoproteins Proteins 0.000 claims description 2
- 102000003886 Glycoproteins Human genes 0.000 claims description 2
- 208000031886 HIV Infections Diseases 0.000 claims description 2
- 208000037357 HIV infectious disease Diseases 0.000 claims description 2
- 229940122199 Insulin secretagogue Drugs 0.000 claims description 2
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 claims description 2
- IVUGBSGLHRJSSP-UHFFFAOYSA-N LimKi 3 Chemical compound S1C(NC(=O)C(C)C)=NC=C1C1=CC(C(F)F)=NN1C1=C(Cl)C=CC=C1Cl IVUGBSGLHRJSSP-UHFFFAOYSA-N 0.000 claims description 2
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims description 2
- 108010007859 Lisinopril Proteins 0.000 claims description 2
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 claims description 2
- 101710151321 Melanostatin Proteins 0.000 claims description 2
- UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 claims description 2
- 229910002651 NO3 Inorganic materials 0.000 claims description 2
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 claims description 2
- 102400000064 Neuropeptide Y Human genes 0.000 claims description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
- 101150014691 PPARA gene Proteins 0.000 claims description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 2
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 2
- 102000009822 Sterol Regulatory Element Binding Proteins Human genes 0.000 claims description 2
- 108010020396 Sterol Regulatory Element Binding Proteins Proteins 0.000 claims description 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 2
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims description 2
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 claims description 2
- 208000035868 Vascular inflammations Diseases 0.000 claims description 2
- 239000003288 aldose reductase inhibitor Substances 0.000 claims description 2
- 229940062527 alendronate Drugs 0.000 claims description 2
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 2
- 125000004691 alkyl thio carbonyl group Chemical group 0.000 claims description 2
- OTBXOEAOVRKTNQ-UHFFFAOYSA-N anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960001694 anagrelide Drugs 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 2
- 108010014210 axokine Proteins 0.000 claims description 2
- 150000004663 bisphosphonates Chemical class 0.000 claims description 2
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 claims description 2
- 229960004195 carvedilol Drugs 0.000 claims description 2
- 230000015556 catabolic process Effects 0.000 claims description 2
- 229940047495 celebrex Drugs 0.000 claims description 2
- MVCQKIKWYUURMU-UHFFFAOYSA-N cetilistat Chemical compound C1=C(C)C=C2C(=O)OC(OCCCCCCCCCCCCCCCC)=NC2=C1 MVCQKIKWYUURMU-UHFFFAOYSA-N 0.000 claims description 2
- 229950002397 cetilistat Drugs 0.000 claims description 2
- 201000001883 cholelithiasis Diseases 0.000 claims description 2
- 230000015271 coagulation Effects 0.000 claims description 2
- 238000005345 coagulation Methods 0.000 claims description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 125000000422 delta-lactone group Chemical group 0.000 claims description 2
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 claims description 2
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 229960003722 doxycycline Drugs 0.000 claims description 2
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims description 2
- 229940125542 dual agonist Drugs 0.000 claims description 2
- 210000002889 endothelial cell Anatomy 0.000 claims description 2
- 230000008753 endothelial function Effects 0.000 claims description 2
- 239000003623 enhancer Substances 0.000 claims description 2
- GLGOPUHVAZCPRB-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CN=C2[C]1C=CC=C2 GLGOPUHVAZCPRB-LROMGURASA-N 0.000 claims description 2
- 229960004468 eptifibatide Drugs 0.000 claims description 2
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims description 2
- 229960000815 ezetimibe Drugs 0.000 claims description 2
- 229940012952 fibrinogen Drugs 0.000 claims description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 2
- 229960003883 furosemide Drugs 0.000 claims description 2
- 208000001130 gallstones Diseases 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 2
- 230000013632 homeostatic process Effects 0.000 claims description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 2
- BBPRUNPUJIUXSE-DXKRWKNPSA-N ifetroban Chemical compound CCCCCNC(=O)C1=COC([C@H]2[C@H]([C@@H]3CC[C@H]2O3)CC=2C(=CC=CC=2)CCC(O)=O)=N1 BBPRUNPUJIUXSE-DXKRWKNPSA-N 0.000 claims description 2
- 229950004274 ifetroban Drugs 0.000 claims description 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 229940058690 lanosterol Drugs 0.000 claims description 2
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 claims description 2
- 208000006132 lipodystrophy Diseases 0.000 claims description 2
- 206010024627 liposarcoma Diseases 0.000 claims description 2
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims description 2
- 229960002394 lisinopril Drugs 0.000 claims description 2
- 229960004773 losartan Drugs 0.000 claims description 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims description 2
- 239000002697 lyase inhibitor Substances 0.000 claims description 2
- 230000036210 malignancy Effects 0.000 claims description 2
- 229960000299 mazindol Drugs 0.000 claims description 2
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 claims description 2
- 229960004023 minocycline Drugs 0.000 claims description 2
- 229960005170 moexipril Drugs 0.000 claims description 2
- 230000002107 myocardial effect Effects 0.000 claims description 2
- BSIZUMJRKYHEBR-QGZVFWFLSA-N n-hydroxy-2(r)-[[(4-methoxyphenyl)sulfonyl](3-picolyl)amino]-3-methylbutanamide hydrochloride Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N([C@H](C(C)C)C(=O)NO)CC1=CC=CN=C1 BSIZUMJRKYHEBR-QGZVFWFLSA-N 0.000 claims description 2
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 claims description 2
- 229960004255 nadolol Drugs 0.000 claims description 2
- 229960000698 nateglinide Drugs 0.000 claims description 2
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 claims description 2
- 229950000973 omapatrilat Drugs 0.000 claims description 2
- 239000000199 parathyroid hormone Substances 0.000 claims description 2
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 claims description 2
- 229960000395 phenylpropanolamine Drugs 0.000 claims description 2
- 239000003358 phospholipase A2 inhibitor Substances 0.000 claims description 2
- 239000003075 phytoestrogen Substances 0.000 claims description 2
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 claims description 2
- 229960001289 prazosin Drugs 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 229960003712 propranolol Drugs 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 229960003401 ramipril Drugs 0.000 claims description 2
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 230000002441 reversible effect Effects 0.000 claims description 2
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 2
- 229960004425 sibutramine Drugs 0.000 claims description 2
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 claims description 2
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims description 2
- 229960002256 spironolactone Drugs 0.000 claims description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 2
- 150000003536 tetrazoles Chemical class 0.000 claims description 2
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims description 2
- 229960005001 ticlopidine Drugs 0.000 claims description 2
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 claims description 2
- 229960004394 topiramate Drugs 0.000 claims description 2
- 229960005461 torasemide Drugs 0.000 claims description 2
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 claims description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 2
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 claims 2
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 claims 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims 2
- 229940122142 Lipoxygenase inhibitor Drugs 0.000 claims 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 claims 1
- WZJLGICGNMAUFC-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1h-fluorene Chemical compound C12=CC=CC=C2CC2=C1CCCC2 WZJLGICGNMAUFC-UHFFFAOYSA-N 0.000 claims 1
- WRFHGDPIDHPWIQ-UHFFFAOYSA-N 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-n-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound O=C1N(CC=2C=C(COCC)C(=CC=2)C=2C(=CC=CC=2)S(=O)(=O)NC=2C(=C(C)ON=2)C)C(CCCC)=NC21CCCC2 WRFHGDPIDHPWIQ-UHFFFAOYSA-N 0.000 claims 1
- ROJNYKZWTOHRNU-UHFFFAOYSA-N 2-chloro-4,5-difluoro-n-[[2-methoxy-5-(methylcarbamoylamino)phenyl]carbamoyl]benzamide Chemical compound CNC(=O)NC1=CC=C(OC)C(NC(=O)NC(=O)C=2C(=CC(F)=C(F)C=2)Cl)=C1 ROJNYKZWTOHRNU-UHFFFAOYSA-N 0.000 claims 1
- YZQLWPMZQVHJED-UHFFFAOYSA-N 2-methylpropanethioic acid S-[2-[[[1-(2-ethylbutyl)cyclohexyl]-oxomethyl]amino]phenyl] ester Chemical compound C=1C=CC=C(SC(=O)C(C)C)C=1NC(=O)C1(CC(CC)CC)CCCCC1 YZQLWPMZQVHJED-UHFFFAOYSA-N 0.000 claims 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims 1
- NFFXEUUOMTXWCX-UHFFFAOYSA-N 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-n-[[4-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound C1=C(C(=O)NCC=2C=CC(=CC=2)C(F)(F)F)C(OC)=CC=C1CC1SC(=O)NC1=O NFFXEUUOMTXWCX-UHFFFAOYSA-N 0.000 claims 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims 1
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 claims 1
- 229940127517 Hormone Receptor Modulators Drugs 0.000 claims 1
- 102000016267 Leptin Human genes 0.000 claims 1
- 108010092277 Leptin Proteins 0.000 claims 1
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 claims 1
- 102000003982 Parathyroid hormone Human genes 0.000 claims 1
- 108090000445 Parathyroid hormone Proteins 0.000 claims 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 claims 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 claims 1
- 229940121373 acetyl-coa carboxylase inhibitor Drugs 0.000 claims 1
- 229940102884 adrenalin Drugs 0.000 claims 1
- 239000000674 adrenergic antagonist Substances 0.000 claims 1
- 239000002160 alpha blocker Substances 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 229960004530 benazepril Drugs 0.000 claims 1
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 claims 1
- 239000002981 blocking agent Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 230000003011 chondroprotective effect Effects 0.000 claims 1
- 239000013256 coordination polymer Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- ZZCHHVUQYRMYLW-HKBQPEDESA-N farglitazar Chemical compound N([C@@H](CC1=CC=C(C=C1)OCCC=1N=C(OC=1C)C=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 ZZCHHVUQYRMYLW-HKBQPEDESA-N 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 229940039781 leptin Drugs 0.000 claims 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 1
- 229940040145 liniment Drugs 0.000 claims 1
- 239000000865 liniment Substances 0.000 claims 1
- 230000008604 lipoprotein metabolism Effects 0.000 claims 1
- 235000012680 lutein Nutrition 0.000 claims 1
- 229960005375 lutein Drugs 0.000 claims 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims 1
- 239000001656 lutein Substances 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 229960001319 parathyroid hormone Drugs 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 239000009260 qiming Substances 0.000 claims 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 claims 1
- 229960001455 quinapril Drugs 0.000 claims 1
- 108091006084 receptor activators Proteins 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 239000002485 serotonin 2C agonist Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 claims 1
- 235000021286 stilbenes Nutrition 0.000 claims 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 claims 1
- 229960004699 valsartan Drugs 0.000 claims 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract description 3
- 238000008214 LDL Cholesterol Methods 0.000 abstract description 3
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 54
- 239000000203 mixture Substances 0.000 description 51
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 34
- 239000000243 solution Substances 0.000 description 33
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 22
- 239000007787 solid Substances 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 125000000304 alkynyl group Chemical group 0.000 description 16
- 125000000623 heterocyclic group Chemical group 0.000 description 16
- 235000019439 ethyl acetate Nutrition 0.000 description 15
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
- 150000001412 amines Chemical class 0.000 description 13
- 239000011734 sodium Substances 0.000 description 13
- 239000000543 intermediate Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 229910001868 water Inorganic materials 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 10
- 238000003818 flash chromatography Methods 0.000 description 10
- 238000006722 reduction reaction Methods 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000012043 crude product Substances 0.000 description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- 239000000377 silicon dioxide Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 8
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 229910052744 lithium Inorganic materials 0.000 description 8
- 229910052938 sodium sulfate Inorganic materials 0.000 description 8
- 235000011152 sodium sulphate Nutrition 0.000 description 8
- 125000003396 thiol group Chemical group [H]S* 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 102000004316 Oxidoreductases Human genes 0.000 description 6
- 108090000854 Oxidoreductases Proteins 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 125000002947 alkylene group Chemical group 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 239000007937 lozenge Substances 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000006186 oral dosage form Substances 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 229910052700 potassium Inorganic materials 0.000 description 6
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 6
- 229960002429 proline Drugs 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- 125000003282 alkyl amino group Chemical group 0.000 description 5
- 239000003529 anticholesteremic agent Substances 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- 150000002596 lactones Chemical class 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 4
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 4
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 4
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 102000004895 Lipoproteins Human genes 0.000 description 4
- 108090001030 Lipoproteins Proteins 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 229940127226 anticholesterol agent Drugs 0.000 description 4
- 125000004658 aryl carbonyl amino group Chemical group 0.000 description 4
- 125000004104 aryloxy group Chemical group 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 4
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 4
- 125000005553 heteroaryloxy group Chemical group 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 4
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 4
- 235000013930 proline Nutrition 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 3
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 3
- NPOAOTPXWNWTSH-UHFFFAOYSA-N 3-hydroxy-3-methylglutaric acid Chemical compound OC(=O)CC(O)(C)CC(O)=O NPOAOTPXWNWTSH-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 108010006654 Bleomycin Proteins 0.000 description 3
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 description 3
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 description 3
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 3
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 3
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical group CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 3
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 229940123464 Thiazolidinedione Drugs 0.000 description 3
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 125000005110 aryl thio group Chemical group 0.000 description 3
- 229960001561 bleomycin Drugs 0.000 description 3
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 3
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000000055 hyoplipidemic effect Effects 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- JWHHANVGNNWIRI-UHFFFAOYSA-N methanol phosphoric acid hydrate Chemical compound O.OC.OP(O)(O)=O JWHHANVGNNWIRI-UHFFFAOYSA-N 0.000 description 3
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 3
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 3
- 229960001237 podophyllotoxin Drugs 0.000 description 3
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 235000010288 sodium nitrite Nutrition 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Substances C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 3
- 229960001722 verapamil Drugs 0.000 description 3
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- LTMQZVLXCLQPCT-UHFFFAOYSA-N 1,1,6-trimethyltetralin Chemical compound C1CCC(C)(C)C=2C1=CC(C)=CC=2 LTMQZVLXCLQPCT-UHFFFAOYSA-N 0.000 description 2
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- MVDXXGIBARMXSA-PYUWXLGESA-N 5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-PYUWXLGESA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 2
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 2
- 101150041968 CDC13 gene Proteins 0.000 description 2
- JKYWXCQFUCCROI-UHFFFAOYSA-N C[Si](C)(C)N(F)[Si](C)(C)C.[Li] Chemical compound C[Si](C)(C)N(F)[Si](C)(C)C.[Li] JKYWXCQFUCCROI-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000002705 Glucose Intolerance Diseases 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- AHLBNYSZXLDEJQ-UHFFFAOYSA-N N-formyl-L-leucylester Natural products CCCCCCCCCCCC(OC(=O)C(CC(C)C)NC=O)CC1OC(=O)C1CCCCCC AHLBNYSZXLDEJQ-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 229940123934 Reductase inhibitor Drugs 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 108010073771 Soybean Proteins Proteins 0.000 description 2
- DGMOQCHIPOPXEK-UHFFFAOYSA-N Spermic acid 2 Chemical compound OC(=O)CCNCCCCNCCC(O)=O DGMOQCHIPOPXEK-UHFFFAOYSA-N 0.000 description 2
- 102100024550 Sphingomyelin phosphodiesterase 2 Human genes 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 2
- 208000032109 Transient ischaemic attack Diseases 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 239000012670 alkaline solution Substances 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 2
- 150000001602 bicycloalkyls Chemical group 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- IAQRGUVFOMOMEM-UHFFFAOYSA-N but-2-ene Chemical compound CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 229960005110 cerivastatin Drugs 0.000 description 2
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 230000001906 cholesterol absorption Effects 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 2
- 239000005516 coenzyme A Substances 0.000 description 2
- 229940093530 coenzyme a Drugs 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- QQKNSPHAFATFNQ-UHFFFAOYSA-N darglitazone Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCC(=O)C(C=C1)=CC=C1CC1SC(=O)NC1=O QQKNSPHAFATFNQ-UHFFFAOYSA-N 0.000 description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 2
- 229960004166 diltiazem Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229960003765 fluvastatin Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004447 heteroarylalkenyl group Chemical group 0.000 description 2
- 235000011167 hydrochloric acid Nutrition 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical compound C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 description 2
- 229960003987 melatonin Drugs 0.000 description 2
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- CXHHBNMLPJOKQD-UHFFFAOYSA-M methyl carbonate Chemical compound COC([O-])=O CXHHBNMLPJOKQD-UHFFFAOYSA-M 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- 229960001110 miglitol Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 108040005466 neutral sphingomyelin phosphodiesterase activity proteins Proteins 0.000 description 2
- 238000006772 olefination reaction Methods 0.000 description 2
- 239000003538 oral antidiabetic agent Substances 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000008024 pharmaceutical diluent Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 239000003428 phospholipase inhibitor Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 229940068065 phytosterols Drugs 0.000 description 2
- 229960005095 pioglitazone Drugs 0.000 description 2
- 229960002797 pitavastatin Drugs 0.000 description 2
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 2
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000009862 primary prevention Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229960000672 rosuvastatin Drugs 0.000 description 2
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 2
- 229960002370 sotalol Drugs 0.000 description 2
- 229940001941 soy protein Drugs 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 2
- 229960001693 terazosin Drugs 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- CXGTZJYQWSUFET-IBGZPJMESA-N tesaglitazar Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1 CXGTZJYQWSUFET-IBGZPJMESA-N 0.000 description 2
- 229950004704 tesaglitazar Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 201000010875 transient cerebral ischemia Diseases 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 150000003672 ureas Chemical class 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- VSYDNHCEDWYFBX-UHFFFAOYSA-N (1-methylcyclopentyl) 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OC1(C)CCCC1 VSYDNHCEDWYFBX-UHFFFAOYSA-N 0.000 description 1
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- LDDMACCNBZAMSG-BDVNFPICSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-(methylamino)hexanal Chemical compound CN[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO LDDMACCNBZAMSG-BDVNFPICSA-N 0.000 description 1
- ZXEIEKDGPVTZLD-NDEPHWFRSA-N (2s)-2-dodecylsulfanyl-n-(4-hydroxy-2,3,5-trimethylphenyl)-2-phenylacetamide Chemical compound O=C([C@@H](SCCCCCCCCCCCC)C=1C=CC=CC=1)NC1=CC(C)=C(O)C(C)=C1C ZXEIEKDGPVTZLD-NDEPHWFRSA-N 0.000 description 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- MXBCYQUALCBQIJ-RYVPXURESA-N (8s,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 MXBCYQUALCBQIJ-RYVPXURESA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- YGEPYVAQKIHLFY-FYWRMAATSA-N (e)-3-(3,5-dimethoxy-4-octoxyphenyl)-1-[4-(3,4-dimethylphenyl)piperazin-1-yl]prop-2-en-1-one Chemical compound C1=C(OC)C(OCCCCCCCC)=C(OC)C=C1\C=C\C(=O)N1CCN(C=2C=C(C)C(C)=CC=2)CC1 YGEPYVAQKIHLFY-FYWRMAATSA-N 0.000 description 1
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
- COLOHWPRNRVWPI-UHFFFAOYSA-N 1,1,1-trifluoroethane Chemical compound [CH2]C(F)(F)F COLOHWPRNRVWPI-UHFFFAOYSA-N 0.000 description 1
- JLHMJWHSBYZWJJ-UHFFFAOYSA-N 1,2-thiazole 1-oxide Chemical compound O=S1C=CC=N1 JLHMJWHSBYZWJJ-UHFFFAOYSA-N 0.000 description 1
- JUXAVSAMVBLDKO-UHFFFAOYSA-N 1-(1-azabicyclo[2.2.2]octan-3-yl)-3-[3-(1h-indol-3-yl)-1-oxo-1-spiro[1,2-dihydroindene-3,4'-piperidine]-1'-ylpropan-2-yl]urea Chemical compound C1N(CC2)CCC2C1NC(=O)NC(C(=O)N1CCC2(C3=CC=CC=C3CC2)CC1)CC1=CNC2=CC=CC=C12 JUXAVSAMVBLDKO-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- IFYLTXNCFVRALQ-UHFFFAOYSA-N 1-[6-amino-2-[hydroxy(4-phenylbutyl)phosphoryl]oxyhexanoyl]pyrrolidine-2-carboxylic acid Chemical compound C1CCC(C(O)=O)N1C(=O)C(CCCCN)OP(O)(=O)CCCCC1=CC=CC=C1 IFYLTXNCFVRALQ-UHFFFAOYSA-N 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- AAVNREISIOCBAF-UHFFFAOYSA-N 1-phenylsulfanyltetrazole Chemical compound C1=NN=NN1SC1=CC=CC=C1 AAVNREISIOCBAF-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- SXFWKZNLYYRHMK-UHFFFAOYSA-N 1h-indolo[7,6-f]quinoline Chemical class C1=CC=C2C3=C(NC=C4)C4=CC=C3C=CC2=N1 SXFWKZNLYYRHMK-UHFFFAOYSA-N 0.000 description 1
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- ZENKESXKWBIZCV-UHFFFAOYSA-N 2,2,4,4-tetrafluoro-1,3-benzodioxin-6-amine Chemical group O1C(F)(F)OC(F)(F)C2=CC(N)=CC=C21 ZENKESXKWBIZCV-UHFFFAOYSA-N 0.000 description 1
- LSIXBBPOJBJQHN-UHFFFAOYSA-N 2,3-Dimethylbicyclo[2.2.1]hept-2-ene Chemical compound C1CC2C(C)=C(C)C1C2 LSIXBBPOJBJQHN-UHFFFAOYSA-N 0.000 description 1
- MKJQESRCXYYHFR-UHFFFAOYSA-N 2-[7-(2,2-dimethylpropanoylamino)-4,6-dimethyl-1-octyl-2,3-dihydroindol-5-yl]acetic acid;sulfuric acid Chemical compound OS(O)(=O)=O.CC(C)(C)C(=O)NC1=C(C)C(CC(O)=O)=C(C)C2=C1N(CCCCCCCC)CC2.CC(C)(C)C(=O)NC1=C(C)C(CC(O)=O)=C(C)C2=C1N(CCCCCCCC)CC2 MKJQESRCXYYHFR-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- FSJOLBAFVKSQQJ-UHFFFAOYSA-N 2-ethylpyrazol-3-amine Chemical compound CCN1N=CC=C1N FSJOLBAFVKSQQJ-UHFFFAOYSA-N 0.000 description 1
- MTAODLNXWYIKSO-UHFFFAOYSA-N 2-fluoropyridine Chemical compound FC1=CC=CC=N1 MTAODLNXWYIKSO-UHFFFAOYSA-N 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- JESRNIJXVIFVOV-UHFFFAOYSA-N 2-methylpyrazol-3-amine Chemical compound CN1N=CC=C1N JESRNIJXVIFVOV-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- CZMRCDWAGMRECN-UHFFFAOYSA-N 2-{[3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- FVYKQVCMPMEWOU-UHFFFAOYSA-N 3,4-dimethyl-4-oxidomorpholin-4-ium Chemical compound CC1COCC[N+]1(C)[O-] FVYKQVCMPMEWOU-UHFFFAOYSA-N 0.000 description 1
- SRKIBXBMSGIQFP-UHFFFAOYSA-N 3-[4-(2,6-dimethylheptyl)phenyl]-n-(2-hydroxyethyl)butanamide Chemical compound CC(C)CCCC(C)CC1=CC=C(C(C)CC(=O)NCCO)C=C1 SRKIBXBMSGIQFP-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- FUSNOPLQVRUIIM-UHFFFAOYSA-N 4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-n-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide Chemical compound O=C1NC(C)(C)CN1C(N=C1N)=NC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 FUSNOPLQVRUIIM-UHFFFAOYSA-N 0.000 description 1
- MXNQOXJLUJUCGE-UHFFFAOYSA-N 4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-n-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide;hydrochloride Chemical compound Cl.O=C1NC(C)(C)CN1C(N=C1N)=NC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 MXNQOXJLUJUCGE-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- ICGLPKIVTVWCFT-UHFFFAOYSA-N 4-methylbenzenesulfonohydrazide Chemical compound CC1=CC=C(S(=O)(=O)NN)C=C1 ICGLPKIVTVWCFT-UHFFFAOYSA-N 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 125000005330 8 membered heterocyclic group Chemical group 0.000 description 1
- KJJYAKVYKNDOTE-UHFFFAOYSA-N 8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione Chemical compound C1COC(=O)CCC(C)(C)C(=O)C(C)CC(C)CCCC2(C)OC21 KJJYAKVYKNDOTE-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- DJQOOSBJCLSSEY-UHFFFAOYSA-N Acipimox Chemical compound CC1=CN=C(C(O)=O)C=[N+]1[O-] DJQOOSBJCLSSEY-UHFFFAOYSA-N 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 229940123413 Angiotensin II antagonist Drugs 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 102000009515 Arachidonate 15-Lipoxygenase Human genes 0.000 description 1
- 108010048907 Arachidonate 15-lipoxygenase Proteins 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 1
- 239000002081 C09CA05 - Tasosartan Substances 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 101100012465 Caenorhabditis elegans fce-2 gene Proteins 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- IFYLTXNCFVRALQ-OALUTQOASA-N Ceronapril Chemical compound O([C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)P(O)(=O)CCCCC1=CC=CC=C1 IFYLTXNCFVRALQ-OALUTQOASA-N 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 description 1
- BMOVQUBVGICXQN-UHFFFAOYSA-N Clinofibrate Chemical compound C1=CC(OC(C)(CC)C(O)=O)=CC=C1C1(C=2C=CC(OC(C)(CC)C(O)=O)=CC=2)CCCCC1 BMOVQUBVGICXQN-UHFFFAOYSA-N 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 229920002911 Colestipol Polymers 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 101100393023 Crocus sativus GLT2 gene Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000283715 Damaliscus lunatus Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 101100018928 Drosophila melanogaster InR gene Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000007659 Fibroadenoma Diseases 0.000 description 1
- 101800004295 Glucagon-like peptide 1(7-36) Proteins 0.000 description 1
- 101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000007390 Glycogen Phosphorylase Human genes 0.000 description 1
- 108010046163 Glycogen Phosphorylase Proteins 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102100039064 Interleukin-3 Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- JXLYSJRDGCGARV-PJXZDTQASA-N Leurosidine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-PJXZDTQASA-N 0.000 description 1
- LPGWZGMPDKDHEP-HLTPFJCJSA-N Leurosine Chemical compound C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC LPGWZGMPDKDHEP-HLTPFJCJSA-N 0.000 description 1
- LPGWZGMPDKDHEP-GKWAKPNHSA-N Leurosine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@]6(CC)O[C@@H]6[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C LPGWZGMPDKDHEP-GKWAKPNHSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 229940127470 Lipase Inhibitors Drugs 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- HBNPJJILLOYFJU-VMPREFPWSA-N Mibefradil Chemical compound C1CC2=CC(F)=CC=C2[C@H](C(C)C)[C@@]1(OC(=O)COC)CCN(C)CCCC1=NC2=CC=CC=C2N1 HBNPJJILLOYFJU-VMPREFPWSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 101100189356 Mus musculus Papolb gene Proteins 0.000 description 1
- 101100518501 Mus musculus Spp1 gene Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 229910019093 NaOCl Inorganic materials 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 108010015847 Non-Receptor Type 1 Protein Tyrosine Phosphatase Proteins 0.000 description 1
- IMURMCJVQOCBEN-UHFFFAOYSA-N ON1N=NC2=C1C1=C(C=C2)C=NC=C1 Chemical group ON1N=NC2=C1C1=C(C=C2)C=NC=C1 IMURMCJVQOCBEN-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 229940126033 PPAR agonist Drugs 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229940122054 Peroxisome proliferator-activated receptor delta agonist Drugs 0.000 description 1
- HRHKSTOGXBBQCB-UHFFFAOYSA-N Porfiromycine Chemical compound O=C1C(N)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)C3N(C)C3CN12 HRHKSTOGXBBQCB-UHFFFAOYSA-N 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 229940121912 Progesterone receptor agonist Drugs 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 229940083324 Selective androgen receptor modulator Drugs 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 description 1
- 108010054082 Sterol O-acyltransferase Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 244000042038 Tropaeolum tuberosum Species 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- NWLFOBZKYXKBOF-NSVAZKTRSA-N [(1s,2s)-2-[[2,2-dimethylpropyl(nonyl)carbamoyl]amino]cyclohexyl] 3-[[(4r)-2,2,5,5-tetramethyl-1,3-dioxane-4-carbonyl]amino]propanoate Chemical compound CCCCCCCCCN(CC(C)(C)C)C(=O)N[C@H]1CCCC[C@@H]1OC(=O)CCNC(=O)[C@H]1C(C)(C)COC(C)(C)O1 NWLFOBZKYXKBOF-NSVAZKTRSA-N 0.000 description 1
- AUYLVPGDOVEOML-UHFFFAOYSA-N [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(piperidin-1-ylmethoxy)phenyl]methanone Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 AUYLVPGDOVEOML-UHFFFAOYSA-N 0.000 description 1
- DGUKYXBCVXHEII-UHFFFAOYSA-N [Li+].C[Si](C)(C)P[Si](C)(C)C Chemical compound [Li+].C[Si](C)(C)P[Si](C)(C)C DGUKYXBCVXHEII-UHFFFAOYSA-N 0.000 description 1
- YVBSAPDHRXHFHV-UHFFFAOYSA-N [chloro(methoxy)methyl]benzene Chemical compound COC(Cl)C1=CC=CC=C1 YVBSAPDHRXHFHV-UHFFFAOYSA-N 0.000 description 1
- MLDWSQWMXACHHN-SNAWJCMRSA-N abamine Chemical class C=1C=C(F)C=CC=1CN(CC(=O)OC)C\C=C\C1=CC=C(OC)C(OC)=C1 MLDWSQWMXACHHN-SNAWJCMRSA-N 0.000 description 1
- JXLYSJRDGCGARV-KSNABSRWSA-N ac1l29ym Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-KSNABSRWSA-N 0.000 description 1
- 229940085750 ace inhibitors and calcium channel blockers Drugs 0.000 description 1
- 125000004036 acetal group Chemical group 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- UGAPHEBNTGUMBB-UHFFFAOYSA-N acetic acid;ethyl acetate Chemical compound CC(O)=O.CCOC(C)=O UGAPHEBNTGUMBB-UHFFFAOYSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 229960003526 acipimox Drugs 0.000 description 1
- 229910052768 actinide Inorganic materials 0.000 description 1
- 150000001255 actinides Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000001323 aldoses Chemical class 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 125000002009 alkene group Chemical group 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000005001 aminoaryl group Chemical group 0.000 description 1
- WGQKYBSKWIADBV-UHFFFAOYSA-N aminomethyl benzene Natural products NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 1
- 150000003927 aminopyridines Chemical class 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- UMGDCJDMYOKAJW-UHFFFAOYSA-N aminothiocarboxamide Natural products NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003388 anti-hormonal effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 125000001317 arsoryl group Chemical group *[As](*)(*)=O 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000005015 aryl alkynyl group Chemical group 0.000 description 1
- 125000005199 aryl carbonyloxy group Chemical group 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 125000005164 aryl thioalkyl group Chemical group 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 125000005325 aryloxy aryl group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- FLNKWZNWHZDGRT-UHFFFAOYSA-N azane;dihydrochloride Chemical compound [NH4+].[NH4+].[Cl-].[Cl-] FLNKWZNWHZDGRT-UHFFFAOYSA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 229940087430 biaxin Drugs 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- RPZUHXGURBWKSQ-UHFFFAOYSA-N bis(trimethylsilyl)phosphane Chemical compound C[Si](C)(C)P[Si](C)(C)C RPZUHXGURBWKSQ-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000005389 breast carcinoma in situ Diseases 0.000 description 1
- 201000003149 breast fibroadenoma Diseases 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- WOBLPDAWNVAVAS-UHFFFAOYSA-N butyl carboxy carbonate Chemical compound CCCCOC(=O)OC(O)=O WOBLPDAWNVAVAS-UHFFFAOYSA-N 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- ZTWZVMIYIIVABD-OEMFJLHTSA-N candoxatril Chemical compound C([C@@H](COCCOC)C(=O)OC=1C=C2CCCC2=CC=1)C1(C(=O)N[C@@H]2CC[C@@H](CC2)C(O)=O)CCCC1 ZTWZVMIYIIVABD-OEMFJLHTSA-N 0.000 description 1
- 229950004548 candoxatril Drugs 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical group [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 125000001721 carboxyacetyl group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
- 229930188550 carminomycin Natural products 0.000 description 1
- XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 229950001725 carubicin Drugs 0.000 description 1
- 229940063628 catapres Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 229950005749 ceronapril Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000024042 cholesterol ester storage disease Diseases 0.000 description 1
- 208000013760 cholesteryl ester storage disease Diseases 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 1
- 229960005025 cilazapril Drugs 0.000 description 1
- 229960002174 ciprofibrate Drugs 0.000 description 1
- KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- 229950003072 clinofibrate Drugs 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 1
- 229960002604 colestipol Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- JEVCWSUVFOYBFI-UHFFFAOYSA-N cyanyl Chemical compound N#[C] JEVCWSUVFOYBFI-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000004956 cyclohexylene group Chemical group 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 229950006689 darglitazone Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 230000036576 dermal application Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- XNMQEEKYCVKGBD-UHFFFAOYSA-N dimethylacetylene Natural products CC#CC XNMQEEKYCVKGBD-UHFFFAOYSA-N 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 125000005066 dodecenyl group Chemical group C(=CCCCCCCCCCC)* 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 229960001389 doxazosin Drugs 0.000 description 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
- VJECBOKJABCYMF-UHFFFAOYSA-N doxazosin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 VJECBOKJABCYMF-UHFFFAOYSA-N 0.000 description 1
- 229960000220 doxazosin mesylate Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
- 201000007273 ductal carcinoma in situ Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229950002375 englitazone Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 1
- 229960004563 eprosartan Drugs 0.000 description 1
- ADFCQWZHKCXPAJ-GFCCVEGCSA-N equol Chemical compound C1=CC(O)=CC=C1[C@@H]1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-GFCCVEGCSA-N 0.000 description 1
- 235000019126 equol Nutrition 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 125000002573 ethenylidene group Chemical group [*]=C=C([H])[H] 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 description 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 229940001490 fosamax Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- XUBOMFCQGDBHNK-UHFFFAOYSA-N gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCNC(C)C1 XUBOMFCQGDBHNK-UHFFFAOYSA-N 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 125000005059 halophenyl group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- YSAKFRWFAVUMQK-UHFFFAOYSA-N hydrazine;pyridine-4-carboxylic acid Chemical compound NN.OC(=O)C1=CC=NC=C1 YSAKFRWFAVUMQK-UHFFFAOYSA-N 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- RNIXSZHNJLUJGC-UHFFFAOYSA-N hydroxy(nitro)cyanamide Chemical compound N#CN(O)[N+]([O-])=O RNIXSZHNJLUJGC-UHFFFAOYSA-N 0.000 description 1
- 230000000871 hypocholesterolemic effect Effects 0.000 description 1
- TVZISJTYELEYPI-UHFFFAOYSA-N hypodiphosphoric acid Chemical compound OP(O)(=O)P(O)(O)=O TVZISJTYELEYPI-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229950010293 imanixil Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- ADFCQWZHKCXPAJ-UHFFFAOYSA-N indofine Natural products C1=CC(O)=CC=C1C1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 229960004427 isradipine Drugs 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 102000005861 leptin receptors Human genes 0.000 description 1
- 108010019813 leptin receptors Proteins 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229960003208 levomefolic acid Drugs 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 229910001416 lithium ion Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000011059 lobular neoplasia Diseases 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- 229960002137 melagatran Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000011700 menaquinone-7 Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- HKIWSNQLOOLXOH-UHFFFAOYSA-N methanol;2,2,2-trifluoroacetic acid;hydrate Chemical compound O.OC.OC(=O)C(F)(F)F HKIWSNQLOOLXOH-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-UHFFFAOYSA-N methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
- ZUZLIXGTXQBUDC-UHFFFAOYSA-N methyltrioctylammonium Chemical compound CCCCCCCC[N+](C)(CCCCCCCC)CCCCCCCC ZUZLIXGTXQBUDC-UHFFFAOYSA-N 0.000 description 1
- 229960004438 mibefradil Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229940064639 minipress Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- KRMKZDOWCOBWNU-UHFFFAOYSA-N n-[2,6-di(propan-2-yl)phenyl]-2-tetradecylsulfanylacetamide Chemical compound CCCCCCCCCCCCCCSCC(=O)NC1=C(C(C)C)C=CC=C1C(C)C KRMKZDOWCOBWNU-UHFFFAOYSA-N 0.000 description 1
- XYHAZQCTATWYDN-UHFFFAOYSA-N n-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]-2-[4-[2-([1,3]oxazolo[4,5-b]pyridin-2-ylsulfanyl)ethyl]piperazin-1-yl]acetamide Chemical compound CSC1=CC(C)=NC(SC)=C1NC(=O)CN1CCN(CCSC=2OC3=CC=CN=C3N=2)CC1 XYHAZQCTATWYDN-UHFFFAOYSA-N 0.000 description 1
- WGESLFUSXZBFQF-UHFFFAOYSA-N n-methyl-n-prop-2-enylprop-2-en-1-amine Chemical class C=CCN(C)CC=C WGESLFUSXZBFQF-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 description 1
- 239000002660 neuropeptide Y receptor antagonist Substances 0.000 description 1
- 230000002276 neurotropic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 229940033757 niaspan Drugs 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 description 1
- 229960000227 nisoldipine Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- IOQPZZOEVPZRBK-UHFFFAOYSA-N octan-1-amine Chemical compound CCCCCCCCN IOQPZZOEVPZRBK-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 229940127017 oral antidiabetic Drugs 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- UQZKYYIKWZOKKD-UHFFFAOYSA-N orphenadrine hydrochloride Chemical compound [Cl-].C=1C=CC=C(C)C=1C(OCC[NH+](C)C)C1=CC=CC=C1 UQZKYYIKWZOKKD-UHFFFAOYSA-N 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229960002582 perindopril Drugs 0.000 description 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- FVZVCSNXTFCBQU-UHFFFAOYSA-N phosphanyl Chemical group [PH2] FVZVCSNXTFCBQU-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000371 poly(diallyldimethylammonium chloride) polymer Polymers 0.000 description 1
- 229920002851 polycationic polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- VZOPRCCTKLAGPN-ZFJVMAEJSA-L potassium;sodium;(2r,3r)-2,3-dihydroxybutanedioate;tetrahydrate Chemical class O.O.O.O.[Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O VZOPRCCTKLAGPN-ZFJVMAEJSA-L 0.000 description 1
- DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- WFXFYZULCQKPIP-UHFFFAOYSA-N prazosin hydrochloride Chemical compound [H+].[Cl-].N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 WFXFYZULCQKPIP-UHFFFAOYSA-N 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000003147 proline derivatives Chemical class 0.000 description 1
- 150000003148 prolines Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- ALSCEGDXFJIYES-UHFFFAOYSA-N pyrrolidine-2-carbonitrile Chemical compound N#CC1CCCN1 ALSCEGDXFJIYES-UHFFFAOYSA-N 0.000 description 1
- DATJETPTDKFEEF-UHFFFAOYSA-N pyrrolidine-3-carbonitrile Chemical compound N#CC1CCNC1 DATJETPTDKFEEF-UHFFFAOYSA-N 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 229930185107 quinolinone Natural products 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229950010098 rentiapril Drugs 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 1
- 229960004937 saxagliptin Drugs 0.000 description 1
- 108010033693 saxagliptin Proteins 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000013275 serotonin uptake Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940110862 starlix Drugs 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 description 1
- 150000003461 sulfonyl halides Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960000651 tasosartan Drugs 0.000 description 1
- ADXGNEYLLLSOAR-UHFFFAOYSA-N tasosartan Chemical compound C12=NC(C)=NC(C)=C2CCC(=O)N1CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 ADXGNEYLLLSOAR-UHFFFAOYSA-N 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 229940108485 tenormin Drugs 0.000 description 1
- 229940061354 tequin Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- UUBIWGRMBVAUIK-UHFFFAOYSA-N tetracyclo[5.5.2.04,13.010,14]tetradeca-1(13),4,6,10(14),11-pentaene Chemical compound C1CC2=CC=C3CCC4=CC=C1C2=C43 UUBIWGRMBVAUIK-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 229940068778 tocotrienols Drugs 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000004385 trihaloalkyl group Chemical group 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 125000005065 undecenyl group Chemical group C(=CCCCCCCCCC)* 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- HHJUWIANJFBDHT-KOTLKJBCSA-N vindesine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(N)=O)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 HHJUWIANJFBDHT-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045999 vitamin b 12 Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229960001522 ximelagatran Drugs 0.000 description 1
- 229940072251 zithromax Drugs 0.000 description 1
- 229960002769 zofenopril Drugs 0.000 description 1
- IAIDUHCBNLFXEF-MNEFBYGVSA-N zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Description
200522950 (1) 九、發明說明 本案主張2 003年9月25日申請之美國臨時申請案序 號6 0 / 5 0 5,8 9 3的優先權。所述之申請案的整體教示係以 引用方式倂入本文。 【發明所屬之技術領域】 本發明有關可作爲降血膽固醇劑及降血脂劑的化合物 及醫藥組成物。本發明尤其有關(1) 3 -羥基一 3 -甲基 戊一醯基一輔酶 A還原酶(HMG - CoA還原酶)的特定 抑制劑,該酶包括藉著鍵合基連接於HMG -鍵結用功能 部位側鏈的含吡啶或含嘧啶之核心,(2 )含有該等化合 物之醫藥組成物及(3 )採用該等醫藥組成物降低血淸膽 固醇濃度且調節血淸脂質濃度的方法。 【先前技術】 美國專利第5,260,440號及Reissue 37314揭示具有 以下結構之羅素他汀(r 〇 s u v a s t a t i η )
羅素他汀亦揭示於 M a s a m i c h i W a t a n a b e 等人 (Bioorgan ic & Medicinal Chemistry ( 1 997 ),5 ( 2) 200522950 (2) 43 7 - 444 )中。 8月 5 一 日本專利申請案0 6 2 5 6 3 1 8 — A (對應於2 0 0 1年 1日授證之日本專利3 1 9 7 9 7 1 )揭示具有以下結構之 烷酯基嘧啶衍生物 co2r3 rV^r2
A 其中R】、R2及R3可個別爲Η、烷基、芳基或雜芳基 Α可爲NR7R8,其中R7及R8可個別特別係爲Η、烷 芳基及雜芳基。揭示此等化合物係爲用以製備HMG -還原酶抑制劑的中間物。
Beck 等人.,Synthesis and Biological Activity of HMG— C o A Reductase Inhibitors. 1. Lactones of Pyri and Pyimidine -Substituted 3,5-Dihydroxy-6-heptenoic (-heptanoic) Acids, J. Med. C h e m. 1990,33,5 2- (在日本專利申請案06256318-A中提及)揭示具有 結構之化合物 ,且 基、 Co A •New d i n e - 6 0° 以下
其中Y可爲CH或N; A— B 可爲一CH=CH—; -7- 200522950 (3) R1可爲烷基,包括CH3H7 ; R2可爲芳基,包括4 — FC6H4 ;且 R3可爲烷基或芳基; 該化合物可自具有以下結構之中間物製備
EP367895 (日本專利申請案06256318-A中提及)揭 示經嘧啶基取代之羥基酸、內酯及酯類,其係爲膽固醇生 物合成之抑制劑且具有以下結構
R1 其中R 1可爲烷基 Q可爲芳基; X 可爲—C2CH2 —或—CH=CH—; R6 —CHCH2CCH2COOR7 Y可爲〇Η如 或其內酯; 且R2可爲一N(R8)2,其中各R8係個別爲C〗—C4 烷基或兩R8 —起與氮原子形成5 -、6 -或7 —員視情況 經取代之環的一部分,其可含有另一個氧雜原子,以4 -嗎啉基爲佳。此等化合物可使用具有以下結構之中間物製 備 -8- 200522950
COOC2H5 1 /R1 【發明內容】 根據本發明,提供特定之含吡啶及含嘧啶之化合物, 其因爲抑制3 —甲基一戊二醯基輔酶A還原酶(HMG -CoA還原酶)的能力而爲膽固醇生物合成的強效抑制劑。 尤其,在最廣義之化學化合物態樣中,本發明提供一 種具有式I之化合物
其中X係爲N或CR5; R〗及R2係相同或相異且個別選自Η、烷基、烷氧基 烷基、芳基烷基、環烷基、烯基、環烯基、芳基、雜芳基 或環雜烷基; R3係爲芳基、雜芳基、環烷基或環雜烷基; R4係爲Η、丨兀基、環院基、鹵院基、院氧基院基、火7C 基硫烷基、烷基磺醯基、芳基磺醯基、烷氧基羰基、芳氧 基鑛基、雜方氧基羯基、院基胺基幾基、方基胺基纟灰基、 烷基硫基羰基、雜芳基胺基羰基、烷基胺基磺醯基、烷基 -9 - 200522950 (5) 羰基、芳基羰基、雜芳基羰基或雜芳基磺醯基; R 5係爲Η或低院基; Ζ係爲 co2r6 或 〇
.ΟΗ R7 R6係爲Η或低烷基或金屬離子(諸如鹼金靡或驗土 金屬), R7係爲Η或低院基; 且/係表示單鍵或雙鍵(可爲順式或反式) 且包括其醫藥上可接受之鹽(其中R6係爲H) ^ 酯、其前藥酯及其所有立體異構物。 較佳係Z基團爲游離酸、其生理上可接受且可水解之 酯或δ內酯、或鹼金屬鹽、鹼土金屬鹽、胺鹽或胺基酸鹽 形式。 較佳者爲本發明式I化合物,其中 R1及個別選自烷基、環烷基及芳基; R3係爲芳基、雜芳基或環雜烷基; h係爲Η、烷基、低烷基羰基、低烷基磺醯基或低烷 氧基羰基。 更佳者係爲本發明式I化合物,其中Ri係爲芳基 (尤其是下文所定義之經取代芳基); R2係爲烷基或環烷基; R3係爲芳基、雜芳基或環雜烷基; -10" 200522950 (6) R4係爲Η、烷基、低烷基羰基、低烷基磺醯基、低烷 氧基羰基; 且/係爲雙鍵,以反式爲佳,且 Ζ係爲
或其鹼金屬或鹼土金屬鹽、或其胺基酸鹽、或其胺鹽。
再更佳者係爲本發明式I化合物,其中 R】係爲經取代之芳基,以4 —氟苯基、4_氟—3-甲 基苯基或3,5—二甲基苯基爲佳; R2係爲烷基或環烷基,以異丙基、第三丁基或環丙 基爲佳;
係爲芳基(以苯基爲佳)、環雜烷基(以四氫噻 吩二氧化物爲佳)、或雜芳基(以吡唑、噻二唑、嘧啶、 吡畊、苯并咪唑、三唑、四唑、吡啶基、噻唑、哼唑或異 噚唑爲佳),其中前述基團可視情況經1、2或3個取代 基所取代,該取代基可爲烷基胺基羰基、環雜烷基、雜芳 基、烷基、鹵素、羧基、烷氧基羰基或烷氧基; R4係爲Η、C】—C4烷基(以甲基爲佳)、Ci — C4烷 基羯基(以甲基鑛基或佳)或Ci- C4院基磺醯基(以甲 磺酿基爲佳); 〆係爲雙鍵,以反式爲佳且 z係爲 -11 - 200522950 (7)
或其鹼金屬或鹼土金屬鹽或其胺基酸鹽或其胺鹽。 本發明最佳之式I化合物具有以下結構
或其鹼金屬或鹼土金屬(諸如Na、K或Ca)鹽、其胺基 酸鹽(諸如精胺酸)或其胺鹽,其中R8及R9係相同或相 異,且個別選自 Η、鹵素及/或烷基(以4 一氟、4 一氟 —3 —甲基或3,5—二甲基爲佳);且 R2係爲烷基.或環烷基,以異丙基、第三丁基或環丙 基爲佳; R3係爲下列基團中之一: 200522950 (8)
ch3
COOH
R4係爲Η、烷基(以甲基爲佳)、或4 —甲氧基玉 基、C】—C4烷基羰基(以甲基羰基爲佳)、C】—(:4烷氧 基羰基(以甲氧基羰基爲佳)或G-C4烷基磺醯基(以 甲磺醯基爲佳); R5係爲甲基。 -13 - 200522950 Ο) 另一態樣中,本發明提供一種醫藥組成物,可作爲降 血脂或降血中膽固醇劑,或降血中三酸甘油醋劑,或抗阿 茲海默氏症劑,或抗骨質疏鬆劑,及其他本發明所述之用 途,其含有降血脂或降血中膽固醇或降血中三酸甘油酯、 或抗阿茲海默氏症、或抗骨質疏鬆量或其他治療有效量 (視應用而定)之本發明式I化合物,結合有醫藥上可接 受之載體。 另一態樣中,本發明提供一種方法,用以在需要治療 之患者體內抑制膽固醇生物合成或降低血淸膽固醇濃度及 /或調節血淸膽固醇濃度諸如降低LDL膽固醇及/或增 加H D L膽固醇,及/或降低三酸甘油酯,或治療血脂質 異常、混合型血脂質異常、血脂質過高、血中膽固醇過 高、血中α —脂蛋白過低、Β型LDL、Α型LDL、血中脂 蛋白過高或血中三酸甘油酯過高及載脂蛋白B代謝之其他 異常,或降低La ( a )之濃度,或治療或預防其他與膽固 醇有關之疾病,或治療或預防或逆轉動脈硬化之發展,或 預防或治療阿茲海默氏症,或預防或治療骨質疏鬆症及/ 或骨質減少,或降低發炎標誌諸如C -反應性蛋白,或預 防或治療低階血管發炎,或預防或治療中風,或預防或治 療癡呆,或預防及治療冠狀心臟病(包括心肌梗塞之初期 及二期預防),或預防或治療穩定及不穩定心絞痛,或冠 心病之初期預防,或心血管疾病之二期預防,或預防或治 療末稍血管疾病,預防或治療末稍動脈疾病,或預防或治 療急性血管徵候群,或預防或降低進行心肌血管重建過程 -14- 200522950 (10) 的風險’或預防或治療微血管疾病諸如腎病變、神經病 變、視網膜病變及腎病徵候群或預防或治療高血壓,其係 將治療有效量之本發明前文定義的結構I化合物或含有該 化合物之醫藥組成物。 此外’根據本發明,提供一種預防或治療糖尿病(尤 其是第2型糖尿病)及相關疾病諸如胰島素抵抗性、血糖 過高、血中胰島素過高、高血液濃度之脂肪酸或甘油、肥 胖、X徵候群、糖尿病倂發症、代謝異常徵候群及相關疾 病及性功能障礙的方法,其中將治療有效量之結構I化合 物或含該化合物之組成物投藥於需治療之患者。 此外,根據本發明,提供一種預防及治療下列損傷的 方法:癌瘤損傷(諸如胸部之原位導管癌及胸部之原位小 葉癌)、癌前期損傷(諸如胸部之纖維腺瘤及前列腺上皮 內贅瘤(PIN )、腸胃惡性腫瘤、脂肉瘤及各種其他上皮 腫瘤(包括胸部、前列腺、結腸、卵巢、胃及肺)、由癌 誘發之虛弱(疲勞)、應激性大腸徵候群、克隆氏症 (Crohn、disease )、胃潰瘍及膽結石、及HIV感染、其 他感染性疾病、藥物誘發之脂肪營養不良及增殖性疾病諸 如銀屑病,其中將有效量之結構I化合物或含該化合物之 組成物投藥於需治療之人類患者。 此外,根據本發明,提供一種改善凝血穩態(包括降 低血纖維蛋白溶酶原活化抑制劑(PAI ) - 1活性、減少 纖維蛋白原及/或減少血小板凝集),及或改善內皮功能 的方法,其中治療有效量之結構I化合物或含該化合物之 -15- 200522950 (11) 組成物係投藥於需治療之患者。 此外’根據本發明,提供一種治療以下疾病之方法: 與膽固醇有關之疾病、糖尿病及相關疾病、心血管疾病、 則文及下文所疋義之腦血管疾病及其他前述疾病,其中治 療有效里之結構I化合物與降血脂劑、及/或脂暂調節劑 及/或抗糖尿病劑及/或心血管藥劑、腦血管藥劑及/或 其他類型療劑之組合物係投藥於需治療之患者。 在前述投藥以組合物的本發明方法中,結構I化合物 相對於其他療劑(視其操作模式而定)之使用重量比係介 於0 · 0 1 : 1至約5 0 0 : 1範圍內,以約〇 · 5 : 1至約1 〇 〇 : 1 爲佳。 【實施方式】 根據本發明,提供可用於抑制HMG- CoA還原酶之 化合物’該抑制劑可作爲降血膽固醇劑、降血脂劑、血脂 質代謝異常藥劑、降血脂劑、降血中三酸甘油酯劑、抗阿 茲海默氏症劑及抗骨質疏鬆劑與其他本發明所述之應用。 本發明所使用之術語 ''冠心病〃係表示心肌梗塞、心 肌血管重建過程、心絞痛、心血管性死亡及急性冠狀徵候 本發明所使用之術語 ''心血管疾病或病症〃係表示冠 狀動脈之動脈硬化、心肌梗塞(包括原發性MI及繼發性 MI )、復發性心肌梗塞、心絞痛(包括穩定及不穩定性 心絞痛)、充血性心臟衰竭及猝發性心臟死亡。 -16- 200522950 (12) 本發明所採用之術語 ''腦血管疾病或病症π係表示大 腦梗塞或中風(因血管阻塞或出血所致)、或短暫性缺血 發作(TIA )、暈厥、顱內及/或顱外動物之動脈硬化及 其類者。 本發明所使用之術語 ''與膽固醇有關之疾病"係表示 涉及高濃度LDL膽固醇之疾病、涉及LDL受體之調節的 疾病、涉及高濃度HDL膽固醇之疾病、血脂異常、血脂 過高、B型高LDL、A型高LDL、血中膽固醇過高、血中 α —脂蛋白過低(低HDL膽固醇徵候群)、血中脂蛋白 過高、高Lp ( a )濃度、血中三酸甘油酯過高、載脂蛋白 B代謝之其他異常、混種家族性、推測家族性結合及非家 族性(非 FH )型原發性血中膽固醇過高(包括 Fredericks on型II a及lib)、膽固醇酯儲存疾病及脂固醇 酯轉移蛋白疾病及相關疾病。 總稱爲 ''徵候群X〃或代謝異常徵候群(如:iohanson, J· Clin. Endocrinol. Metab.,1 997,82,7 2 7 · 7 3 4 及其他干lj 物所詳述)之症狀、疾病及病症係包括血糖過高及/或糖 尿病前期胰島素抵抗徵候群,且具有初期胰島素抵抗生成 之血糖過高、血脂異常及蔔萄糖耐受性不良之特徵,其可 進展成第Π型糖尿病,具有血糖過高之特徵,可進展成 糖尿病倂發症。 術語''糖尿病及相關疾病〃係表示第II型糖尿病、 第I型糖尿病、葡萄糖耐受性不良、肥胖、血糖過高、X 徵候群、代謝異常徵候群、糖尿病倂發症及血中胰島素過 -17- 200522950 (13) 高。 總稱爲 ''糖尿病倂發症〃之狀況、疾病及病症係包括 視網膜病變、神經病變及腎病變,及其他已知之糖尿病倂 發症。 本發明所採用之術語、、其他類型療劑〃係指一或多種 抗糖尿病劑(除式I化合物外)、一或多種抗肥胖劑、及 /或一或多種降脂劑、一或多種脂質調節劑(包括抗動脈 硬化劑)、其他類型之抗動脈硬化劑、及/或一或多種抗 血小板劑、一或多種高血壓療劑、一或多種抗癌劑、一或 多種關節炎療劑、一或多種抗骨質疏鬆劑、一或多種免疫 調節性疾病之療劑、及/或一或多種神經性厭食用療劑。 本發明所採用之術語 ''脂質調節〃劑係指降低LDL 及/或升高HDL及/或降低三酸甘油酯及/或降低總膽 固醇之藥劑及/或其他已知用於治療脂質障礙之機制。 本發明所採用之術語 ''其他類型抗動脈硬化劑〃係指 習用抗動脈硬化劑,包括脂肪氧化酶抑制劑、AC AT抑制 劑、PPAR α促效劑、雙重 PPAR α 7促效齊U、CETP抑 制劑、抗氧化劑、PPAR (5促效劑、磷脂酶抑制劑包括 PLA - 2抑制劑及/或其他已知之抗動脈硬化劑。 術語醫藥上可接受之 ''鹽〃及 ''鹽類〃係指與無機及 有機鹼形成之鹼性鹽類。該等鹽類係包括銨鹽;鹼金屬 鹽,諸如鋰、鈉及鉀鹽;鹼土金屬鹽,諸如鈣及鎂鹽;與 有機鹼之鹽,諸如胺類鹽(例如二環己基胺鹽、苯扎明 (benzathine) 、N —甲基一 D —還原葡糖胺及海巴青黴素 -18- 200522950 (14) (hy dr aba mine )鹽);及與胺基酸如精胺酸、離胺酸及 其類者之鹽;及兩性離子,所謂之 ''內鹽〃。以無毒性、 醫藥上可接受之鹽類爲佳,唯亦可使用其他鹽類,例如用 於單離或純化產物。以鈉及鈣鹽爲佳。 術語醫藥上可接受之、'鹽〃及 ''鹽類〃亦包括酸加成 鹽。此等係與下列酸形成:例如強無機酸,諸如礦酸,例 如硫酸、隣酸或鹽酸諸如H C1或Η B r,強有機酸羧酸,諸 如具有1至4個碳原子之烷羧酸,其可未經取代或經例如 鹵素所取代,例如乙酸,諸如飽和或不飽和二羧酸,例如 草酸 '丙二酸、琥珀酸、順丁烯二酸、反丁烯二酸、苯二 甲酸或對苯二甲酸,諸如羥基羧酸,例如抗壞血酸、乙醇 酸、乳酸、蘋果酸、酒石酸或檸檬酸,諸如胺基酸(例如 天冬胺酸或穀胺酸或離胺酸或精胺酸)或苄酸,或有機磺 酸諸如(C ! - C4 )烷基或芳基磺酸,其未經取代或經例如 鹵素所取代,例如甲磺酸或對一甲苯磺酸。 當結構I化合物係爲酸形式時,其可形成醫藥上可接 受之鹽’諸如鹼金屬鹽諸如鋰、鈉或鉀,鹼土金屬鹽諸如 #5或錶’及鋅或鋁及其他陽離子諸如銨或膽鹼,胺基酸鹽 諸如離胺酸(D或L ),胺鹽諸如二乙醇胺、乙二胺、第 二丁基胺、第三辛基胺、三一(羥基甲基)胺基甲烷 (TRIS) 、N—甲基葡糖胺(nmg)、三乙醇胺、二環己 基胺、甲基胺及脫氫松香胺。 下文係爲各種基團之定義,其可經丨至4個或更多個 取代基所取代。應明瞭各個取代基每次出現各可相同或相 -19- 200522950 (15) 異。此等取代基可出現於提供安定之化合物的任何位置及 任何組合。 除非另有陳述,否則術語'、烷基〃或、、烷〃在本發明 中單獨或作爲另一基團之一部分使用時係同時包括直鏈及 分支鏈烴’含有1至2 0個碳,以1至1 0個碳爲佳,1至 8個碳更佳’正鏈者諸如甲基、乙基、丙基、異丙基、丁 基、第二丁基、異丁基、戊基、己基、異己基、庚基、 4’ 4一二甲基戊基、辛基、2,2,4_三甲基一戊基、壬 基、癸基、Η 碳基、十一碳基、其各種分支鏈異構物及 其類者。低烷基係表示含有1至6個碳原子之基團。除非 另有陳述,否則烷基可視情況經1至4個取代基所取代。 該等取代基係包括鹵基,例如F、B r、C1或I或c F 3,院 基、烷氧基、芳基、芳氧基、芳基(芳基)或二芳基、芳 基烷基、芳基烷氧基、烯基、環烷基、環烷基烷基、環烷 基烷氧基、胺基、羥基、羥基烷基、醯基、環雜烷基、雜 方基、雜方氧基、雜芳基院基、雜芳基院氧基、芳氧基院 基、烷硫基、芳基烷硫基、芳氧基芳基、烷基醯胺基、院 醯基胺基、芳基羰基胺基、硝基、氰基、硫醇、鹵院基、 三鹵烷基及/或烷硫基, Ο R 1 4 ’ 可經一或多個R I 5所取代之烷基, 可經一或多個R 15所取代之烯基, 可經一或多個R 15所取代之炔基, 可經一或多個R!5所取代之環烷基, -20- 200522950 (16) 可經一或多個R ! 5所取代之芳基, 可經一或多個R Μ所取代之雜環, S R 1 4, S 0 2 R 1 4 , COOR14, C ( Ο ) R】4, C Ο N R 16 R 17, SO2NR16R17 5 S02N ( H ) C ( O ) R14, S02N ( H ) C02R14,其中 R14 非 H N R 16 R 17, N ( RI6 ) S02R17, N ( Ri6 ) C ( O ) mR】7 ( 1,2 ) N ( RI6 ) C ( O ) NR17R18, N ( R】6 ) S02NRI7R]8, OC ( O ) R】4, OC ( O ) OR]4, CO ( O ) NR]7R18, C ( 0 ) N ( H ) SO2NR1 7R1 8 J c ( 0 ) N ( H ) S02R17, 合氧基(或酮基,即=〇), 硫代(即,=S ), 亞胺基(即,二NR】9), N R ] 9 — C (二 NR20) R21 ’ -21 - 200522950 (17) NR19 - c (二 NR20) NR21R22 C ( = NRi 9 ) NR20R21 5 OC ( - NR19 ) NR20R21 ? OC (二 NR]9) R20’ C ( = NR!9 ) R20, C (=NRl9) 〇R】4’ Ri 4係選自H、C】—C 8院基、C 2 — C 8烯基、C2 - C8 炔 基、 c3 —C 8環院基、C 6 — c10芳基或C l - C9雜環, 其 各 可經 1 至3個個別出現之 R15所取代, Ri 6、R]7及R】8個別選自C】—C8 烷基、c2 - C8 烯 基、 c2 〜C8炔基、C 3 — C 1 8環烷基、C6- _ C】〇芳基或 C】 __ C9雜環,其各可經1至3個個別出現之R15所取代,或 R】6及Rl7或Rl6及R!8或Rl7及可藉伸院基或伸嫌基 鏈連接形成5 -至8 -員雜環性環,其係如雜環所定義, 其中取代基可爲一或多個R, 5, 、R2G、R21或R22個別選自 Η、硝基、氰基、 ΟΗ、0 (Cl— C6 烷基)、c (0) R14、c (0) NR16R】7、 CC)2Ri4 (其限制條件爲 非 η ) 、 S02R14 、 S〇2NRl6Rn、烷基、C2— C8 烯基、C2 - C8 炔基、 8壤纟兀基、c6— C】G芳基或Cl— C9雜環,或R】9及 R 2 〇 p hl A 及 R21 或 19及 R22 或 R2G 及 R21 或 R2G 及 R22 " 21及R22可藉伸烷基或伸烯基鏈連接形成5一至8- 貝雑環 t4: 逆^ ’其可視情況經一或多個R】5所取代。 R ] 5係選自 -22- 200522950 (18) 鹵素, 硝基, 氰基, OR24, 視情況經鹵素所取代之烷基, 視情況經鹵素所取代之環烷基, 視情況經鹵素、羥基、硝基、甲氧基、三氟甲基、氰 基、甲酯基、CONH2或CHO所取代之芳基, 視情況經鹵素、羥基、硝基、甲氧基、三氟甲基、氰 基、甲酯基、CONH2或CHO所取代之雜環, S R 2 4, C 〇 2 R 2 4, C (〇)R24, C 〇 N R 2 5 R 2 6, S 〇 2 N R 2 5 R 2 6, N R 2 5 R 2 6, N ( R25 ) SO2R26 ^ N ( R2〇 C (〇)mR26 ( 1,2 ), N ( R25 ) C (〇)NR26R27, N ( R25 ) S〇2NR26R27, 〇C (〇)R24, 〇C (〇)〇R24, S 0 2 R 2 4 5 SO2N ( H) C (〇)R24 , -23- 200522950 (19) S02N (H) C〇2R24,其中 R24 非 Η, c ( ο ) Ν ( Η ) S02NR25SR26, C ( 〇 ) Ν ( η ) S02R24, 〇c ( ο ) nr25r26, NR28-C ( = NR2 9) R3〇j NR28 - C( = nR29) 〇r24, NR28 - C ( = NR29 ) NR30R31 ^ C ( = NR28 ) NR29R30 ^ oc( —NR28) R29j OC ( = NR28 ) NR29R30 ^ OC ( = NR28) 〇r24 , R24係選自未經取代之烯基、未經取代之炔基、未經 取代之環烷基、未經取代之芳基、未經取代之雜環, R25、Rh及R27係選自未經取代之烷基、未經取代之 烯基、未經取代之炔基、未經取代之環烷基、未經取代之 芳基、未經取代之雜環,或R25與R26或R25與R27或R26 與R2 7係錯伸j:元基或伸嫌基鏈連接以形成5至8員未經取 代之雜環性環,且 R2 8、R29、R3G、R3】係選自硝基、氰基、未經取代之 烷基、未經取代之烯基、未經取代之炔基、未經取代之環 烷基、未經取代之芳基、未經取代之雜環,或與 或R28與R30或R28與r31或r29與R3g或r29與或 R3〇與R31係藉伸烷基或伸烯基鏈連接以形成5至8尋未 經取代之雜環性環。 -24- 200522950 除非另有陳述,否則術語 ''環烷基〃在本發明中單獨 或作爲另一基團之一部分使用時係包括含有1至3個環之 飽和或部分不飽和(含有1或2個雙鍵)環狀烴基,包括 單環烷基、雙環烷基(或雙環烷基)及三環烷基,共含有 3至2 0個形成環之碳,以3至1 0個形成環之碳爲佳,且 其可稠合於1或2個如芳基所述之芳族環,包括環丙基、 環丁基、環戊基、環己基、環庚基、環辛基、環癸基及環 十二碳基、環己烯基、
其中任何基團可視情況經1至4個取代基所取代,其每次 出現可相同或相異,諸如鹵素、烷基、烷氧基、羥基、芳 基、芳氧基、芳基烷基、環烷基、烷基醯胺基、烷醯基胺 基、合氧基、醯基、芳基羰基胺基、雜芳基、環雜烷基、 胺基、院基胺基、硝基、氰基、硫醇及/或烷基硫基及/ 或用於烷基之任何取代基。 本發明單獨或作爲另一基團之一部分的術語'、環烯 基〃係指含有3至1 2個碳之環狀烴,以5至1 〇個碳及1 或2個雙鍵爲佳。例示環烯基係包括環戊烯基、環己烯 基、运庚條基、環辛烯基、環己二烯基及環庚二烯基,其 可視情況如環烷基所述般地經取代。 -25- 200522950 (21) 本發明單獨或作爲另一基團之一部分的術語、、烷醯 基〃或 ''烷基羰基〃係指鍵合於羰基之烷基。 除非另有陳述,否則本發明單獨或作爲另一基團之一 部分使用的術語 '、低烯基〃或''烯基〃係指正鏈中具有2 至20個碳(以2至1 2個碳爲佳,而1至8個碳更佳)且 正鏈中包括一至六個雙鍵之直鏈或分支鏈基團,諸如乙烯 基、2—丙烯基、3 — 丁烯基、2— 丁烯基、4 —戊烯基、3 一戊烯基、2—己烯基、3-己烯基、2-庚烯基、3 -庚烯 基、4一庚烯基、3 —辛烯基、3 -壬烯基、4 —癸烯基、3 一十一碳烯基、4 一十二碳烯基、4,8,12 —十四碳三烯 基及其類者,其可視情況經1至4個取代基所取代,即鹵 素、鹵烷基、烷基、烷氧基、烯基、炔基、芳基、芳基烷 基、環烷基、胺基、羥基、雜芳基、環雜烷基、烷醯基胺 基、烷基醯胺基、芳基羰基-胺基、硝基、氰基、硫醇、 院基硫基及/或本發明所列之烷基取代基中任一種。 除非另有陳述,否則本發明單獨或作爲另一基團之一 部分使用的術語、、低炔基〃或'、炔基〃係指正鏈中具有2 至20個碳(以2至1 2個碳爲佳,而2至8個碳更佳)且 正鏈中包括一個參鍵之直鏈或分支鏈基團,諸如2 -丙炔 基、3 — 丁炔基、2 — 丁炔基、4 —戊炔基、3 -戊炔基、2 一己炔基、3 —己炔基、2 —庚炔基、3 —庚炔基、4 一庚炔 基、3 —辛炔基、3 -壬炔基、4一癸炔基、3 -十一碳炔 基、4 ~十二碳炔基及其類者,其可視情況經丨至4個取 代基所取代’即鹵素、鹵烷基、烷基、烷氧基、烯基、炔 -26- 200522950 (22) 基、芳基、芳基烷基、環烷基、胺基、雜 基、羥基、烷醯基胺基、烷基醯胺基、芳基 硝基 '氰基、硫醇及/或烷基硫基及/或本 基取代基中任一種。 本發明單獨或作爲另一基團之一部分使 基烯基〃及 '、芳基炔基〃係指前述具有芳基 及炔基。 當前文定義之烷基具有單鏈以在兩相異 其他基團時,其稱爲 ''伸烷基〃,且可視情 前文針對''烷基〃所定義的取代基所取代, 例如烷基、鹵基、羥基、烷氧基及/或環烷 當前文定義之烯基及前文所定義之炔基 以於兩相異碳原子連接於其他基團時,其個 基〃及 ''伸炔基〃,且可視情況經1或2個 基〃及'\炔基〃所定義的取代基所取代。 本發明單獨或作爲另一基團之一部分使 素〃或 ''鹵基〃係指氯、溴、氟及碘與CF2 佳。 術語、、金屬離子〃係指鹼金屬離子, 鋰,及鹼土金屬離子’諸如鎂及鈣,與鋅及 除非另有陳述,否則在本發明中單獨或 之一部分使用的術語 ''芳基〃係指環部分中 個碳之單環及雙環芳族基團(諸如苯基或萘 蔡基及2 -萘基)’且可視情況包括一至三 芳基、環雜烷 :羯基一胺基、 :發明所列之烷 用的術語 ''芳 取代基的烯基 碳原子連接於 況經1或2個 該取代基諸如 基。 個別具有單鏈 別稱爲 ''伸烯 前文針對 ''烯 用的術語 ''鹵 I,以氯或氟爲 諸如鈉、紳或 鋁。 作爲另一基團 含有 6至 10 基,包括1 一 個稠合於碳環 -27- 200522950 (23) 性環或雜環性環(諸如芳基、環烷基、雜芳基或環雜烷基 環例如 ,〇>,仅>,
的附加環,且可視情況經由有效碳以1、2或3個選自下 列者之基團所取代:氫、鹵基、鹵烷基、烷基、烷氧基、 鹵苯基、苄醯氧基、鹵烷氧基、烯基、三氟甲基、三氟甲 氧基、炔基、環烷基-烷基、環雜烷基、環雜烷基烷基、 芳基、雜芳基、芳基烷基、芳氧基、芳氧基烷基、芳基烷 氧基、芳硫基、芳基偶氮基、雜芳基烷基、雜芳基烯基、 雜芳基雜芳基、雜芳基氧基、羥基、硝基、氰基、胺基、 經取代之胺基(其中該胺基包括1或2個取代基,其係爲 烷基、烷醯基、芳基或定義中所提及之任何其他芳基化合 物)、硫醇、院基硫基、芳基硫基、雜方基硫基、芳基硫 基烷基、烷氧基芳基硫基、烷基羰基、芳基羰基、烷基胺 基羰基、芳基胺基羰基、烷氧羰基、胺基羰基、烷基羰基 氧基、芳基羰基氧基、烷基羰基胺基、芳基羰基胺基、芳 基亞磺醯基、芳基亞磺醯基烷基、芳基磺醯基胺基或芳基 磺醯胺基羰基及/或本發明所列之烷基取代基中之任一 種。 -28- 200522950 (24) 除非另有陳述,否則本發明單獨或作爲另一基團之一 部分使用的術語 '、低烷氧基〃、 '、烷氧基〃、、'芳氧基” 或方k氧基〃係包括連接於氧原子的任何前述烷基、芳 烷基或芳基。 除非另有陳述,否則本發明單獨或作爲另一基團之一 J分使用的術語經取代之胺基〃係指經一或二個取代基 所取代之胺基’該取代基可相同或相異,諸如烷基、芳 基、方基烷基、雜芳基、雜芳基烷基、環雜烷基、環雜烷 基烷基、環烷基、環烷基烷基、鹵烷基、羥基烷基、烷氧 基院基或硫院基。此等取代基可進一步經羧酸及/或任何 用於則述烷基的取代基所取代。此外,該胺基取代基可與 其所連.接之氮原子一起形成1 -吡咯烷基、i —哌啶基、1 一氮呼基、4 一嗎啉基、4 一硫雜嗎啉基、丨一哌哄基、4 — 烷基—1 一哌畊基、4 一芳基烷基—1 一哌哄基、4 一二芳基 烷基一 1 —哌畊基、1 —吡咯烷基、丨一哌啶基或丨一氮呼 基,其視情況經烷基、烷氧基、烷基硫基、鹵基、三氟甲 基或羥基所取代。 除非另有陳述,否則本發明單獨或作爲另一基團之一 部分使用的術語 ''低烷硫基〃、 '、烷基硫基〃、 '、芳基硫 基〃或 ''芳烷基硫基〃係包括連接於硫原子之任何前述烷 基、芳烷基或芳基。 除非另有陳述,否則本發明單獨或作爲另一基團之一 部分使用的術語 ''低烷基胺基〃、 '、烷基胺基〃、 '、芳基 胺基〃或 ''芳基烷基胺基〃係包括連接於氮原子之任何前 -29- 200522950 (25) 述院基、芳基或芳基院基。 除非另有陳述,否則本發明單獨或作爲另一基團之一
I Ο V 部分使用的術語、、醯基〃係指連接於羰基(S )之有機基 團;醯基之實例係包括任何連接於羰基之R ,或R4基團, 諸如烷醯基、烯醯基、芳醯基、芳烷醯基、雜芳醯基、環 烷醯基、環雜烷醯基及其類者。 除非另有陳述,否則本發明早獨或作爲另一基團之一 部分使用的術語 ''環雜烷基〃係表示5 -、6 -或7 -員飽 和或部分不飽和環,其包括1或2個經由碳原子連接之雜 原子諸如氮、氧及/或硫,或可能時視情況經鍵合基 (CH2 ) r (其中r係爲1、2或3 )連接之雜原子,諸如
及其類者。前述基團可包括1至4個取代基,諸如烷基、 鹵基、合氧基及/或任何本發明所列之烷基取代基。此 外,任何環雜烷基環皆可稠合於環烷基、芳基、雜芳基或 -30- 200522950 (26) 環雜烷基環。 除非另有陳述,否則本發明單獨或作爲另一基團之一 部分使用的術語 '、雜芳基〃係表示5〜或6 —員芳族環, 其包括1、2、J或4個雜原卞諸如氮、氧或硫,及稠合於 芳基、環院基、雜方基或^雜院基環之環(例如苯并噻吩 基、吲哚基)且包括可能之N -氧化物。該雜芳基可視情 況包括1至4個取代基’諸如任何前文針對烷基所列示之 取代基。雜芳基之實例係包括下列者:
-31 - 200522950 (27)
及其類者。 本發明單獨或作爲另一基團之一部分使用的術語 ''環 雑烷基烷基〃係表示經由C原子或雜原子連接於(CH2 ), 鏈之前文定義環雜烷基。 本發明單獨或作爲另一基團之一部分使用的術語 ''雜 芳基烷基〃或''雜芳基烯基〃係指經由C原子或雜原子連 -32- 200522950 (28) 接於前文定義之一 (C Η2 ) r〜鏈、伸烷基或伸烯基的雜芳 基。 本發明所使用之術語 ''多_基烷基〃係指包括2至9 個(以2至5個爲佳)鹵基取代基諸如F或C1 (以F爲 佳)之前文定義 ''烷基〃,諸如CF3CH2、CF3或 CF3CF2CH2 〇 本發明所使用之術語 ''雜環〃或、、雜環基〃係表示雜 芳基或環雜烷基。 本發明所使用之術語 多鹵基院氧基〃係指包括2至 9個(以2至5個爲佳)鹵基取代基(諸如ρ或C1,以F 爲佳)之前文定義、、院氧基〃或、、院基氧基〃,諸如 CF3CH2〇、CF30 或 CF3CF2CH2〇。 如前文定義,烷基、烯基、炔基、環烷基及雜環基團 可經由一或多個單鍵連接於一或多個連接原子。此外,此 等基團可藉雙鍵連接於連接原子,且此等基團可稱爲 '、亞 烷基〃、'、亞烯基〃、 '、亞炔基〃、、、亞環烷基〃或 '、亞 雜環〃基。實例包括亞甲基(=ch2 )、亞乙基 (=CHCHa )、亞乙烯基(=c=ch2)、亞環己基 及2 —亞吡喃基( ;。此等基團可如前文針 對院基、烯基、炔基、環烷基及雜環所述般地經取代。 本發明化合物之所有立體異構物皆爲所預期者,不論 是摻合物或純或實質純形式。本發明化合物可具有位於任 何碳原子上之不對稱中心,包括任一者或R取代基。因 此’式1化合物可存在鏡像異構或非鏡像異構形式或其混 -33- 200522950 (29) 合物形式。製備方法可採用消旋物、鏡像異構物或非鏡像 異構物作爲起始物質。製備非鏡像異構或鏡像異構產物 時’其可藉習用方法例如層析或分步結晶加以分離。 本發明化合物可在特定氮原子上具有不對稱中心。因 此’此寺異構物或其混合物係爲本發明之一部分。 本發明化合物亦可顯示其他對掌性情況,諸如滯轉異 構化。因此,此等異構物或其混合物係爲本發明之一部 分。 本發明所採用之術語 ''前藥酯類〃包括藉著式I化合 物之一或多個羥基與經烷基、烷氧基或芳基所取代之醯化 劑採用熟習此技術者已知用以生成乙酸酯、特戊酸醋、甲 基碳酸酯、苄酸酯及其類者之方法進行反應所形成之酯類 及碳酸酯。此外’技術界已知用於羧酸及磷酸酯類諸如甲 基、乙基、苄基及其類者之前藥酯類係包括於本發明。 該等前藥酯類之實例係包括 CH3C02CH2 — , ch3co2ch2 — · t—c4h9co2ch2—,或
CH 〇 (占 h3)2 c2h5ococh2— e 適當之前藥酯類的其他實例係包括
-34- 200522950 (30) 其中Ra可爲Η、烷基(諸如甲基或第三丁基)、芳基烷 基(諸如苄基)或芳基(諸如苯基);Rd係爲Η、烷基、 鹵素或烷氧基,Re係爲烷基、芳基、芳基烷基或烷氧 基’且係爲0、1或2。 本發明化合物可藉以下方法(流程圖1至4 )製備。 -35- 200522950 (31) 流程圖1
lc
鹼/thf 36- 200522950 (32) 流程圖1描繪式I化合物(其中X = N )之合成。先 前已知之酯 1 ( Masamichi Watanabe 等人,Bioorganic & Medicinal Chemistry ( 1 9 9 7 ) ,5 ( 2 ) ,437-444; Eur. Pat· App· 1 993,18 ρρ· Ep 5 2 1 47 1 )可藉著在甲苯或二氯 甲烷中使用DIBAL還原以產生醇2。化合物2可藉著在 二氯甲烷中使用 Dess-Martin氏派歐H定院(periodina n e) 或在催化量之TEMPO自由基及溴化鉀存在下於二氯甲烷 或乙酸乙酯中使用經緩衝之漂白劑(N aO C 1 )氧化,以產 生醛 3。化合物 3 可藉著與先前已知之硕 5 (Brodfuehrer,Paul R·等人,PCT Int. Appl. ( 2002 ), WO 029 8 8 5 4 )及有機鹼諸如雙三甲基甲矽烷基醯胺鋰、 鈉或鉀反應而轉化成關鍵之中間烯烴4。化合物4於T H F 或D M F中於鹼諸如雙三甲基甲矽烷基醯胺鋰、鈉或鉀存 在下,以芳基胺、環雜烷基胺或雜芳基胺5 a處理,產生 6。式6化合物可藉著以質子酸水溶液諸如鹽酸、硫酸或 對一甲苯磺酸處理以產生I a,之後以鹼水溶液諸如氫氧化 鈉皂化以產生lb。 或6可藉著先以鹼諸如雙三甲基甲矽烷基醯胺鋰處 理,之後以fUHal ( 7 )諸如對應之院基鹵、磺醯鹵/ 酐、醯基鹵/酐及氯甲酸烷酯及其類者處理以產生8,而 轉化成式Ϊ化合物(R4非Η,諸如烷基、烷基磺醯基、烷 酿基、丨兀興基基寺,化合物I c )。如則般移除縮丙嗣基 及皂化產生式Ϊ c之化合物。I c可藉著以酸(以無機酸爲 佳,諸如HC1或_ H2S04 )處理鹽Ic而轉化成游離酸 -37- 200522950 (33) 或化合物4可藉著於THF或DMF中以預先組合之胺 R3R4NH (化合物5b )及鹼諸如雙三甲基甲矽烷基醯胺鋰 及其類者處理而直接轉化成化合物8。如前述般地移除縮 丙酮基及皂化產生式Ic化合物。 或式I c化合物可如流程圖1所示般地自中間物1或3 製備。
或化合物ό或8可藉著與酸諸如三氟乙酸於二氯甲烷 或氯仿中反應而個別轉化成內酯Id或Ie,其可藉著以氫 氧化鈉水溶液處理而轉化成式I化合物(化合物lb或 Ic)(流程圖2 )。 流程圖2
-38- 200522950 (34) 特定之式I化合物(其中x = CR5 )可如流程圖3所 述般地自先前已知之中間物9 ( Huebsch, Walter等人, Ger. Offen. ( 1992),DE 4023308; Huebsch,Walter 等 人,Eur. Pat. Appl· ( 1992),EP 465 970 )製備。9 之氫 化鋰鋁還原產生苄醇1 〇,其可於乙醇中在三氟乙酸存在 下於氫化使用碳上鈀進一步還原產生 n(R5二甲基)。 其他式I所述含有R5基團之中間物可使用技術界已知之 一般轉變(例如氧化、烷基化、置換、加成及其類者)自 中間物1 0或其經保護同質物製備。 胺基吡啶1 1可藉著在水中以亞硝酸鈉及四氟硼酸處 理而轉化成氟吡啶12。12於THF或DMF中,在鹼諸如 雙三甲基甲矽烷基醯胺鋰、鈉或鉀存在下,以雜環胺 R3NH2 (化合物5a)處理,產生13。化合物13可藉著以 氫化物還原劑諸如DIB AL還原而轉化成醇14。醇14成 爲醛1 5之氧化可藉著於催化量之KBr及TEMPO存在下 在EtOAc或二氯甲院中使用NaOCl或藉著於二氯甲院中 使用Dess-Martin氏派歐啶烷來完成。於dmAP存在下以 BOC酐處理15產生化合物16,其可在強鹼諸如雙三甲基 甲矽烷基醯胺鋰、鈉或鉀存在下以碾5 (參照流程圖!) 處理轉化成烯烴1 7。1 7於溶劑諸如二氯甲烷或氯仿中以 酸諸如三氟乙酸(TFA )處理,產生內酯If,其可轉化成 對應之鹽Ig。Ig可藉著以酸諸如HC1或H2S04處理而轉 化成對應之游離酸。 或化合物1 2可經由還原、氧化、烯烴化及脫保護, -39- 200522950 (35) 而轉化成式Ih之化合物,其中R4非Η。 特定之式If、Ig及Ih化合物(其中R5 = Η )亦可經 由立體較不受阻之乙酯的選擇性水解,之以使用技術界已 知之方法及試劑將形成之酸9 a脫羧基(例如以C u粉末/ 喹啉加熱,U.S.,440 5 5 5 2,2 0 Sep· 1 9 8 3 )而製備。形成 之異構物9b可依中間物1 1所述方式用以合成式If、Ig 或Ig之化合物(其中R5=H)。 特定之式I化合物(其中x = CR5且R5係爲烷氧基烷 基,即式Ii化合物)亦可如流程圖3所述般地自化合物9 製備。因此,9之胺基轉化成氟基可使用亞硝酸鈉及四氟 硼酸達成,以產生9c。9c與5b之偶合可產生9d,其可 使用乙硼烷還原以產生醇9e。9e於THF或DMF中,於 鹼性條件(NaH、LiH及其類者)下,以烷基鹵、三氟甲 磺酸烷酯及其類者處理可產生9f。9f轉化成式Ii化合物 可經由前述還原、氧化、烯烴化及脫保護進行。 -40- 200522950 (36)
特定之式I化合物(其中"爲—CH2— CH2 —)可經由ί隹 化氫化自對應之不飽和中間物或其他式I之不飽和化合物 (其中 /胃/ )製備,之後以酸類及/或鹼水溶液處 -41 - 200522950 (37) 理,如流程圖4所示。 流程圖4
含有二羥基酸HMG — CoA鍵結功能部位側鏈之化合 物可製備成較佳之高對掌性(homochiral)形式,或可製 備爲消旋混合物(3 S *,5 R * )且稍後可離析得到3 S,5 R 異構物。 以下中間物係爲新穎化合物且形成本發明之一部分: 中間物 lb、 lc、 2 至 4、 6、 8、 9a 至 9f、 13a、 14a、 15a、17a及11至19,其可由]、式表不: -42- 200522950 (38) A.
Q
S〇2烷基 其中R l及R 2係相m f 问或相骞,且個別選自烷基、烷氧 基院基、芳基院基、環卢甘 兀基、烯基、環烯基、芳基、雜芳 基或環雜烷基;且 Q係爲HOCH2—或
其中R!及R2係如前定義, R3係爲芳基、雜芳基、環烷基或雜環烷基; R4係爲Η、烷基、環烷基、鹵烷基、烷氧基烷基、烷 基硫烷基、烷基磺醯基、芳基磺醯基、烷氧羰基、芳氧羰 基、雜芳氧羰基、烷基胺基羰基、芳基胺基羰基、雜芳基 胺基羰基、烷基胺基磺醯基、醯基、芳基羰基、雜芳基羰 基或雜芳基磺醯基;且 Qi係爲HOCH2—或 -43- 200522950 (39)
其中Ri及R2係如前定義,且Q2係爲H2N、F、R3HN — 或 R3R4N—,
R5係爲一 COOH、低烷基、H、COO烷基、—CH20H 或院基〇 -。 D.
其中R】、R2及R5係如前定義,且Q3係爲R3HN — R 3 R 4 N 一 ’ R3、 N— I PG (其中P G係爲保護基
Q4係爲一 COO烷基 諸如 本發明化合物係爲3 -羥基- 3 -甲基一戊二酸基輔 酶A ( HMG — CoA )還原酶之抑制劑,因此可用於抑制膽 固醇生物合成及/或降低三酸甘油酯,方式如同阿托代他 汀(a t 〇 r v a s t a t i η )、普代他汀(p ι· a v a s t a t i n )、半代他汀 • 44 - 200522950 (40) (simvastatin )、洛代他汀(lovastatin )、史代他汀 (cerivastatin)、羅蘇代他汀(rosuvastatin)、氛代他 汀(fluvastatin)、匹代他汀(pitavastatin)及其類者。 本發明另一態樣係爲一種醫藥組成物,其含有至少一 種本發明式I化合物,結合有醫藥媒劑或稀釋劑。該醫藥 組成物可採用習用固體或液體媒劑或稀釋劑及適於所需投 藥模式之類型的醫藥添加劑來調配。該等化合物可藉經由 路徑投藥,例如使用錠劑、膠囊、顆粒或粉末形式,或其 可藉非經腸路徑以可注射製劑形式投藥。該等劑型每劑含 有0.1至1 5 00毫克活性化合物,使用於治療。投藥用之 劑量係視單元劑量、徵候及患者之年齡及體重而定。 本發明化合物可依如同建議用於抑制膽固醇生物合成 之已知化合物諸如普代他汀(pravastatin )、洛代他汀 (lovastatin)、辛代他汀(s i m v a s t a t i η )、羅蘇代他汀 (rosuvastatin)、阿托代他汀(atorvastatin)、史代他 汀(cerivastatin )、氟代他汀(fluvastatin )、匹代他汀 (pitavastatin )及其類者的方式投藥於哺乳類,諸如人 類、犬類、貓類及其類者。因此,本發明化合物可在單劑 約〇 .〗至5 0 〇毫克用量或每日1至4次個別劑量形式(以 每日0.5至200毫克爲佳)或使用持續釋放形式投藥。 式I之Η M G C ο A還原酶抑制劑可與所有可與Η M G CoA還原酶抑制劑結合使用的療劑結合使用。 因此,若需要,則結構I化合物可與一或多種降血脂 劑或脂質降低劑或脂質劑或脂質調節劑及/或一或多種療 -45- 200522950 (41) 劑結合使用,該療劑係包括抗糖尿病劑、抗肥胖劑、 血壓劑、血小板凝集抑制劑、抗阿茲海默氏症、抗 劑、抗骨質疏鬆劑、及/或激素替補療劑、及/或其 劑、及/或其他心血管藥劑(包括抗心絞痛劑、抗心 整劑、抗動脈硬化劑、抗發炎劑、抗血小板劑、抗心 竭劑)、抗癌劑、抗感染劑、激素替補劑、生長激素 泌劑、選擇性雄激素受體調節劑(S ARM )、及/或 可於相同劑型或於個別劑型經口投藥或藉注射投藥 劑。 可視情況與本發明式I化合物結合使用之降血脂 脂質降低劑或其他脂質劑或脂質調節劑可包括1,2 或更多MTP抑制劑、HMG CoA還原酶抑制劑、角鯊 成酶抑制劑、P P A R α促效劑、p p A R雙重a / r促效 P PAR (5促效劑、纖維酸衍生物、AC AT抑制劑、脂肪 酶抑制劑、膽固醇吸收抑制劑、迴腸Na+ /膽汁酸協 運子抑制劑、L D L受體活性之調高劑、膽固醇酯轉移 抑制劑、膽汁酸隔離劑及/或菸酸及其衍生物。 本發明所採用之MTP抑制劑係包括美國專 5,595,872號、美國專利第5,739,135號、美國專 5,7 1 2,2 79號、美國專利第5,7 60,24 6號、美國專 5,827,875號、美國專利第5,88 5,983號及美國專 5,962,440號所揭示之MTP抑制劑。較佳者係爲各個 專利及申請案所揭示之各個較佳Μ T P抑制劑。 所有前述美國專利及申請案皆以引用方式倂入本: f几局 癡呆 他療 律不 臟衰 促分 其他 的療 劑或 ,3 - 烯合 劑、 氧化 同轉 蛋白 利第 利第 利第 利第 前述 -46- 200522950 (42) 採用於本發明之最佳MTP抑制劑係包括美國專利第 5,7 3 9,1 3 5號及第5,7 12,2 79號及美國專利第5,76〇,246號 所列示之較佳MTP抑制劑。 最佳MTP抑制劑係爲9 — [4一 [4〜[[2一( 2,2,2一 三氟乙氧基)玉醯基]胺基]一 1 一雜’卩定基]丁基]一 N 一 (2,2,2-三氟乙基)—9H_莽一 9一羧醯胺
適用於本發明之角鯊烯合成酶抑制劑係包括(但不限 於)美國專利第5,7 1 2,3 96號所揭示之α —亞磷羧基—磺 酸酯,其係由 Biller 等人,J. Med. Chem·,1988,Vol. 31, Ν ο . 1 〇,p p〗8 6 9 — 1 8 7 1所揭示者,包括類異戊間二烯(膦 基-甲基)膦酸酯及其他已知之角鯊烯合成酶抑制劑,例 如美國專利第4,871,721號及第4,924,024號及Biller, S,A·,Neuenschwander,K·,Ponpipom,M.M·,and Poulter, C. D. 9 Current Pharmaceutical Design, 2 ? 1-40 ( 1 996 )戶斤 揭示。 此外,其他適用於本發明之角鯊烯合成酶抑制劑係包 括 P. Ortiz de Mintellano 等人,J. Med. Chem·,1977,20, 24 3 -249所揭示之類钶烯焦磷酸酯,Corey and Vol ante,J· Am. C hem. Soc.,1976,98,129 1-1293 所揭示之法呢基二 -47 - 200522950 (43) 磷酸酯同質物 A及前角鯊烯焦磷酸酯(PS Q — PP )同質 物、McClard,R.W.等人,J.A.C.S.,1987,109,5544 所記 載之膦基膦酸酯及 Capso n,T.L.,PhD dissertation,June, 1987,Dept· Med. C hem. U of Utah,Abstract, Table of Contents, pp 16,17,40-43,48-51,Summary 所揭示之環丙 烷。 其他適用於本發明之降血脂劑包括(但不限於)纖維 酸衍生物,諸如吩諾纖維酸酯(fenofibrate )、吉非布札 (gemfibrozil )、克洛纖維酯(c 1 o f i b r a t e )、本札纖維 酸酯(bezafibrate)、西普纖維酸醋(ciprofibrate)、克 諾纖維酸醋(clinofibrate )及其類者,丙丁酣(probucol ),及美國專利第3,674,8 3 6號揭示之相關化合物,以吩 諾纖維酸酯(fenofibrate )、丙丁酚及吉非布札( gemfibrozil)爲佳,膽汁酸隔離劑諸如消膽胺( cholestyramine )、考來替潑(colestipol)及 DEAE-Sephadex ( Secholex ®,Policexide ® )及查利士膠( cholestagel ) ( Sankyo/Geltex)及月旨司特 it (lipostabil )(Rhone-Poulenc) 、Eisai E-5050 ( N —經取代之乙醇 胺衍生物)、依馬尼西(imanixil ) ( HOE — 402 )、四氫 里他汀(tetrahydrolipstatin) (THL)、伊司馬甲錫垸基 磷酸膽驗(istigmastanylphos-phorylcholine ) ( SPC,
Roche )、胺基環糊精(Tailabe Seiyoku )、Ajinomoto AJ-8 14 (藍香油烴衍生物)、亞油甲苄胺(Sumitomo )、 Sa n doz 58-035、American Cyan a mid CL-277,082 及 -48- 200522950 (44) CL-2 8 3,5 4 6 (經二取代之脲衍生物)、菸酸(ER niacin, Niaspan)、阿西比莫(acipimox)、阿西弗瑞(acifran )、新黴素、對—胺基水楊酸、阿斯匹靈(aspirin )、聚 (二烯丙基甲基胺)衍生物(諸如美國專利第4,7 5 9,923 號所揭示)、四級胺聚(氯化二烯丙基二甲基銨)及陽離 子聚合體(ionene )諸如美國專利第4,027,009號所揭 示,及其他已知之血淸膽固醇降低劑。 其他降血脂劑可爲AC AT抑制劑(亦具有抗動脈硬化 活性),諸如 Drugs of the Future 24,9·15 ( 1999), (A v a s i m i b e ) ; 、、The A C A T inhibitor, Cl-1001 is effecive in the prevention and regression of aortic fatty streak area in hamsters 〃 ,Nicolosi et al, Atherosclerosis (Shannon,Irel ) . ( 1 99 8 ) ,1 37 ( 1) ,7 7- 8 5 ; '、The pharmacological profile of FCE 2 7 6 7 7 · a novel A C A T inhibitor with potent hypolipidemic activity mediated by selective suppression of the hepatic secretion of A p o B 1 00-con taining lipoprotein 〃 , Ghiselli, Gian carlo,
Cardiovasc, Drug Rev. ( 1 99 8 ) ,16(1) ,16-30 ; 、、RP 7 3 1 6 3 : a bioavailable alkylsulfinyl-diphenylimidazole ACAT inhibitor 〃,Smith, C·,et al,Bioorg. Med. Che m. Lett. ( 1996 ) ,6 ( 1) ,4 7- 5 0 ; A C A T inhibitors · physiologic mechanisms for hypolipidemic and a n t i -atherosclerotic activities in experimental animals 〃 ,
Krause et a], Editor ( s) · Ruffolo, Robert R.? Jr.; -49 - 200522950 (45)
Hollinger, M a η n f r e d A., Inflammation : Mediators
Pathways ( 1 9 9 5 ) ,173-98,Publisher · CRC,Boca Raton,
Fla. ; 、、ACAT inhibitors : potential anti-atherosclerotic agents" ,Sliskovic e t a 1, C u r r. Med. Che m. ( 1 994 ) ,1 (3 ) ,204-25 ; Inhibitors of acyl -C o A · cholesterol O-acyl transferase ( ACAT ) as hypocholesterolemic agents. 6. The first water-soluble ACAT inhibitor with lipid-regulating activity. Inhibitors of acyl-CoA : cholesterol acyltransferase ( ACAT) . 7. Development of a series of substituted N - p h e n y 1 - N ’ - [ ( 1 -phenylcyclopentyl ) methyl] ureas with enhanced hypocholesterolemic activity” ,Stout e t a 15 Chemtracts · Org. Chem. ( 1995 ) , 8 ( 6 ) , 359-62 , or TS-962 (Taisho Pharmaceutical Co. Ltd ) ? as well as F-1394, CS-505 , F-12511 , HL-004 , K-10085 andYIC-C8-434 所 揭示。 降血脂劑可爲LDL受體活性調高劑,諸如MD - 700 (Taisho Pharmaceutical Co· Ltd )及 LY295427 ( Eli Lilly )。 其他脂質劑或脂質調節劑可爲膽固醇酯轉移蛋白抑制 劑(CETP ),諸如 Pfizer’s CP-5 29,4 1 4 (托西推比 (torcetrapib))及 WO/003 8 722 及 EP 8 1 844 8 ( Bayer) 及 EP 992496 所揭示者,及 Pharmacia’s SC — 744 及 SC — 7 9 5 及 CETi-]及 JTT— 705。 •50- 200522950 (46) 降血脂劑可爲迴腸N a + /膽汁酸協同轉運子抑制劑, 諸如 Drugs of the Future, 24,425-430 ( 1999)所揭示。 可與本發明結合使用之ATP檸檬酸酯裂解酶抑制劑 可包括例如美國專利第5,44 7,9 5 4號所揭示者。 其他脂質劑亦包括植物雌激素化合物,諸如W0 00/ 30665所揭示,包括單離之大豆蛋白質、大豆蛋白質濃縮 物或豆粉及異黃酮諸如吉尼史汀(genistein )、戴得畊 (daidzein )、葛來史汀 (g 1 y c i t e i η ) 或伊可醇 (equol ),或植物固醇、植物甾烷醇、生育三烯酚,如 WO 2000/015201 所揭示; /3 —內醯胺膽固醇吸收抑制劑,諸如E P 6 7 5 7 1 4所揭 示; HDL調高劑,諸如LXP促效劑、PPAR α —促效劑及 /或FXR促效劑; α —葡糖苷酶抑制劑,醛糖還原酶抑制劑及/或LDL 分解代謝促進劑,諸如ΕΡ 1 022272所揭示; 鈉一質子交換抑制劑,諸如D Ε 1 9 6 2 2 2 2 2所揭示; LDL -受體誘發劑或類固醇糖苷,諸如美國專利第 5,698,527 號及 GB 2304106 所揭示; 抗氧化劑,諸如-胡蘿蔔素、抗壞血酸、α -生育 酚或視黃醇,如W0 94/1 5 592所揭示,及維生素C及抗 高半胱胺酸劑,諸如葉酸、葉酸鹽、維生素Β 6、維生素 Β 1 2及維生素Ε ; 異菸酸肼,如W0 97/3 55 76所揭示; -51 - 200522950 (47) 膽固醇吸收抑制劑、HMG - CoA合成酶抑制劑或羊毛 甾醇脫甲基酶抑制劑,如W Ο 9 7 / 4 8 7 0 1所揭示; PPAR 6促效劑,用以治療血脂異常; P PAR α促效劑,用以治療血脂異常; 雙重PPAR a / r促效劑,諸如慕瑞塔扎( muraglitazar) ( Bristol Myers-Squibb)、特沙塔扎( tesaglitazar ) ( AstraZeneca )或 MK- 7 67 ( Merck/
Ky orin/B anyu ) ; 或固醇調節元素鍵結蛋白—I ( SREBP - 1 ),如 WO 200 0/05 05 74所揭示,例如鞘脂質,諸如神經醯胺或 中性神經鞘髓磷脂酶(N - SMase )或其碎片。 較佳降血脂劑係爲膽固醇吸收抑制劑,諸如伊吉提買 (ezetimibe )、膽固醇酯轉移蛋白(C E T P )抑制劑諸如 托西推比(torcetrapib)及 JEE — 705、雙重 PPARa/5 促效劑諸如暴瑞塔扎(m u r a g 1 i t a z a r )及特沙塔扎( tesaglitazar),及菸酸及 / 或查利士膠(ch〇iestagel)。 前述美國專利係以引用方式倂入本文。所採用之劑量 及劑型係出示於Physician’s Desk Reference及/或前述 專利中或係爲技術界已知。 本發明式I化合物相對於降血脂劑(若存在)之使用 重量比係介於約5 0 0 : 1至約1 ·· 5 0 0範圍內,以約1 0 0 : 1至約1 :〗0 0爲佳。 投藥劑量須根據患者年齡、體重及狀況與投藥路徑、 劑型及投藥計劃及所需結果來謹慎地調整。 -52- 200522950 (48) 降血脂劑或其他脂質劑或脂質調節劑所使用之劑量及 調配物係揭示於前文討論之各個專利及申請案中。 其他待使用之降血脂劑或其他脂質劑或脂質調節劑可 應用之劑量及調配物係列示於最新版之Physician’s Desk Reference 中。 經口投藥時,令人滿意之結果可採用量介於約0.0 1 毫克至約5 00毫克範圍內(以約0.1毫克至約100毫克爲 佳)每日一至四次之MTP抑制劑來得到。 較佳經口劑型,諸如錠劑或膠囊,含有量爲約1至約 5 0 〇毫克,較佳約2至約4 0 0毫克,更佳約5至約2 5 0毫 克之MTP抑制劑,每日一至四次。 角鯊烯合成酶抑制劑可使用介於約1 〇至約200毫克 且較佳約2 5毫克至約2 0 0毫克範圍內之量的劑劑。 較佳經口劑型,諸如錠劑或膠囊,含有量爲約〇. 1至 約200毫克,較佳約0.5至約80毫克,更佳約1至約40 毫克之HMG CoA還原酶抑制劑。 較佳經口劑型,諸如錠劑或膠囊,含有量約1 〇至約 5 00毫克,較佳約25至約200毫克的角鯊烯合成酶抑制 劑。 抗動脈硬化劑包括脂肪氧化酶(1 5 - LO )抑制劑, 諸如WO 9 7 / 1 2 6 1 5所揭示之苯并咪唑衍生物、 WO 97/ 1 26 1 3 所揭示之 15 — LO 抑制劑、WO 96/3 8 1 4 4 所 揭示之異噻唑酮及 Sen dobry等人''Attenuation of diet-induced atherosclerosis in rabbits with a highly selevtive -53- 200522950 (49) 1 5-liposygenase inhibitor lacking significant antiox properties, Brit. J. Pharmacology ( 1 99 7 ) 120, 1206,及 Cornicelli 等人,'、15-Lipoxygenase and its Inhibition : A Novel Therapeutic Target for V a s Disease" Current Pharmaceutical Design,1 999,5, 所揭示之1 5 - L O抑制劑。 式I化合物及降血脂劑可一起使用於相同經口劑 同時服用之個別經口劑型中。 前述組成物可使用前述劑型以單一或分次劑量每 至四次地投藥。可建議患者先以低劑量組合物開始, 調至高劑量組合物。 可視情況與式I之Η M G — C ο A還原酶抑制劑結 用的抗糖尿病劑可爲1、2、3或更多種抗糖尿病劑或 血糖劑,包括胰島素促分泌劑或胰島素敏化劑,其可 雙胍、磺醯脲、葡糖苷酶抑制劑、醛糖還原酶抑制 P P A R r促效劑諸如噻唑烷二酮、P P A R α促效劑(諸 維酸衍生物)、PP AR (5拮抗劑或促效劑、aP2抑制 PPAR a / r雙重促效劑、二肽基肽酶IV ( DP4 ) 劑、S GLT2抑制劑、糖原磷酸化酶抑制劑及/或美葛 (m e g 1 i t i n i d e )及/或類高血糖素胜肽—1 ( G L P — 1 及/或PTP — 1 B抑制劑(蛋白質酪胺酸磷酸酶一 1 B 劑)及胰島素及緩釋型胰島素(Basulin ™ ( Flamel ) ο 抗糖尿病劑可爲經口抗高血糖劑,以雙胍爲佳, i d ant 119 9- c υ 1 a r 1 1-20 型或 日一 漸漸 合使 抗高 包括 劑、 如纖 劑、 抑制 提尼 )^ 抑制 ) 諸如 -54- 200522950 (50) 美弗明(m e t f o r m i η )或吩弗明(p b e n f o r m i η )或其鹽,以 美弗明HC1爲佳。 當抗糖尿病劑爲雙胍時,結構I化合物相對於雙胍之 使用重量比係介於約〇 · 〇 〇 1 : 1至約1 0 : 1範圍內,以約 0.01 : 1至約5 : 1爲佳。 抗糖尿病劑亦可較佳地爲磺醯脲,諸如優降糖 (glyburide)(亦稱爲葛來本克買(glibenclamide))、 葛來米比瑞 (glimepiride )(揭示於美國專利第 4,3 79,7 8 5號中)、葛來比瑞(glipizide )、葛來克瑞 (gliclazide)或克洛普買(chlorpropamide)、其他已知 之磺醯脲或其他可作用於B -細胞之ATP相依性通道的 抗高血糖劑,以優降糖(glyburide)及葛來比瑞 (glipizide )爲佳,其可使用相同或個別之經口劑型投 藥。 結構I化合物可採用相對於磺醯脲介於約〇 · 〇1 : 1至 約100 ·· 1範圍內之重量比,以約0.02 ·· 1至約5 ·· 1爲 佳。 經口抗糖尿病劑亦可爲葡糖苷酶抑制劑,諸如阿+ 司(acarbose)(揭示於美國專利第 4,904,769號)或米 葛里托(miglitol )(揭示於美國專利第4,63 9,43 6號)’ 其可使用相同或個別之經口劑型投藥。 結構I化合物可於相對於葡糖苷酶抑制劑之重量& # 於約0.0〗:1至約1 0 0 : 1範圍內的情況下使用’以約 0 · 0 5 : 1至約1 0 : 1爲佳。 -55- 200522950 (51) 結構I化合物可與下列者結合使用:P P A R 7促效劑 諸如噻唑烷二酮經口抗糖尿病劑或其他胰島素敏化劑(其 於NIDDM患者體內具有胰島素敏感性效應)諸如托葛塔 宗(troglitazone) ( Warner-Lambert5 s Rezulin ®,揭示 於美國專利第4,5 72,9 1 2號)、若西塔宗(rosiglitazone )(SKB )、比葛塔宗(pioglitazone ) ( Takeda )、
Mitsubishi’s MCC — 5 5 5 (揭示於美國專利第 5,5 94,0 1 6 號)、Glaxo-Welcome’sGL-262570、因葛塔宗( englitazone) (CP-68722,Pfizer)或達葛塔宗( darglitazone) ( CP-86325,Pfizer)、伊沙葛塔宗( isaglitazone ) ( MTI / J&J ) 、JTT - 50 1 ( JPNT /
P&U ) 、L - 895645 ( Merck) 、R — 1 1 9 7 02 ( S anky 〇/WL )、NN — 23 44 ( Dr. Reddy/ NN )或 YM— 440 (
Yamanouchi ),以若西塔宗(rosiglitazone)及比葛塔宗 (pioglitazone )爲佳。 結構I化合物之用量相對於噻唑烷二酮之重量比係介 於約 0 · 01 : 1至約 1 〇 〇 : 1範圍內,以約 0.0 5 : 1至約 1 0 : 1爲佳。 可在含有結構I化合物之單一錠劑中摻入低於約1 5 0 毫克之量的經口抗糖尿病劑之磺醯脲及PPAR r促效劑。 結構I化合物亦可與抗高血糖劑諸如胰島素或緩釋型 胰島素(Basulin ™ )或與類高血糖素胜肽—1 ( GLP -1 )或模擬物諸如GLP - 1 ( 1 — 36 )醯胺、GLP - 1 ( 7 -36 )醯胺、GLP - 1 ( 7 — 37 )(如Habener之美國專利第 -56- 200522950 (52) 5,6 1 4,4 92號所揭示,其揭示以引用方式倂入本文)及 AC2993 (Aniylin)及 LY— 315902 (Lilly)結合使用,其 可經注射、鼻內、吸入或經皮或經頰裝置投藥。 若存在’則美弗明(metf〇rmin )、磺醯脲諸如優降 糖(glyburide)、葛來米比瑞(giimepiri(ie)、葛來比瑞 (glipizide)、克洛普買(chlorpropamide)或葛來克瑞 (gliclazide )及葡糖苷酶抑制劑阿卡伯司(acarb〇se )或 米葛里托(miglitol )或胰島素(可注射、肺部、經頰或 經口)可使用於前述調配物中,且如physician,s Desk Reference ( PDR)所示般之用量及投藥。 若存在’則美弗明或其鹽可採用每日介於約5 0 0至約 2 0 00毫克範圍內之量,其可使用單次或分次劑量每日投 藥一至四次。 若存在’則PPAR抗糖尿病劑可採用每日介於約〇.〇1 至約2000毫克範圍內之量,其可使用單次或分次劑量每 曰投藥一至四次。 若存在’則胰島素及其他前述抗糖尿病劑可採用 Physician’s Desk Reference所示之調配物、用量及投藥方 式。 若存在’則GLP - 1胜肽或模擬物可以經口頰部調配 物、經鼻投藥或非經腸投藥,如美國專利第5,3 46 ; 701號 (TheraTech)、第 5,6 1 4,492 號及第 5,631,224 號所述, 其係以引用方式併入本文。 抗糖尿病劑或其他脂質劑亦可爲PPAR調節劑,諸如 -57- 200522950 (53) P P A R α / r雙重促效齊}j,諸如特沙塔扎(t e s a g 1 i t a z a r ) (AstraZeneca )、慕瑞塔扎(muraglitazar) ( Bristol Myers — Squibb ) 、 MK — 76 7 ( Merck / Kyorin /
Banyu) 、GW — 409544 ( Glaxo — Wellcome) 、K R P 2 9 7 (Kyorin Merck)及 Murakami 等人 ^ A Novel Insulin Sensitizer Acts As a Coligand for Peroxisome Proliferation-Activated Receptor Alpha ( P P A R alpha ) and PPAR gamma. Effect on PPAR alpha Activation on Abnormal Lipid Metabolism in Liver of Zucker Fatty Rats’,,Diabetes 47,184 卜 1847 ( 1998)及 2000 年 9 月 18日申請之美國申請案序號 09/664,5 98 (代理人檔案 L A 2 9 )所揭示者,其揭示係以引用方式倂入本文,採用 本發明所列之劑量,其中指稱之較佳化合物有利於使用在 本發明。 抗糖尿病劑可爲SGLT2抑制劑,諸如美國專利第 6,4 1 4,1 2 6號及第6,5 1 5 5 1 1 7號所揭示,採用本發明所列之 劑量。較佳者係爲前述專利所稱之較佳化合物。 抗糖尿病劑可爲 aP2抑制劑,諸如美國專利第 6 5 5 4 8,5 2 9號所揭示,採用本發明所列之劑量。較佳係爲 前述專利所述之較佳化合物。 抗糖尿病劑可爲 DPP4抑制劑’諸如美國專利第 6,3 95,767號、美國專利第6,5 73,2 8 7號、美國專利第 6,395,767 號(BMS-477118 (較佳)、BMS-471211 及 BMS 5 3 8;3 0 5 ) 、WO 99/3 8 5 0 1、WO 99/462 72、 -58- 200522950 (54) WO 99/67279 ( PROBIODRUG ) 、WO 99/6 72 7 8 (
PROBIODRUG ) 、W099/6 1 43 1 ( PROBIODRUG ) 、NVP —LAF — 237、Hughes 等人,Biochemistry,38 ( 36 ), 11597-11603,1999 所揭示之 NVP — DPP728A ( 1— [[[2 — [(5 -氰基吡啶一 2—基)胺基]乙基]胺基]乙醯基]一 2-氰基—(S )—吡咯烷)(Novartis ) 、TSL — 225 (色胺 醯基一 1,2,3,4 —四氫—異D奎啉—3 -羧酸(Yamada等 人,Bioorg. & Med. Chem. Lett. 8 ( 1 99 8 ) 1 5 3 7- 1 5 40 所揭 示)、Ashworth 等人,Bioorg. & Med. Chem. Lett· Vol· 6, No. 22,pp 1163-1166 及 2745-2748 ( 1996)所揭示之 2 -氰基吡咯烷及4 -氰基吡咯烷,採用前述參考資料所列 之劑量。 可視情況與本發明式I化合物結合使用之美葛提尼 (nieglitinide)可爲瑞帕葛尼(repaglinide)或 Starlix ® (Novartis)、耐特葛尼(nateglinide) (Novartis)或 KAD 1 229 (PF/Kissei),以瑞帕葛尼(repaglinide) 爲佳。 抗糖尿病化合物可爲極黑激素(m e 1 a η 〇 c 〇 r t i η )受體 促效劑,諸如WO 99/64002揭示之螺哌啶( spiropiperidine ) 〇 式I之HMG CoA還原酶抑制劑係在相對於美葛提尼 (meglitinide ) 、PPAR 調節劑諸如 PPAR 促效劑、 P P A R α促效齊彳、P P A R δ促效劑或拮抗劑、P P A R a / r雙 重促效劑、aP2抑制齊!J、DP4抑制劑或SGLT2抑制劑或其 •59- 200522950 (55) 他抗糖尿病劑之重量比介於約0 . 〇 l ·· 1至約1 〇 0 : 1範圍 內使用,以約0 · 0 5 : 1至約10 : 1爲佳。 其他可視情況與式I之HMG CoA還原酶抑制劑一起 使用的類型之療劑可爲1、2、3或更多種抗肥胖劑,包括 石3腎上腺素能促效劑、脂酶抑制劑、血淸素及/或多巴 胺調節劑/模擬物、正腎上腺素(NE )調節劑/模擬 物、aP2抑制劑、甲狀腺受體yg藥物、PTP 一 1 b抑制劑、 食慾抑制劑、P P A R調節劑包括p p a R 7拮抗劑、P P A R α 促效劑、PPAR 5拮抗劑、CCKA促效劑、纖體素 (leptin )受體活化劑、神經肽Y拮抗劑、褪黑激素一 4 一受體(MC4R )促效劑、CB - 1倒轉促效劑、脂肪酸氧 化調高劑或誘發劑(諸如 Famoxin ® Genset ) 、5 — Η T 2 c促效劑及乙醯基C ο A羧化酶(A C C )抑制劑。 可視情況與式I化合物結合使用之θ 3腎上腺素能促 效劑可爲 AJ9677 ( Takeda/Dainippon ) 、L7 5 0 3 5 5 (Merck)或CP331648 (Pfizer)或其他已知之3促效 劑,如美國專利第 5,5 4 1,2 0 4號、第 5,7 7 0,6 1 5號、第 5,491,134 號、第 5,776,983 號及第 5,488,064 號所揭示, 以 AJ9677 、 L750,355 及 CP331648 爲佳。 可視情況與式Ϊ化合物結合使用之神經肽Y拮抗劑包 括 WO 0113917 ( BMS )或美國專利第 6;2】8,4 08號 (Synaptic )及 WO 0 1 1 4 3 7 6 ( Banyu)所描述者。 可視情況與式I化合物結合使用之脂酶抑制劑可爲歐 里司特(o】istat)或 ATL - 962 (A】izy】ne),以歐里司特 -60- 200522950 (56) (orlistat)爲佳。 可視情況與式I化合物結合使用的血淸素及多巴胺調 節劑/模擬物及/或正腎上腺素調節劑/模擬物可爲西布 托胺(s i b u t r a m i 11 e )。 可視情況與式I化合物結合使用之食慾抑制劑可爲托 比瑞買(topi 1’a mate) 、Axokine ® ( Regeneron)(睫神 經營養因子的同質物)、得沙吩塔胺(dexamphetamine ) 、吩特胺(phentermine )、苯基丙醇胺或氯苯咪吲哚 (mazindol),以得沙吩塔胺(dexamphetamine)或托比 瑞買(topiramate )爲佳 ° 可視情況與式I化合物結合使用之甲狀腺受體/3化合 物可爲 WO 97/2 1 993 ( U. Cal SF ) 、WO 99/003 5 3 (KaroBio ) 、GB 98/2 84425 ( KaroBio )及 2000 年 2 月 17日申請之美國臨時申請案60/ 1 8 3,22 3所揭示之甲狀腺 受體配位體,以KaroBio申請案及前述美國臨時申請案之 化合物爲佳。 可使用之A C C抑制劑的實例係包括W 0 0 3 / 0 7 2 1 9 7所 描述者。 可採用之 C B — 1促效劑的實例係包括 S R- 1 4 1 7 1 6 (Sanofi)及 FLV — 319 ( Folvay)。 可使用之5 — HT2c促效劑的實例係包括WO 00/7 70 1 0 所揭示之化合物。 本發明可使用之 CCKA促效劑係包括 Glaxo-Smith Kline’s GI — 181,771 及 Sanofi’s SR146,131 〇 -61 - 200522950 (57) 可爲抗肥胖及/或抗糖尿病劑的PTP - 1 B抑制劑包 括 WO 99/585,521、WO 99/58518、WO 99/58522 及 W〇99/6 1 43 5所揭示者。 所採用之抗肥胖劑亦可爲Pfizer's P5 7或 C P — 6 4 4,6 7 3 ( P h y t 〇 p h a r m 認證)。 前述各種抗肥胖劑可使用於與式I化合物相同之劑型 中或於不同之劑型中,劑量及投藥計劃通常係技術界或 PDR已知。 可與本發明HMG CoA還原酶抑制劑結合使用之抗高 血壓劑係包括ACE抑制劑、血管收縮素II受體拮抗劑、 MR促效劑、NEP抑制劑諸如卡朵沙提(candoxatril )、 NEP/ ACE抑制劑及鈣通道阻斷劑(諸如唯瑞帕米( verapamil)及比西酸阿洛氐平(amlodipine besylate)、 丁一通道錦拮抗劑(諸如米貝弗氏(mibefradil)、石一腎 上腺素阻斷劑、利尿劑、α -腎上腺素阻斷劑(諸如甲磺 酸朵沙若辛(doxazosin mesylate)及提瑞若辛HC1 ( terazosin HC1 )、雙重作用受體拮抗劑(DARA )、心臟 衰竭藥物諸如地高辛(digoxin )及其他類型抗高血壓 劑。 可使用於本發明之血管收縮素轉化酶抑制劑包括含有 氫硫基(一 S -)部分者,諸如經取代之脯胺酸衍生物, 諸如前述Ondetti等人之美國專利第4,046,8 89號所揭示 之任一者,以卡托比(captopril) ,gp,1 一 [(2S) — 3 一氫硫基一 2 -甲基丙醯基]-L 一脯胺酸,爲佳,及經取 -62- 200522950 (58) 代之脯胺酸的氫硫基醯基衍生物,諸如美國專利第 4,3 1 6,9 06號所揭示之任一者,以若吩諾比(zofenopril) 爲佳。 可使用於本發明之含氫硫基ACE抑制劑的其他實例 包括揭示於 Clin. Exp. Pharmacol. Physiol· 10 :】31 ( 1983)之瑞提比(rentiapril) (吩提比(fentiapril) Santen);及比唯比(prvopril)及 YS980。 可使用於本發明之血管收縮素轉化酶抑制劑的其他實 例係包括前述美國專利第4,3 74,829號所揭示之任一種’ 以N-(1 一乙氧羰基一 3—苯基丙基)一 L一丙胺醯—L — 脯胺酸(即因那列比(enalapril ))爲佳,美國專利第 4,45 2,7 90號所揭示之經膦酸酯取代的J安基或亞胺基酸或 鹽類中之任一種,以(S ) — 1 一 [6 —胺基—2 —[[羥基一 (4 一苯基丁基)膦基]氧基]一 1 一合氧基羥基]一 L一脯胺 酸或(西若那比(ceronapril ))爲佳,前述美國專利第 4,1 6 8,267號所揭示之膦基烷醯基脯胺酸,以弗辛諾比 (fosinopril )爲佳,美國專利第4,3 3 7,20 1號所揭示之經 膦基烷醯基取代之脯胺酸中之任一種,及前述美國專利第 4,43 2,97 1號所揭示之膦醯胺酸酯。 較佳 A C E抑制劑係爲卡托比(c a p t 〇 p r i 1 )、弗辛諾 比(fosinopril)、因那列比(enalapril)、里辛諾比( lisinopril)、西塔比(cetapril)、西列扎比(cilazapril )、因達列比(inda】april )、司拜瑞比(spirapril )、派 瑞朵比(perindopril)、西瑞那比(ceranapril)、奎那比 -63- 200522950 (59) (q u i li a p r i 1 )、本那扎比(b e n a z e p r i 1 )、吩提比( fentiapril)、瑞米比(ramipril)及莫西比(moexipril) o NEP/ACE抑制齊U因其具有中性肽鏈內切酶(NEP) 抑制活性及血管收縮素轉化酶(ACE )抑制活性而亦可使 用於本發明。適用於本發明之NEP/ ACE抑制劑的實例係 包括美國專利第 5,3 62,72 7號、第 5,3 6 6,9 73號、第 5,22 5,4 0 1 號、第 4,722,8 1 0 號、第 5,223,5 1 6 號、第 4.749.6 8 8 號、第 5,5 5 2,3 97 號、第 5,5 04,0 8 0 號、第 5.6 1 2,3 5 9號、第 5,5 2 5,72 3號、歐洲專利申請案第 0599,444 號、第 0481,522 號、第 0599,444 號、第 0 5 9 5,61 0號、歐洲專利申請案第 05 3 43 63A號、第 5 3 4,3 96 號及第 5 3 4,492 號及歐洲專利申請案第 0629627A2號所揭示者。 較佳者係爲前述專利/申請案中所稱較佳之NEP / A CE抑制劑及其劑量,該等美國專利係以引用方式倂入本 文;最佳者係爲歐馬帕垂列(〇 m a p a t r i 1 a t )、吉莫帕垂列 (gemopatrilat ) ([S[(R*,R* )] 一六氫—6— [(2 —氫 硫基一 1 一合氧基一 3 —苯基丙基)胺基]一 2,2 —二甲基 —7 -合氧基—1H —氮呼—1—乙酸]及CGS 30440。 適用於本發明之血管收縮素11受體拮抗劑(本發明 亦稱爲血管收縮素II拮抗劑或All拮抗劑)包括(但不 限於)爾貝沙滇(irbesartan )、洛沙滇(I osartan )、唯 沙》県(v a 1 s a r t a η )、坎得沙搞(c a n d e s a r t a η )、特索沙滇 -64- 200522950 (60) (tasosartan )或伊波沙滇(eprosartan ),以爾貝沙滇( irbesartan )、洛沙滇(1 〇 s a r t a η )或唯沙滇(v a 1 s a r t a η ) 爲佳。 較佳經口劑型,諸如錠劑或膠囊,含有量介於約0.1 至約5 0 0毫克範圍內之ACE抑制劑或All拮抗劑,以約5 至約200毫克爲佳,而約10至約150毫克更佳。 應認知ACE抑制劑及All掊抗劑之較佳劑量係如最 新版 Physician’s Desk Reference ( PDR)所歹U。 適用於本發明之雙重作用受體拮抗劑(DARA )係包 括2000年2月25日申請之美國申請案序號09/513,779 及2000年6月26日申請之序號09/6 04,322所揭示者。 適用於本發明之較佳抗高血壓劑的其他實例係包括歐 馬帕垂列(omapatrilat) (Vanlev ®)、吉莫帕垂列( gemopatrilat )、比西酸阿洛氏平(amlodipine besy late ) (Nor vase®)、普瑞若辛(prazosin) HC1(
Minipress ®)、唯瑞帕米(verapamil)、尼非氐平( nifedipine)、氏提真(diltiazem)、非洛氏平( felodipine)、尼索氏平(nisoldipine)、伊瑞氏平( isradipine)、尼卡氏平(nicardipine) 、yS阻斷劑諸如那 朵洛(nadolol)、阿滇諾洛(atenolol) (Tenormin ®) 、索塔洛(sotalol )、提瑞若辛(terazosin )、朵沙若辛 (doxazosin)、卡唯氐洛(carvedilol)及普瑞諾洛( propranolol)及可樂定(cion idine) HC1 (Catapres ®) 〇 -65- 200522950 (61) 可與式I化合物結合使用之利尿劑包括氫氯噻畊 (hydrochlorothiazide)、托瑞西買(to rase mide)、弗若 西貝(furosemide)、螺內酯及趑磺苯酸胺(incjapamide )° 可與本發明式I化合物結合使用之抗血小板劑包括阿 斯匹靈、克洛比朵吉(clopidogrel )、提克洛比定 (ticlopidine)、二吡啶達摩(dipydidamole) 、CS— 747 (Lilly)、阿西色買(abciximab)、提若弗本( tirofiban)、伊提弗本特(eptifibatide)、阿那吉來( anagrelide ) 及伊弗托本(ifetrobail ),以克洛比朵吉 (clopidogrel)及阿斯匹靈爲佳。 可與本發明式I化合物結合使用之抗血栓劑係包括美 列扎托(melagatran )及西美列扎托(xinleiagatran ) (Exanta m Astra Zeneca)。 該抗高血壓劑、利尿劑及抗血小板劑可在P D R所示 之量下使用。伊弗托本(ifetroban )可在美國專利第 5,1 0 0,8 8 9號所列之量下使用。 適用於本發明與本發明Η M G C ο A還原酶抑制劑一起 使用的抗阿茲海默氏症劑或抗癡呆劑係包括9 一胺基四氫 π 丫 Π定(tacrine) HCl(Cognex ®)及朵尼比吉( donepezil ) ( A ricept ® ),及 r 一分泌酶抑制劑、/3 — 分泌酶抑制劑及/或抗高血壓劑。所採用之劑量係列於 PDR。 適用於本發明與本發明HMG CoA還原酶抑制劑結合 -66- 200522950 (62) 使用之抗骨質疏鬆劑係包括副甲狀腺激素或雙膦酸酯,諸 如 MK — 217 (阿列朵耐(alendronate) (Fosamax ®)及
Ca受體促效劑及黃體素受體促效劑。採用之劑量係列於 PDR。 若存在’則激素替補療劑之使用劑量係列於最新版 PDR。該等藥劑之實例係包括選擇性雌激素受體調節劑 (SERM )諸如瑞洛西吩(raloxifen )、塔莫西吩 (tamoxifen )或列索西吩(lasoxifen)。 本發明HMG CoA還原酶化合物亦可與酪胺酸激酶抑 制劑諸如WO 2 000/0 5 3 605所揭示者結合使用; 適用於本發明之選擇性雄激素受體調節劑(SARM ) 可爲 LGD — 2226 (Ligand) ‘或 WO 03/011824 所揭示之化 合物。 適用於本發明之抗心律不整劑係包括本發明所列之冷 一阻斷劑,包括索塔洛(sotalol )及阿米歐得榮 (amioderome),本發明所列之鈣通道阻斷劑,包括唯瑞 帕米(verapamil)、尼非氏平(nifedipine)、比西酸阿 洛 S 平(am]odipine besylate)及氐提真(diltiazem), 其亦可與debrillator裝置諸如起搏器結合使用; 輔酶Q sub.10,諸如美國專利第5,3 1 6,7 6 5號、第 4,93 3,165 號、第 4,929,43 7 號所揭示; 調高第III型內皮細胞硝酸合成酶之藥劑,諸如 WO 2 0 00/00 3 746 所揭示; 軟骨保護性化合物,諸如多硫酸化胺基多糖 -67- 200522950 (63) (PSG AG )、葡萄糖胺、軟骨素硫酸酯(C S )、透明質 酸(HA )、戊聚糖多硫酸酯(PPS )、朵西塞克林 (doxycycline)或米諾塞克林(minocycline),諸如 EP 9 7 0 6 9 4所揭示; 環氧合酶(COX ) - 2抑制劑,諸如西列克西 (celecoxib( Celebrex ® (Sear le))或若弗克西( rofecoxib) (Vixx ® (Merck))或糖蛋白 Ila/nib 受 體拮抗劑,諸如 WO 99/4 5 9 1 3所揭示,及提若弗本 (tirofiban)或阿西色買(abciximab); 5 — HT攝取抑制劑,諸如WO 99/44609所揭示; 抗心絞痛劑,諸如血管舒張劑,例如異山梨醇二硝酸 酯或硝基甘油; 生長激素促分泌劑,諸如2 0 0 0年9月1 4日申請之美 國申請案序號09/662,448及2000年5月11日申請之美 國臨時申請案 60/203,3 3 5 所揭示,及 MK — 677 (Merck) 、Pfizer’s CP - 424391 及 Lilly,s LY 444,711 ; 抗動脈硬化劑,諸如本發明所描述之A C A T抑制劑及 脂肪氧化酶抑制劑及磷脂酶抑制劑; 抗感染劑諸如D奎啉酮,例如西普弗沙辛( ciprofloxacin)、歐弗沙辛(ofloxacin)及 Tequin ® ( Bristol-Myers Squibb )、大環內酯諸如紅黴素及克瑞托黴 素(clarithromycin) (Biaxin ® (Abbott))及阿吉托黴 素(azithromycin ( Zithromax ( Pfizer));或 免疫抑制劑(使用於移植)諸如環胞黴素、黴酚酸嗎 -68- 200522950 (64) 啉乙酯(m y c o p h e η ο ] a t e in o f e t i 1 )、硫唑嘌呤( azathioprine)及其類者。 本發明所使用之 ''抗贅瘤劑〃一辭係指防止癌細胞繁 殖之化合物。通常,本發明所使用之抗贅瘤劑藉以下方式 防止癌細胞繁殖:(1 )干擾細胞複製DNA之能力或 (2 )在癌細胞中誘發細胞凋亡。 適用於本發明組合物之抗贅瘤劑的實例係包括(但不 限於)微管安定化劑,諸如紫杉烷,例如帕克里塔色( paclitaxel)(亦稱爲 Taxol ®)、朵西塔色(docetaxel )(亦稱爲Taxotere ®) 、7- 0 -甲基硫基一甲基帕克 里塔色(揭示於U.S· 5,646,176中)、3,一第三丁基一 3^ — N -第三丁氧羰基—4 —脫乙醯基—3 — —脫苯基— 广一 N-脫苄醯基一 4一 0 -甲氧羰基帕克里塔色(揭示 於2000年2月3日申請之USSN 60/ 1 79,965中,及本文 實施例1 7 ) 、C - 4甲基碳酸酯帕克里塔色(揭示於 W0 94/14787)、伊波查隆(epothilo n e),諸如伊波查隆 A、伊波查隆B、伊波查隆C、伊波查隆d、脫氧伊波查 隆 A、脫氧伊波查隆 B、[1S— [1R*,3R*(E) ,7R*, 10S*,UR*,12R*,i6S*]]-7,11-二羥基—8,8, 10,12,16 —五甲基一 3— p —甲基 _2 一 (2 —甲基一 4 一 噻唑基)乙烯基]一 4 一氮雜—17 -氧雜雙環[14.1 ·〇]十七 烷一 5,9 一二酮(揭示於 w〇 99/02514 中)、[1S — [1R*,3R* (E) ,7R*,l〇S*,11R*,12R*,16S*]]-3 一 [2 — [2 — (胺基甲基)一 4 —噻唑基]_ι 一甲基乙烯基] -69- 200522950 (65) —7,11—二羥基一8,8,10,12,16 —五甲基一4,17 — 二氧雜雙環[14.1.0]十七烷—5,9一二酮(揭示於2000年 2月17日申請之USSN 09 / 5 06,48 1及本文實施例7及8 中)、及其衍生物;微管破裂劑;烷基化劑;抗代謝劑; 伊比朵洛毒素(e p i d 〇 p h y 11 〇 t ο X i η );抗贅瘤酶;拓樸異 構酶抑制劑;鹽酸甲基卡肼(procarbazine ):米托珊托 酮(mitoxantrone );鉑配位錯合物;生物反應修飾劑; 生長抑制劑;激素/抗激素療劑;及造血生長因子。 適用於本發明方法之其他類抗贅瘤劑包括(但不限 於)蒽、環類抗生素(anthracycline)類藥物、長春花類藥 物、絲裂黴素、博萊黴素(bleomycin )、胞毒性核苷、 迪斯可莫萊(discodermolide )、碟H定類藥物、二炔j:希類 (d i y n e n e s )、芳香酶抑制劑及鬼臼毒。前述類型中特別 可使用者包括例如阿黴素(d ο X 〇 r u b i c i η )、卡明黴素( carminomycin )、柔紅黴素(daunorubicin)、胺基碟 口令、胺基甲基葉酸(methotrexate)、甲基碟卩令( methopterin )、二氯—胺基甲基葉酸、絲裂黴素C、普弗 若黴素(profiromycin) 、5 —氟尿嚼Π定、6 —氫硫基嘌 D令、金西塔賓(g e m c i t a b i n e )、胞喃Π定阿拉伯糖脊、鬼臼 毒或鬼臼毒藥物,諸如鬼臼乙叉苷(etopo side )、磷酸鬼 臼乙叉苷或鬼臼噻吩苷(teniposide)、溶肉瘤素( melphalan)、長春花驗(vinblastine)、長春新驗( vincristine )、異長春鹼(leurosidine)、長舂驗酿胺( vindesine)、環氧長舂鹼(leurosine)及其類者。其他可 -70- 200522950 (66) 使用之抗贅瘤劑包括雌氮芥(es tram u stine )、順鉑( cisplatin )、碳鉑(carbopl at i η )、環磷醯胺、博萊黴素 (bleomycin)、塔莫西吩(tamoxifen)、伊弗司醯胺( ifosfamide )、溶肉瘤素 (m e 1 p h a 1 a η )、六甲基三聚氰 胺、噻替哌(thiotepa )、阿糖胞苷(cytarabin )、艾得 托沙(idatrexate)、垂美托沙(trimeti. exate)、達卡巴 肼(dacarbazine) 、L —天冬胺酸酶、喜樹鹼( camptothecin) 、CPT — 11、拓樸特坎(topotecan) 、ara-C、拜卡塔醯胺(bicalutamide)、弗路特醯胺( flutamide )、脯胺醯胺酸(leuprolide )、吡啶并苯并吲 哚衍生物、干擾素及間白素。 應瞭解除非另有陳述,否則與本發明化合物結合使用 之療劑的投藥計劃係列示於P D R。 進行本發明治療血中膽固醇過高、血脂過高、血中脂 蛋白過高、血中三酸甘油酯過高或動脈硬化及相關疾病、 或阿茲海默氏症或骨質疏鬆症或其他前述揭示之方法時, 採用含有結構I化合物之醫藥組成物,其含或不含其他膽 固醇降低劑、骨質疏鬆藥劑、阿茲海默氏症藥劑、抗糖尿 病劑及/或抗血脂過高藥劑及/或其他類型療劑,且結合 醫藥媒劑或稀釋劑。該醫藥組成物可採用習用固體或液體 媒劑或稀釋劑及適用於所需投藥模式之醫藥添加劑,諸如 醫藥上可接受之載體、賦形劑、黏合劑及其類者。該等化 合物可使用經口路徑,例如錠劑、膠囊、珠粒、顆粒或粉 末形式’投予哺乳類,包括人類、猴、犬等,或其可鼻內 -71 · 200522950 (67) 或以經皮敷劑投藥。一般固體調配物係含有約0. 1至約 5〇〇毫克式I化合物。用於成人之劑量以介於每日〇.5及 1,〇 〇 〇毫克之間爲佳,其可以單一劑量或以個別劑量形式 每曰投藥1至4次,亦可使用單一劑量每週投藥一次(5 至1 000毫克)。 一般注射用製劑係藉著將25 0毫克結構I化合物無菌 地放置於管瓶內,無菌地冷凍乾燥並密封。使用時,管瓶 之內容物與2毫升生理食鹽水混合,以製得注射製劑。 實施例及本發明其他地方係使用下列縮寫: // L=微升 AcCN=乙腈 a q .=水溶液 Β η =爷基
Boc=第三丁氧羰基 b p =沸點
Cbz =苄氧羰基或苄氧羰基或苄基氧基羰基 DEAD =偶氮基二羧酸二乙酯
Dess— Martin氏派歐啶烷=1,1,1_三(乙醯氧 基)—1,一 氫—1,2-苯并吗索(benziodoxol) — 3 一(1 Η )—酮 D I水二去離子水 DIBAL=氫化二異丁基鋁 DIPEA =二異丙基乙胺 D M PU =1,3 —二甲基-3,4,5,6 —四氫一2 -72- 200522950 (68) (1 Η ) -嘧啶酮 EDAC=3 —乙基一 3〃 —(二甲胺基)丙基—碳化二 醯亞胺鹽酸鹽(或1 一 [(3-(二甲基)胺基)丙基])一 3 -乙基碳化二醯亞胺鹽酸鹽)
Et =乙基 Et2NH=二乙胺 FMOC二荞基甲基氧基羰基 g =克 h或 h r =小時 HOAc或AcOH =乙酸 H0AT = 1 -羥基一 7 —氮雜苯并三唑 H0BT或HOBT· H20=1—羥基苯并三唑水合物 HPLC =高效液相層析 i — BU =異丁基 L =公升 LC/ MS =高效液相層析/質譜 LDA=二異丙基醯胺鋰
LiHDMS =雙(三甲基甲矽烷基)醯胺鋰 LiN(TMS)二Li雙(三甲基甲矽烷基)醯胺 MCPMA二間一氯一對一苄酸 M e =甲基 m e q =毫當量 m g二毫克 m i η =分鐘 -73- 200522950 (69) mL二毫升 m m ο 1二毫莫耳 m ο 1 =莫耳 m ρ =熔點 MS 或 Mass Spec =質譜 MTBE二甲基第三丁基醚
NaHMDS二雙(三甲基甲矽烷基)醯胺鈉 n— BuLi=正丁基鋰 Ν Μ M = N —甲基嗎啉 Ν Μ Ο二甲基嗎啉Ν -氧化物 NMR=核磁共振光譜
Pd/ C=碳上鈀
Ph =苯基 PPh3 =三苯膦 P t Ο 2二氧化鉑 PTSH=N-苯基硫基四唑
PyBOP試劑=六氟磷酸苯并三唑—1 一基氧基三吡咯 院基鱗
Red — AL=氫化雙(2—甲氧乙氧)鋁鈉 RT,rt =室溫 sat或 sat’d =飽和 TEA=三乙基胺 TEMPO=2,2,6,6 —四甲基一]一哌啶基氧基自由 -74- 200522950 (70) TFA =三氟乙酸 TLC =薄層層析 TMS二三甲基甲矽烷基 TPAP二過釕酸四丙基錢 實施例 以下實施例係出示本發明較佳實施例。實施例中所列 之化合物名稱(除非另有陳述)可使用ChemDraw Ultra v 6·0·4中之AutoNom ( v 2.1 )功能轉化成結構圖示。 實施例1
此化合物係根據 M a s a m i c h i W a t a n a b e e t a 1. (Bioorganic & Medicinal Chemistry ( 1997) ,5 ( 2), 4 3 7-444 ; Eur. Pat. Appl. 1 993,18pp. EP 52 1 1 47 1 ) 〇 所 記載之方法製備。 -75- 200522950 (71)
來自A部分之化合物(3.7克,1〇·〇毫莫耳)於1〇0 毫升甲苯中之溶液在—70°C下逐滴添加DIBAL(在二氯 甲烷中1M,25毫升,25毫莫耳)。在一 70 °C下攪拌〇.5 小時後,反應混合物藉著謹慎地添加飽和氯化銨溶液且於 RT攪拌0.5小時而中止反應。分離有機層’以MgSCU乾 燥,濃縮,所得之粗產物進行快速層析(矽膠/己烷-EtOAc 80 : 20至20 : 8 0梯度,產生標題化合物之白色固 體(2克,61%產率)。
B部分之標題化合物(2克,6.2毫莫耳)、TEMPO 自由基(Aldrich Chemical Co.,10 毫克)及 KBr( 73 笔 克)於20毫升EtOAc中之溶液在〇°C於攪拌下使用〇·5 小時逐滴添加經緩衝之漂白劑溶液(約〇·9Μ,藉添加固 體碳酸氫鈉調至Ρ Η 9.4 )。混合物連續以1 / 2飽和之硫 代硫酸鈉、〗N NaOH及鹽水洗滌。將有機層乾燥 (MgS04)並濃縮,產生標題化合物1.98克(粗產率99 % )。 -76- 200522950 (72)
C部分之標題化合物(1 . 9 8克,6 . 1毫莫耳)及
(Brodfuehrer,Paul R.等人,PCT Int. Appl. ( 2002 ),WO 0298854,2.79 克,6.1 毫莫耳)於 25 毫升 THF 中之溶液在一7 8 °C於攪拌下逐滴添加雙(三甲基甲矽烷 基)醯胺鋰(在THF中1M,7.75毫升,7.75毫莫耳)。 在-78°C下15分鐘後,混合物藉著添加飽和NaHC03而 中止反應,以EtOAc萃取,乾燥(MgS04 ),濃縮,粗產 物以快速層析純化(矽膠/己烷EtOAc 1 00 : 0至50 : 50 梯度)產生1 · 1克標題化合物之蒼色發泡狀固體。
雙(三甲基甲矽烷基)醯胺鋰(在THF中1.0M,407 毫升,0.47莫耳)在0°C於氮下以65分鐘添加於2-甲基 —2 Η — [ 1,2,4 ]三唑一 3 —基胺(3 7 · 5 克,0 · 3 7 莫耳,如 -77- 200522950 (73)
Barascut,Jean L·等人,Bull. Soc. Chim. Fr· ( 1973), (5)第2部分,U49— 53所述般製備)及碘甲烷(66.6 毫升,1.11莫耳)於THF(1.2公升)中之攪動溶液中。 在〇 °C下攪拌1 . 5小時後,以1 0分鐘添加附加之雙(三甲 基甲矽烷基)醯胺鋰(在THF中1.0M,90毫升,0.09莫 耳)。攪拌另2.5小時後,一份之】H NMR顯示有9%起 始物質,74%所需產物(甲基—(2—甲基—2Η— [1,2, 4]三唑一3 —基)胺)及 17%三甲基化產物(二甲基一 (2 —甲基一 2Η—[1,2,4]三唑一 3 —基)一胺),反應 以水(〜7毫升)中止反應並於真空中蒸發。濾出在反應 體積減少至500毫升時所形成之白色固體。將濾液蒸發產 生22 8克粗產物。粗產物進行層析(鋁活性1/ EtOAc — CH2C12)產生 20·1 克(48%)甲基一(2 —甲基一2H — [1,2,4]三唑—3 —基)一胺。 NMR ( CDC13 ) 5 7·40 ( 1H,s) ,4.71 ( 1H,寬 峰 s) ,3.48(3H,s),及 2.92(3H,d,J=5.0Hz)。 13C NMR ( CDC13) ppm 156.0,147.8,32.9,及 29.9。 甲基一 (2 —甲基一2H— [1,2,4]三卩坐一 3 —基)一 胺(如前製備,51 .5克,0·46莫耳)於1公升THF中之 攪拌溶液在一 60°C於氮下使用15分鐘添加1Ν雙(三甲 基甲矽烷基)醯胺鋰溶液(4 80毫升,0.48莫耳)。使混 合物來到1 0 °C並攪拌1 5分鐘。反應混合物冷卻至—60 t,形成之漿液以30分鐘移至步驟D標題化合物(200 -78- 200522950 (74) 克,0.3 6 5莫耳)於1公升THF中在— 6(TC下之攪拌溶 液。以1小時使反應混合物來到—17°C,以EtOAc稀 釋,連續以飽和NaHC〇3溶液及鹽水洗滌。將有機層乾燥 並濃縮,所得之粗產物進行快速層析(砂膠/己垸一
EtOAclOO: 〇至50: 50梯度)產生176克白色固體。此 物質自 MeOH —水再結晶,產生標題化合物之白色固體 (1 70 克)。 F.
F
依如同步驟E所述方式製備之標題化合物(2 3 4克’ 402.7毫莫耳)於1公升THF中之溶液中添加IN HCL (403毫升)。反應混合物於RT攪拌6小時,之後添加 NaOH (32.5克)在150毫升水中之溶液,之後添加1〇〇 毫升甲醇。反應混合物於RT攪拌1 · 5小時’以水(2 0 0 毫升)稀釋,並以EtOAc ( 3 x 5 0 0毫升)萃取。將水層濃 縮,殘留物進行逆相層析(C 1 8二氧化矽/水-乙腈 100: 0至70: 30)產生標題化合物之白色固體(166.8 克);分析LC滯留時間=3.30分鐘(YMC ODS S5 4·6 mm X 5 0mm管柱/甲醇-水—磷酸,4分鐘10:90:0.2 至 90: 10: 0.2梯度,4毫升/分鐘流速);(M + H) + 4 8 5 (羧酸)。 -79 - 200522950 (75)
實施例1 A 實施例1 C部分化合物亦可如下製備° A·
(25 0.27 克,1.〇 莫耳,Robl,Jeffrey A·; Chen, Bang-Chi; Sun, Chong-Qing·美國專利第 6,6 2 0,8 2 1號)及硫酸 S —甲基異硫脲陽離子(1 6 2 · 8 4 克,0.585莫耳)於750毫升HMPA中之混合物在攪拌下 於l〇〇t加熱24小時,使之來到RT並以EtO Ac稀釋。 混合物連續以飽和N aH C 03及鹽水洗滌,以硫酸鈉乾燥並 濃縮,產生2 8 6克標題化合物。 B.
-80- 200522950 (76) 步驟A之標題化合物(2 8 6克,0.8 8 7莫耳)於1 . 5 公升M e Ο Η中之溶液在—4 0 °C至-2 0 °C於攪拌下分小批量 添加DDQ ( 1 54克)。混合物使之來到RT並攪拌30分 鐘。此以水稀釋,單離形成之固體,以1 : 1水-乙醇洗 滌,產生標題化合物之白色固體(221克)。 C.
此化合物係自步驟B化合物依如同實施例1步驟B 之標題化合物所述的方式製備。
過氧化氫(30%,5 0 0毫升)於RT下使用1小時添 加於步驟C化合物(424克,1.45莫耳)、七鉬酸銨四水 合物(26.8克,0.022莫耳)及氯化三辛基甲基銨 Aliquat ® 336,Aldrich) ( 58.7 克,0.145 莫耳)於 CH2C12 ( 3公升)中之攪拌溶液(發現放熱導致溶劑回 流)。反應混合物於RT攪拌3小時,連續以水、飽和硫 代硫酸鈉及水洗滌。將有機層乾燥並濃縮,產生470克標 題化合物。 -81 - 200522950 (77) E.
____S〇2Me 此化合物係自步驟D化合物依如同實施例i之步驟c 化合物所述方式製備。 實施例2
F
-82- 200522950 (78) 90: 10: 1)產生 2 —甲基一 2H—吡唑一 3 —基胺與甲 (2 Η _吡唑—3 —基)一胺之1 : 1混合物(〇 · 8克) 混合物於5毫升Ν —甲基吡咯烷酮(ΝΜΡ )中之溶液 於實施例1步驟Α之標題化合物(3克,8 · 0毫莫耳 碳酸鉀(1.5克)於15毫升NMP中之攪拌混合物中 合物於RT攪拌14小時,以二氯甲烷稀釋,以水洗 將有機相乾燥(MgS04 )並濃縮,產生粗產物。此者 快速層析(矽膠/己烷—EtOAc 9 : 1至2 : 1梯度) 0.75克標題化合物(及1.35克起始未反應硕)。 B. 基― 。此 添加 )及 。混 滌, 進行 產生
氫化鉀(經洗滌,24毫克,0.59毫莫耳)於RT 加於步驟A標題化合物(94毫克,0.245毫莫耳)及 甲氧苄基氯(42.2毫克,0.27毫莫耳)於〇·5毫升 中之攪拌溶液中。在RT下攪拌1小時後,混合物以 N a H C 0 3中止反應,以二氯甲烷萃取,乾燥並濃縮。 物以快速層析純化(矽膠/己烷一 E t 0 A c 8 0 : 2 0 ) 40毫克標題化合物之膠質固體。 下添 4 一 DMF 飽和 粗產 產生 -83- 200522950 (79) C.
步驟B化合物(0.3克)如實施例1步驟B標題化合 物合成所述般地使用DIB AL還原,產生0.15克標題化合 物。 D.
步驟c化合物(1 00毫克)係如實施例3步驟F之標 題化合物合成所述般地氧化,產生7 5毫克標題化合物。 E.
此化合物係如實施例1步驟D標題化合物所述般地 製備。 -84- 200522950 (80) F.
來自步驟E之化合物(9 0毫克)於二氯甲烷(5毫 升)中之溶液於RT下以TF A ( 0.5毫升)處理6小時。 混合物以飽和NaHC03洗滌,乾燥並濃縮,產生標題化合 物之膠質固體(75毫克)。
來自步驟F之化合物(10毫克)於THF ( 0.1毫升) 中之溶液中添加IN NaOH (0.022毫升)及水(0.028毫 升)。反應混合物於RT下攪拌0 · 5小時,濃縮’殘留物 進行逆相層析(C] 8二氧化矽/ MeOH -水0 : 1〇〇至 1 00 : 0梯度)產生標題化合物之白色固體(5毫克)’分 析 LC 滯留時間=2.9 分鐘(YMC ODS S5 4·6 mm x50mm 管柱/甲醇一水—TFA,4分鐘 1 0 : 90 ·· 0. 1至90 : 1 〇 : 0.1梯度,4毫升/分鐘流速);(M + H ) + 5 9 0 (殘 -85- 200522950 (81) 酸)。 實施例3
F
F
(3 克;Huebsch,Walter 等人,G e r · Ο f f e η · ( 1 9 9 2 ), DE 4023308; Huebsch,Walter等人,歐洲專利申請案 (1 992 ) ,EP 465 970 )於50毫升THF中之攪拌溶液在 —78°C下添加於THF中之1M LAH(25毫升)。混合物 於〇°C下攪拌1小時,藉添加飽和NaHCCh中止反應,以 EtOAc萃取。有機層以硫酸鈉乾燥,濃縮產生2.65克標 -86- 200522950 (82) 題化合物。
步驟 A標題化合物(2.65克)、三氟乙酸(2毫 升)、10% Pd/C(3克)於50毫升EtOH中之混合物 於氫(5 0 p s i,P a r r搖動器)下搖動8小時。將混合物過 濾,濾液濃縮產生1 . 9克標題化合物。
步驟B標題化合物(1 .9克)於5 0毫升四氟硼酸中 之溶液於-1 〇 °C下分小批量添加3.0克亞硝酸鈉。混合物 於- 1 〇 t攪拌 3 0分鐘,緩緩添加於飽和碳酸氫鈉溶液 中。混合物以 EtOAc萃取,有機相以硫酸鈉乾燥,濃 縮,殘留物以快速層析純化(矽膠/二氯甲烷)產生標題 化合物(1.55克)之白色固體。 -87- 200522950 (83) D.
來自步驟C之標題化合物(1 5克)2 —乙基一 2H -吡 唑一 3 —基胺(1 9· 1克)於THF (250毫升)中之攪拌溶 液於—7 8 °C下添加1 Μ雙三甲基甲矽烷基醯胺鋰(2 1 3毫 升)。混合物使達到RT,之後回流4小時,隨之添加飽 和碳酸氫鈉溶液。混合物以EtOAc萃取,EtOAc層以硫 酸鈉乾燥,濃縮,殘留物快速層析(矽膠/己烷一 EtOAc 90 : 10至80 : 20 )產生標題化合物之棕色固體(12.8 克)。 E.
步驟D之標題化合物(1 2 · 8克)於二氯甲烷(2 0 0毫 升)中之攪拌溶液於—7 8 °C下添加在二氯甲烷中之1 Μ DIB AL ( 96.9毫升)。混合物於—7 81:攪拌1小時,藉添 加水及飽和酒石酸鈉鉀溶液中止反應,於RT攪拌2小 時。混合物以二氯甲烷萃取,有機層以硫酸鈉乾燥,濃縮 -88- 200522950 (84) 產生標題化合物(Π克)之白色固體。
步驟Ε之標題化合物(1 1克)於DMF ( 50毫升)及 二氯甲烷( 3 00毫升)中之攪拌溶液中添加Dess-Martin 氏派歐啶烷(12.6克)。混合物於RT攪拌1小時,以飽 和碳酸氫鈉溶液洗滌,以硫酸鈉乾燥並濃縮。粗產物進行 快速層析(矽膠/己烷—EtOAc 8 0 : 2 0 )產生標題化合物 (7.0克)之棕色固體。
步驟F之標題化合物(7 · 0克)於二氯甲烷(〗0 0毫 升)中之攪拌溶液中連續添加二-第三丁基二碳酸酯 (12.5克)及4 一二甲基胺基吡啶(DMAP,7.01克)。 混合物於RT攪拌5小時,濃縮,殘留物進行快速層析 (矽膠/己烷一 EtO Ac 85 : 15 )產生標題化合物(7.0 克)之棕色固體。 89- 200522950 (85) H.
F
此化合物係如實施例1步驟D之合成所述般地自步
驟G 標題化合物製備。 I.
F
中之 合物 冷溶 甲醇 固體 ODS 10 : (羧
步驟Η之標題化合物(1 1 . 〇克)於9 0毫升二氯甲烷 攪拌溶液於一 1 5 °C下添加三氟乙酸(9 0毫升)。混 於一 15°C攪拌3小時,倒入3N NaOH ( 467毫升)之 液中,濃縮,殘留物進行逆相層析(C 1 8二氧化矽/ —水0: 100至100: 0梯度)產生標題化合物之白色 (4.0克);分析LC滯留時間=1.83分鐘(YMC S5 4.6 mmx50mm管柱/甲醇一水—磷酸,4分鐘 90: 〇·2 至 90: 10: 〇·2 梯度);(Μ + Η) + 497 酸)。 -90- 200522950 (86) 實施例4
F
實施例2步驟D標題化合物(2〇0毫克)於THF ( 5 毫升)中之攪拌溶液在一 78 °C下添加1.0M雙三甲基甲矽 烷基醯胺鋰(5 05微升),反應混合物於一 78 t攪拌15 分鐘。添加碘甲院(2 0 0微升)於反應混合物中,使混合 物達到RT ’攪拌另1小時。混合物以飽和碳酸氫鈉溶液 (3 0毫升)稀釋’以乙酸乙酯(3 0毫升)萃取。乙酸乙 酯層以硫酸鈉乾燥並濃縮。粗產物以快速層析純化(矽膠 /己烷一 EtOAc 90 : 10至70 : 3 0梯度)產生標題化合物 之透明膠(164毫克)。 -91 * 200522950 (87)
標題化合物係如實施例3步驟E之合成所述般地自步 驟A標題化合物製備。
標題化合物係如實施例3步驟F之合成所述般地自步 驟B標題化合物製備。
參 Λ - 標題化合物係如實施例3步驟Η之合成所述般地自 步驟C標題化合物製備。 -92- 200522950 (88)
標題化合物係如實施例3步驟I之合成所述般地自步 驟 D標題化合物製備;分析LC滯留時間二26.7分鐘 (YMC ODS S5 6 mmxl50mm 管柱 / 甲醇—水一磷酸,30 分鐘10:90 :0.2至90:10:0.2梯度,1.5毫升/分鐘 流速);(M + H) + 511 (羧酸)。 實施例5
實施例3步驟D之標題化合物(200毫克)於THF (5毫升)中之攪拌溶液於—78t下添加1.0M雙三甲基 -93- 200522950 (89) 甲矽烷基醯胺 拌1 5分鐘。 應混合物,混 碳酸氫鈉溶液 萃取。乙酸乙 析純化(矽膠 生標題化合物 B. 鋰(5 05微升),反應混合物於一 78 °C下攪 於一 7 8 °C下將甲磺醯氯(7 8微升)添加於反 合物於- 7 8 °C下攪拌1小時。混合物以飽和 (3 0毫升)稀釋,以乙酸乙酯(3 0毫升) 酯層以硫酸鈉乾燥並濃縮。粗產物以快速層 /己烷一EtOAc 90: 10至70: 30梯度)產 之棕色膠(200毫克)。
F
標題化合 驟A標題化合 C. 物係如實施例3步驟E之合成所述般地自步 物製備。
F
標題化合 驟B標題化合 物係如實施例3步驟f之合成所述般地自步 物製備。 -94- 200522950 (90) D.
F
地自 標題化合物係如實施例3步驟H之合成所述 步驟C標題化合物製備。 E.
F
標題化合物係如實施例3步驟I之合成所述般地 驟D標題化合物製備。分析LC滯留時間=23.5 (YMC ODS S5 6 nimxl50mm管柱/甲醇—水一碟酉变 分鐘 10:90:0.2 至 90: 10:0.2 梯度,1.5 毫升 / 流速);(M + H) + 5 75 (羧酸)。 下列化合物係採用實施例1及2所列方法製備: 自步 分鐘 ,30 分鐘 -95- 200522950 (91)
I實施例編號 結構 MS [Μ+Η]+ 1 6 HVTY〇H FOvQk〇H ° . ΝγΝ CiX 535 7 Ό^〇 ΝγΝ 471 8 ΧνΦ^Η〇 Ν丫Ν 485 9 ΗΥΥΎ°Η Xx^i:。 crNH 457 10 Η°ν^γ^ν°Η FX>XkL〇 Νγ>Ν αΝΗ 470 -96- 200522950 (92) 1實施例編號 結構 MS [M+H]+ 11 ΗγγγΟΗ 484 12 Fx\^H〇 ΝγΝ cc 498 13 ;WH〇 I 542 14 ΗΟγχτΟΗ ^r-NH 484 15 H〇VYY〇H Xx^ 526 16 ΗΟγγγΟΗ Nv^N 526 17 H0Y^v/^0H FxxAiH0 συ 532
-97- 200522950 (93) 實施例編號 結構 MS [M+H]+ 18 OVV^h〇 N'vj^,N V 514 19 Η°ΤΤΥΟΗ xv^c〇 Nv^N cr 473 20 HyYV" 乂rNH 487 21 HYTY〇H fxxAoho 471 22 HYTYOH FxxXk Ns^N CHT 550 23 ΗγγγΟΗ FO^ ΝγΝ CHXNH 552 24 ΗΥΥΎ°Η OV^ Νγ>Ν 514 25 Ηγττ0Η fOiA〇H〇 <rNH h〇A 531
-98- 200522950 (94) 實施例編號 結構 MS [M+H]+ 26 HyrrH fT 470 27 ΝγΝ VN 452 28 °rrH ΝγΝ cr—NH 452 29 HYTY0H Xl/C。 472 30 HYTY0H Xi^o ΝγΝ <xN、 486 31 〇Y^Y*°H NV^N <r 454 32 H〇^rr ΝγΝ cr 467 -99- 200522950 (95) 實施例編號 結構 MS [Μ+Η]+ 33 HWOH HO^J Ο ΝγΝ cr 468 34 Η〇ΥΎνΤ〇Η Χν^〇 Υ;〇 Ν/ΝγΝ、受。 550 35 ΗΟνΤΤ Ν丫 Ν σ、 481 36 Ηςττ Νγ>Ν αΝΗ 467 37 hoV^N^oh Η^Τ Ν丫Ν αΝΗ 467 38 ΗΟν^^ΟΗ Η。^ 丫 Νγ>Ν 546 -100- 200522950 (96) 實施例編號 結構 MS [Μ+Η]+ 39 ΝγΝ χτ 501 40 ΗΥΎΎ°Η 广。Ητ: 542 41 ΗΟν^ν°Η H〇vJ ° ΝγΝ 497 42 Η〇ντ^Ύ〇Η Ο Νγ>Ν 、χχ〆 575 43 ηΥΎΎ〇η FxxA… Ν 丫Ν 、把 527 44 HCy^Y^Y°H ΧνφιΓ Νγ^Ν α^χΝΗ 567 45 Hc^r ΎΝ。 αΝ^ 545 -101 - 200522950 (97) 實施例編號 結構 MS [M+H]+_ 1 46 N 丫N cr 468 47 Hc^rr Γ^Ν σ 丫 509 48 ΗΟν^τ^ΎΟΗ Fxx^。 Ν>^Ν CC 484 49 HQv^vOH H〇vJ ° ^CC 527 50 H〇vr^V〇H 0 ΝγΝ αχ^0 605 51 Η〇γ^γ〇Η H〇vJ ° ΝγΝ CQ^ 575 52 hYtyw Χι^。 ΝγΝ σΝΗ 508 -102- 200522950 (98) 實施例編號 結構 MS [Μ+Η]+ 53 Ηςττ0Η " ΝγΝ 611 54 H〇V^Y"〇H HO^^J 0 Χ)γ^ ΝγΝ 630 55 ΗΟν^ν*ΟΗ 0 ΝγΝ cr ο 535 56 HYVYW XVpk〇H〇 ΝγΝ 485 57 ΗΟνΓ^ν»^γ-ΟΗ Χ^Η〇 V。. {X, 549 58 Η0γγγ0Η fx\irk ΝγΝ 众Ν、令。 548 59 Χν^Η〇 ΝγΝ cr*。 548 •103- 200522950 (99) 實施例編號 結構 MS [M+H]+ 60 ΝγΝ frN、 Vn 484 61 H〇vr^Y〇H 〇 ΝγΝ <JXX 598 62 H〇V^V"〇H HO^J 0 Nv^N dXY" 578 63 tTr°i- F^w ΝγΝ cc 581 64 H〇V^V〇H HO^J 0 F^M ΝγΝ dXH 520 65 Η〇ν^Ύ〇Η HOvJ ° ΝγΝ dX、 534 -104- 200522950 (100) 實施例編號 結構 MS [M+H]+ 66 Ν 丫Ν CC 467 67 '、人 Nir 541 68 471 下列化合物係採用實施例3,4及5所列方法製備 實施例編號 結構 MS [M+H]+ 69 F OH OH 0 497 70 ό。"" 485 71 F OH OH 0 483 -105- 200522950 (101) 實施例編號 結構 MS [M+H]+ 72 $ 一。 τ 561 73 +。… νΎ N=N 563 74 +… ΝΤ^Ν〆 N=^ 499 -106-
Claims (1)
- 200522950 十、申請專利範圍 1 . 一種具有下式之化合物其中X係爲N或CR5 ; R!及R2係相同或相異且個別選自Η、烷基、烷氧基 烷基、芳基烷基、環烷基、烯基、環烯基、芳基、雜芳基 或環雜烷基; R3係爲芳基、雜芳基、環烷基或環雜烷基; R4係爲Η、烷基、環烷基、鹵烷基、烷氧基烷基、烷 基硫院基、院基礦釀基、芳基礦釀基、院氧基鑛基、方氧 基羰基、雜芳氧基羰基、烷基胺基羰基、芳基胺基羰基、 烷基硫基羰基、雜芳基胺基羰基、烷基胺基磺醯基、烷基 羰基、芳基羰基、雜芳基羰基或雜芳基磺醯基; R5係爲Η或低烷基; Ζ係爲R6係爲Η或低烷基或金屬離子(諸如鹼金屬或鹼土 金屬); -107- 200522950 (2) R7係爲Η或低烷基; 且/係表示單鍵或雙鍵(可爲順式或反式) 或其醫藥上可接受之鹽(其中R6係爲H)、或其 酯、其前藥酯及其所有立體異構物。 2 ·如申請專利範圍第1項之化合物,其中X係爲 N。 3 ·如申請專利範圍第1項之化合物,其中X係爲 CR5。 4·如申請專利範圍第1項之化合物,其中Z基團爲 游離酸、其生理上可接受且可水解之酯或δ內酯、或鹼金 屬鹽、鹼土金屬鹽、胺鹽或胺基酸鹽形式。 5 ·如申請專利範圍第1項之化合物,其中 R】及R2個別選自烷基、環烷基及芳基; R3係爲芳基、雜芳基或環雜烷基; R4係爲Η、烷基、低烷基羰基、低烷基磺醯基或低烷 氧基親基。 6 ·如申請專利範圍第1項之化合物,其中R Ϊ係爲芳 基;且 R2係爲烷基或環烷基; R3係爲芳基、雜芳基或環雜烷基; h係爲Η、烷基、低烷基羰基、低烷基磺醯基、低烷 氧基鑛基; 6 /係爲雙鍵。 7 ·如申請專利範圍第]項之化合物,其中 •108- 200522950 (3) 係爲 4 —氟笨基、4 —氟一 3 —甲基苯基或 3,5 — 二甲基苯基; R2係爲異丙基、第三丁基或環丙基; R3係爲芳基’其係爲苯基;環雜烷基,其係爲四氫 嚷吩一氧化物;雜芳基,其係爲吡唑、噻二唑、嘧啶、吡 哄、本并咪唑、三卩坐、四唑、吡啶基、噻唑、鳄唑或異口琴 口坐;其各可視情況經1、2或3個取代基所取代,該取代 基可相同或相異且可爲環雜烷基、雜芳基、烷基、鹵素、 竣基、院氧基羰基烷基胺基羰基或烷氧基; R4係爲Η、甲基、甲基羰基、甲氧基羰基或甲磺醯 基; /係爲反式雙鍵;且 Ζ係爲或其鹼金屬或鹼土金屬鹽或其胺基酸鹽或其胺鹽。 8 ·如申請專利範圍第7項之化合物,其中X係爲Ν 或 CR5。 9.如申請專利範圍第1項之化合物,其具有式1或其鹼金屬或鹼土金屬鹽、或胺基酸鹽或胺鹽’其中Rs -109- 200522950 (4) 及R9係相同或相異,且個別選自Η、鹵素及/或烷基; 且 R 2係爲院基或環院基; R3係爲芳基、雜芳基或環雜烷基; R4係爲H'C】—C4烷基、C】—C4烷基羰基、C!— C4 垸氧基鑛基或Ci - C4院基擴釀基。 10.如申請專利範圍第9項之化合物,其中 R8及R9係相同或相異且個別選自4 一氟、4 —氟一 3 —甲基或3,5 —二甲基; R2係爲異丙基、第三丁基或環丙基; Rs係爲下列基團中之一: -110-200522950 (6)R4係爲H、甲基、甲基羰基、甲氧基羰基或甲磺醯 基。200522950 (7) F其中R6係爲H、烷基或鹼金屬鹽。 12.如申請專利範圍第1 1項之化合物,其中R6係爲 甲基胺、銨、二環己基胺、第三丁基、Na或Ca。 1 3 . —種具有以下結構之化合物 Qέ〇2院基 院氧基院 雜芳基或 其中R!及R2係相同或相異,且個別選自烷基 基、芳基烷基、環烷基、烯基、環烯基、芳基 環雜烷基;且 Q 係爲 HOCH2—,Y -113- 200522950 (8) B.其中R!及R2係如前定義,且 R3係爲芳基、雜芳基、環烷基或雜環烷基; R4係爲Η、烷基、環烷基、鹵烷基、烷氧基烷基、烷 基硫烷基、烷基磺醯基、芳基磺醯基、烷氧羰基、芳氧羰 基、雜芳氧羰基、烷基胺基羰基、芳基胺基羰基、雜芳基 胺基羰基、烷基胺基磺醯基、醯基、芳基羰基、雜芳基羰 基或雜芳基磺醯基;且 Q!係爲 HOCH2—,其中R!及R2係如前定義; R5係爲H、低烷基或—COOH、COO烷基、—CH2OH 或烷基〇 ; Q2 係爲 H2N —、F、R3HN —或 R3R4N —, -114- 200522950其中R】、112及R5係如前定義,且q3係爲r3HN-, R 3 R 4 N —或(其中P G係爲保護基), 且Q4係爲一 coo烷基、14· 一種用於抑制HMG CoA還原酶之醫藥組成物, 其包含如申請專利範圍第1項化合物及其醫藥上可接受之 載體。 1 5 . —種醫藥組合物,其包含如申請專利範圍第丨項 化合物以作爲HMG CoA還原酶抑制劑及一或多種降血脂 劑或脂質降低劑或脂質藥劑或脂質調節劑及/或一或多種 療劑用,包括抗糖尿病劑、抗肥胖劑、抗高血壓劑、血小 板凝集抑制劑、抗癡呆劑、抗阿茲海默氏症劑、抗骨質疏 鬆劑、及/或激素替補療劑、及/或其他心血管藥劑、抗 心絞痛劑、抗心律不整劑、抗動脈硬化劑、抗發炎劑、抗 關節炎劑、抗血小板劑、抗心臟衰竭劑、抗癌劑、抗感染 劑、激素替補劑、生長激素促分泌劑、選擇性雄激素受體 調節劑及/或免疫調節劑。 1 6 ·如申請專利範圍第〗5項之醫藥組合物,其中所 -115- 200522950 (10) 採用之降血脂劑或脂質降低劑或其他脂質藥劑或脂質調節 劑或抗動脈硬化劑係包括1,2,3 -或更多MTP抑制 劑、角鯊烯合成酶抑制劑、纖維酸衍生物、p p A R α促效 劑、PPAR雙重a / r促效劑、PPAR 5促效劑、ACAT抑 制劑、脂肪氧化酶抑制劑、膽固醇吸收抑制劑、迴腸N a + /膽汁酸協同轉運子抑制劑、LD L受體活性之調高劑、膽 固醇酯轉移蛋白抑制劑、膽汁酸隔離劑或菸酸及其衍生 物、ATP檸檬酸酯裂解酶抑制劑、植物雌激素化合物、 HDL調高劑、LDL分解代謝促進劑、抗氧化劑、PLA - 2 抑制劑、抗高半胱胺酸劑、HMG - CoA合成酶抑制劑、羊 毛甾醇脫甲基酶抑制劑或固醇調節元素鍵結蛋白一 I藥 劑。 17.如申請專利範圍第1 5項之醫藥組合物,其包含 該HMG CoA還原酶抑制劑及抗糖尿病劑,其包含‘ 1、2、 3或多種抗糖尿病劑或拉高血糖劑,其係爲胰島素促分泌 劑或胰島素敏化劑,選自雙胍、磺醯脲、PTP - 1 B抑制 劑、醛糖還原酶抑制劑、葡糖苷酶抑制劑、PPAR 7促效 劑、PPAR α促效劑、PPAR (5拮抗劑或促效劑、aP2抑制 劑、PPAR a / r雙重促效劑、二肽基肽酶IV ( DP4 )抑 制劑、SGLT2抑制劑、糖原磷酸化酶抑制劑及/或美葛提 尼(m e g 1 i t i n i d e )、胰島素、緩釋型胰島素—B a s u 1 i n ™ 及/或類高血糖素胜肽—1 ( GLP — 1 )或其模擬物。 1 8 .如申請專利範圍第1 7項之醫藥組合物,其中該 抗糖尿病劑係爲1、2、3或多種美弗明(m e t f 〇 r m i η )、 -116- 200522950 (11) 優降糖(g 1 y b u ι· i d e )、葛來米比瑞(g 1 i m e p i r i d e )、葛來 比瑞(glipizide)、克洛普買(chlorpropamide)、葛來 克瑞(gliclazide)、阿卡伯司(acarbose)、米葛里托 (m i g 1 i t ο 1 )、比葛塔宗(p i o g 1 i t a z ο n e )、托葛塔宗 (troglitazone)、若西塔宗(rosiglitazone)、胰島素、 G1— 262570、伊沙葛塔宗(isaglitazone) 、JTT — 501、 NN— 23 44、L8 95 64 5、YM — 440、R— 1 1 9702、AJ967 7、 瑞帕葛尼(repaglinide)、耐特葛尼(nateglinide)、 KAD 1 229、AR — H03 9242、GW- 40 9544、KRP297、 AC2993、LY315902、P32/98、NVP — DPP — 728A、NVP —LAF — 237、慕瑞塔扎(muraglitazar) 、BMS 477,188 及 / 或 BMS 5 3 8,3 0 5。 1 9 ·如申請專利範圍第1 5項醫藥組合物,其中可視 情況採用之其他類型療劑係爲1、2、3或多種抗肥胖劑, 其係爲yS 3腎上腺素能促效劑、脂酶抑制劑、血淸素(及 多巴胺)攝取抑制劑、aP2抑制劑、甲狀腺受體/3藥物、 食慾抑制劑、PTP - 1 B抑制劑、CCKA促效劑、神經肽Y 拮抗劑、褪黑激素- 4 一受體促效劑、P P A R調節劑一其係 爲 PPAR 7拮抗劑、PPAR α促效劑及/或 ppAR 5拮抗 劑、纖體素(leptin )抑制劑諸如纖體素受體活化劑、脂 肪酸氧化調高劑或誘發劑、5 - HT2c促效劑或ACC抑制 劑。 2 0.如申請專利範圍第1 5項醫藥組合物,其中抗肥 胖劑係爲歐里司特(or listat) 、ATL — 962、AJ9677、 -117- 200522950 (12) L 7 5 0 3 5 5、CP 3 3 1 64 8、西布托胺(sibutramine )、托比瑞 買(topiramate) 、axokine、得沙吩塔胺( dexamphetamine)、吩特胺(ph enter mine)、苯基丙醇胺 及/或氯苯咪卩引卩朵(mazindol) ,P57或 CP — 644673 (Pfizer):脂質調節劑係爲MTP抑制劑、角鯊烯合成酶 抑制劑、纖維酸衍生物、LDL受體活性之調高劑、脂肪氧 化酶抑制劑、或AC AT抑制劑,而其他脂質藥劑係爲膽固 醇酯轉移蛋白抑制劑;所用之抗高血壓劑係爲ACE抑制 劑、血管收縮素II受體拮抗劑、NEP抑制劑、NEP/ ACE 抑制劑、鈣通道阻斷劑、T -通道鈣拮抗劑、Θ -腎上腺 素阻斷劑、利尿劑、α —腎上腺素阻斷劑、雙重作用受體 掊抗劑(DARA )或心臟衰竭藥物,其中抗高血壓藥劑係 爲 ACE抑制劑,其係爲卡托比(captopril )、弗辛諾比 (fosinopril)、因那列比(enalapril)、里辛諾比( lisinopril)、奎那比(quinapril)、本那扎比( benazepril )、吩提 J:匕(fentiapril) 、 米比(ramipril) 或莫西比(moexipril ); NEP/ ACE抑制劑,其係爲歐馬帕垂列(omapatrilat )、吉莫帕垂歹lj ( gemopatrilat)或 CGS 30440 ; 血管收縮素II受體拮抗劑,其係爲爾貝沙滇( i i_ b e s a r t a η )、洛沙滇(1 〇 s a r t a η )或唯沙滇( val s artan );比西酸阿洛氏平(amlodipine besylate)、 普瑞若辛(p r a z o s i n ) H C 1、唯瑞帕米(v e r a p a m i 1 )、尼 非氐平(nifedipine )、那朵洛(nadolol )、普瑞諾洛( -118· 200522950 (13) propranolol )或可樂定(ci〇nicnne ) HC卜卡唯氐洛( carvedilol)、阿滇諾洛(aten〇i〇i)、氫氯噻卩井( hydrochloiothiazide)、托瑞西買(torasemide)、弗若西 貝(f u r 〇 s e m i d e )、螺內酯或節擴苯醯胺(丨n d a p a m丨d e ) ;且 脂質S周自卩劑係爲吩諾纖維酸酯(f e n 〇 f i b r a t e )、吉非 布札(gemfibrozil )、克洛纖維酯(c 1 〇 f i b r a t e )、阿唯 西買(avasimide) 、TS — 962、MD— 700、查利士膠( cholestagel)、托西推比(torcetrapib) 、JTT— 705、菸 酸、LY295427、暴瑞塔扎(muraglitazar)及/或伊吉提 買(ezetimibe ) 。 2 1 ·如申請專利範圍第1 5項醫藥組合物,其中該 HMG CoA還原酶抑制劑係與血小板凝集抑制劑結合。 22·如申請專利範圍第21項醫藥組合物,其中該血 小板凝集抑制劑係爲阿斯匹靈、克洛比朵吉( clopidogrel)、提克洛比定(ticlopidine)、二卩比卩定達摩 (dipydidamole)、伊弗托本(ifetroban)、阿西色買( abciximab)、提若弗本 (tirofiban)、伊提弗本特 (eptifibatide )、阿那吉來(anagrelide) 、CS — 747、美 列扎托(m e 1 a g a t r a η )、西美列扎托(X i m e 1 a g a t r a η )、瑞 扎沙賓(r a z a x a b a η )或克洛比朵吉(c 1 o p i d o g r e 1 )與阿斯 匹靈之組合物。 23 .如申請專利範圍第1 5項醫藥組合物,其中其他 療劑係爲抗阿茲海默氏症劑或抗癡呆劑,其係爲9 -胺基 -119- 200522950 (14) 四氫吖啶(tacrine) HC1( Cognex ®)及朵尼比吉( d ο n e p e z i 1 ) ( A ι· i c e p t ® ) 、7 —分泌酶抑制劑、一分 泌酶抑制劑及/或抗高血壓劑; 抗骨質疏鬆劑,其係爲副甲狀腺激素或雙膦酸酯·、阿 列朵耐(alendronate )、Ca受體促效劑或黃體素受體促 效劑; 激素替補療劑,其係爲選擇性雌激素受體調節劑 (SERM ); 酪胺酸激酶抑制劑; 選擇性雄激素受體調節劑; 抗心律不整劑,其係爲Θ -阻斷劑或爲鈣通道阻斷劑 或α —腎上腺素阻斷劑; 輔酶 Q s u b . 1 0 ; 調高第III型內皮細胞硝酸合成酶的藥劑; 軟骨保護性化合物,其係爲多硫酸化胺基多糖 (PSGAG )、葡萄糖胺、軟骨素硫酸酯(cs )、透明質 酸(HA )、戊聚糖多硫酸酯(PPS )、朵西塞克林 (doxycycline)或米諾塞克林(minocycline); 環氧合酶(COX ) - 2抑制劑,其係爲 Celebrex® (Searle)或 Vixx ® (Merck)或糖蛋白 Ila/IIIb 受體 拮抗劑; 5 - Η T攝取抑制劑; 生長激素促分泌劑; 抗動脈硬化劑; -120- 200522950 (15) 抗感染劑或使用於移植之免疫抑制劑或 2 4· —種醫藥組成物,用於治療血中膽 脂異常、血脂過高、血脂蛋白過高、B S LDL、血中三酸甘油酯過高或動脈硬化,或 或骨質疏鬆症,抑制膽固醇生物合成或降低 度及/或調節血淸膽固醇濃度,降低LDL 增加HDL膽固醇,及/或降低三酸甘油酯 異常、混合型血脂異常、B型LDL、A型 高、血中膽固醇過高、血中α —脂蛋白過低 過高或血中三酸甘油酯過高,及載脂蛋白Β 常’或降低La ( a )之濃度,或治療或預防 有關之疾病,或治療或預防或逆轉動脈硬化 防或治療阿茲海默氏症,或預防或治療骨質 骨質減少,或降低發炎標誌諸如C -反應性 或治療低階血管發炎,或預防或治療中風, 癡呆,或預防及治療冠狀心臟病及心肌梗塞 預防,或預防或治療穩定及不穩定心絞痛, 期預防,或心血管疾病之二期預防,或預防 管疾病,預防或治療末稍動脈疾病,或預防 管徵候群,或預防或降低進行心肌血管重建 或預防或治療微血管疾病諸如腎病變、神經 病變及腎病徵候群或預防或治療高血壓’預 病,尤其是第2型糖尿病及相關疾病’胰島 糖過高、血中胰島素過局、血中脂肪酸或甘 抗贅瘤劑。 固醇過局、血 ί LDL ^ A 型 阿茲海默氏症 血淸膽固醇濃 膽固_及/或 ,或治療血脂 LDL、血月旨過 、血中脂蛋白 代謝之其他異 其他與膽固醇 之發展,或預 疏鬆症及/或 蛋白,或預防 或預防或治療 之初期及二期 或冠心病之初 或治療末稍血 或治療急性血 過程的風險, 病變、視網膜 防或治療糖尿 素抵抗性、血 油丨辰度阔、肥 -121 - 200522950 (16) 胖、B型LDL、A型LDL、X徵候群、糖尿病倂發症、代 謝異常徵候群及相關疾病及性功能障礙’預防及治療癌瘤 損傷、癌前期損傷、腸胃惡性腫瘤、脂肉瘤及上皮腫瘤、 由癌誘發之虛弱(疲勞)、應激性大腸徵候群、克隆氏症 (Crohn’s disease)、胃潰瘍及膽結石、及HIV感染、藥 物誘發之脂肪營養不良及增殖性疾病,用以改善凝血穩 態、降低PAI — 1活性、減少纖維蛋白原及/或減少血小 板凝集,及或改善內皮功能,其包含治療有效量之如申請 專利範圍第1項之化合物。 25. 一種醫藥組成物,其用於治療與膽固醇相關之疾 病、糖尿病及相關疾病、心血管疾病、腦血管疾病,其包 含治療有效量之如申請專利範圍第1項之化合物與降血脂 劑及/或脂質調節劑及/或抗糖尿病劑及/或心血管藥 劑、腦血管藥劑及/或其他類型療劑的組合物。 -122- 200522950 七 明 說 單 簡 號 符 表 為代 圖件 表元 代之 定圖 指表 :案代 圖本本 定一二 指c C 無 無 八、本案若有化學式時,請揭示最能顯示發明特徵的化學 式: Z-5-
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50589303P | 2003-09-25 | 2003-09-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200522950A true TW200522950A (en) | 2005-07-16 |
Family
ID=34393081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW093128908A TW200522950A (en) | 2003-09-25 | 2004-09-23 | Hmg-Coa reductase inhibitors and method |
Country Status (6)
Country | Link |
---|---|
US (1) | US7371759B2 (zh) |
EP (1) | EP1667997A1 (zh) |
AR (1) | AR045828A1 (zh) |
PE (1) | PE20050958A1 (zh) |
TW (1) | TW200522950A (zh) |
WO (1) | WO2005030758A1 (zh) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0306615D0 (en) * | 2003-03-22 | 2003-04-30 | Astrazeneca Ab | New use |
FR2861303A1 (fr) * | 2003-10-24 | 2005-04-29 | Sanofi Synthelabo | Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique |
GB0406757D0 (en) | 2004-03-26 | 2004-04-28 | Avecia Ltd | Process and compounds |
US20060058283A1 (en) * | 2004-09-15 | 2006-03-16 | Zymes, Inc. | Compositions comprising ubiquinones |
GB0427491D0 (en) | 2004-12-16 | 2005-01-19 | Avecia Ltd | Process and compounds |
US7553861B2 (en) * | 2005-04-22 | 2009-06-30 | Alantos Pharmaceuticals Holding, Inc. | Dipeptidyl peptidase-IV inhibitors |
GB0524427D0 (en) * | 2005-11-30 | 2006-01-11 | 7Tm Pharma As | Use of receptor ligands in threapy |
EP1968941A1 (en) * | 2005-12-29 | 2008-09-17 | Novartis AG | Pyridinyl amine derivatives as inhibitors of cholesteryl ester transfer protein (cetp) |
CA2650954C (en) | 2006-05-10 | 2014-02-11 | Novartis Ag | Bicyclic derivatives as cetp inhibitors |
US20090181929A1 (en) * | 2006-05-11 | 2009-07-16 | Kazuhide Konishi | Organic compounds |
US20080033019A1 (en) * | 2006-08-07 | 2008-02-07 | Duke University | Cholesterol lowering drug combination |
KR20090080523A (ko) * | 2006-11-15 | 2009-07-24 | 노파르티스 아게 | Cετρ 억제제로서의 헤테로시클릭 유도체 |
US20070172525A1 (en) * | 2007-03-15 | 2007-07-26 | Ramesh Sesha | Anti-diabetic combinations |
US20080064701A1 (en) * | 2007-04-24 | 2008-03-13 | Ramesh Sesha | Anti-diabetic combinations |
US8551524B2 (en) * | 2008-03-14 | 2013-10-08 | Iycus, Llc | Anti-diabetic combinations |
WO2010066593A1 (en) * | 2008-12-08 | 2010-06-17 | F. Hoffmann-La Roche Ag | Combined drug administration |
DE112010001898T5 (de) | 2009-04-27 | 2012-08-02 | Dow Agrosciences Llc | Insektizide Pyridinverbindungen |
KR101157314B1 (ko) * | 2009-06-05 | 2012-06-15 | 주식회사종근당 | 로수바스타틴의 신규한 제조방법, 이 제조에 유용한 중간체 화합물 및 그의 제조방법 |
CN102219780B (zh) * | 2010-04-14 | 2014-08-06 | 上海京新生物医药有限公司 | 制备(3r,5s,e)-7-(2-(n-甲基甲磺酰胺基)-4-(4-氟苯基)-6-异丙基-嘧啶-5-基)-2,2-二甲基-3,5-二氧六环-6-庚烯酸酯的方法 |
CZ305457B6 (cs) | 2011-02-28 | 2015-09-30 | Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. | Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití |
CN102816152B (zh) * | 2011-06-09 | 2015-09-09 | 上海京新生物医药有限公司 | 一种瑞苏伐他汀中间体的制备方法 |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
WO2016065584A1 (en) | 2014-10-30 | 2016-05-06 | Merck Sharp & Dohme Corp. | Piperidine oxadiazole and thiadiazole orexin receptor antagonists |
MD3472153T2 (ro) | 2016-06-16 | 2022-03-31 | Denali Therapeutics Inc | Pirimidin-2-ilamino-1H-pirazoli în calitate de inhibitori L RRK2 pentru utilizare în tratamentul tulburărilor neurodegenerative |
CN111454216B (zh) * | 2019-10-21 | 2021-06-29 | 山东理工职业学院 | HMG-CoA还原酶抑制剂及其中间体的制备方法 |
CN112679490A (zh) * | 2021-01-28 | 2021-04-20 | 安徽美诺华药物化学有限公司 | 瑞舒伐他汀钙含砜结构的手性侧链及其制备方法与用途 |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3674836A (en) * | 1968-05-21 | 1972-07-04 | Parke Davis & Co | 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof |
US4027009A (en) * | 1973-06-11 | 1977-05-31 | Merck & Co., Inc. | Compositions and methods for depressing blood serum cholesterol |
US4046889A (en) * | 1976-02-13 | 1977-09-06 | E. R. Squibb & Sons, Inc. | Azetidine-2-carboxylic acid derivatives |
NO154918C (no) * | 1977-08-27 | 1987-01-14 | Bayer Ag | Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin. |
US4316906A (en) * | 1978-08-11 | 1982-02-23 | E. R. Squibb & Sons, Inc. | Mercaptoacyl derivatives of substituted prolines |
US4168267A (en) * | 1978-10-23 | 1979-09-18 | E. R. Squibb & Sons, Inc. | Phosphinylalkanoyl prolines |
IL58849A (en) * | 1978-12-11 | 1983-03-31 | Merck & Co Inc | Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them |
DE2951135A1 (de) * | 1979-12-19 | 1981-06-25 | Hoechst Ag, 6230 Frankfurt | Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
US4337201A (en) * | 1980-12-04 | 1982-06-29 | E. R. Squibb & Sons, Inc. | Phosphinylalkanoyl substituted prolines |
US4405552A (en) * | 1981-03-03 | 1983-09-20 | Eli Lilly And Company | 1-Benzoyl-3-(arylphyridyl)urea compounds |
US4432971A (en) * | 1981-08-03 | 1984-02-21 | E. R. Squibb & Sons, Inc. | Phosphonamidate compounds |
US4452790A (en) * | 1982-06-23 | 1984-06-05 | E. R. Squibb & Sons, Inc. | Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives |
JPS6051189A (ja) * | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | チアゾリジン誘導体およびその製造法 |
US4722810A (en) * | 1984-08-16 | 1988-02-02 | E. R. Squibb & Sons, Inc. | Enkephalinase inhibitors |
DE3543999A1 (de) * | 1985-12-13 | 1987-06-19 | Bayer Ag | Hochreine acarbose |
US5614492A (en) * | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
US4749688A (en) * | 1986-06-20 | 1988-06-07 | Schering Corporation | Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension |
US4759923A (en) * | 1987-06-25 | 1988-07-26 | Hercules Incorporated | Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives |
US4871721A (en) * | 1988-01-11 | 1989-10-03 | E. R. Squibb & Sons, Inc. | Phosphorus-containing squalene synthetase inhibitors |
US4924024A (en) * | 1988-01-11 | 1990-05-08 | E. R. Squibb & Sons, Inc. | Phosphorus-containing squalene synthetase inhibitors, new intermediates and method |
AU3214689A (en) | 1988-10-06 | 1990-05-01 | Sandoz Ag | Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them |
US5100889A (en) * | 1989-04-03 | 1992-03-31 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease |
US4933165A (en) * | 1989-01-18 | 1990-06-12 | Merck & Co., Inc. | Coenzyme Q10 with HMG-CoA reductase inhibitors |
US4929437A (en) * | 1989-02-02 | 1990-05-29 | Merck & Co., Inc. | Coenzyme Q10 with HMG-CoA reductase inhibitors |
DE3929507A1 (de) | 1989-09-06 | 1991-03-07 | Bayer Ag | Substituierte amino-pyridine |
US5316765A (en) * | 1989-09-07 | 1994-05-31 | Karl Folkers Foundation For Biomedical And Clinical Research | Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies |
US5223516A (en) * | 1990-03-22 | 1993-06-29 | E. R. Squibb & Sons, Inc. | 3,3,3-trifluoro-2-mercaptomethyl-N-tetrazolyl substituted propanamides and method of using same |
DE4022414A1 (de) | 1990-07-13 | 1992-01-16 | Bayer Ag | Substituierte pyrrolo-pyridine |
DE4023308A1 (de) | 1990-07-21 | 1992-01-23 | Bayer Ag | Substituierte pyrido-oxazine |
CA2053340C (en) | 1990-10-18 | 2002-04-02 | Timothy P. Burkholder | Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace |
JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
US5225401A (en) * | 1991-08-12 | 1993-07-06 | E. R. Squibb & Sons, Inc. | Treatment of congestive heart failure |
CA2078758C (en) | 1991-09-27 | 2003-12-09 | Alan M. Warshawsky | 2-substituted indane-2-mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace |
AU657793B2 (en) | 1991-09-27 | 1995-03-23 | Merrell Pharmaceuticals Inc. | Novel 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE |
US5595872A (en) * | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
DK36392D0 (da) * | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
US5447954A (en) * | 1992-05-05 | 1995-09-05 | Smithkline Beecham P.L.C. | Phenylderivate as inhibitors of ATP citrate lyase |
US5552397A (en) * | 1992-05-18 | 1996-09-03 | E. R. Squibb & Sons, Inc. | Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase |
CA2133963C (en) * | 1992-05-15 | 1998-07-07 | Gary A. Flynn | Novel mercaptoacetylamido pyridazo[1,2]pyridazine, pyrazolo[1,2]pyridazine, pyridazo[1,2-a][1,2]diazepine and pyrazolo[1,2-a][1,2]diazepine derivatives useful as inhibitors of enkephalinase and ace |
RU2124503C1 (ru) | 1992-05-18 | 1999-01-10 | И.Р.Сквибб энд Санз, Инк. | Гетероциклические азотсодержащие производные карбоновой кислоты, способ их получения и фармацевтическая композиция |
US5504080A (en) * | 1992-10-28 | 1996-04-02 | Bristol-Myers Squibb Co. | Benzo-fused lactams |
US5712396A (en) * | 1992-10-28 | 1998-01-27 | Magnin; David R. | α-phosphonosulfonate squalene synthetase inhibitors |
HU225294B1 (en) | 1992-12-23 | 2006-09-28 | Bristol Myers Squibb Co | Oxazoline derivatives for synthesis of sidechain-bearing taxanes and preparation thereof |
LT3300B (en) | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
US5646176A (en) * | 1992-12-24 | 1997-07-08 | Bristol-Myers Squibb Company | Phosphonooxymethyl ethers of taxane derivatives |
US5594016A (en) * | 1992-12-28 | 1997-01-14 | Mitsubishi Chemical Corporation | Naphthalene derivatives |
US5662934A (en) | 1993-01-05 | 1997-09-02 | Najarian; Thomas | Compositions and methods for lowering cholesterol while maintaining antioxidant levels |
US5346701A (en) * | 1993-02-22 | 1994-09-13 | Theratech, Inc. | Transmucosal delivery of macromolecular drugs |
JP3197971B2 (ja) | 1993-03-01 | 2001-08-13 | 塩野義製薬株式会社 | 5−カルボアルコキシピリミジン誘導体の合成方法 |
US5508272A (en) | 1993-06-15 | 1996-04-16 | Bristol-Myers Squibb Company | Compounds containing a fused bicycle ring and processes therefor |
US5362727A (en) * | 1993-07-26 | 1994-11-08 | Bristol-Myers Squibb | Substituted azepino[2,1-a]isoquinoline compounds |
US5739135A (en) * | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
US5525723A (en) * | 1993-11-18 | 1996-06-11 | Bristol-Myers Squibb Co. | Compounds containing a fused multiple ring lactam |
US5776983A (en) * | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
US5488064A (en) * | 1994-05-02 | 1996-01-30 | Bristol-Myers Squibb Company | Benzo 1,3 dioxole derivatives |
US5612359A (en) * | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
US5491134A (en) * | 1994-09-16 | 1996-02-13 | Bristol-Myers Squibb Company | Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives |
US5541204A (en) * | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine β 3 adrenergic agonists |
US5620997A (en) | 1995-05-31 | 1997-04-15 | Warner-Lambert Company | Isothiazolones |
US5698527A (en) * | 1995-08-08 | 1997-12-16 | Merck & Co., Inc. | Steroidal glycosides as antihyperlipidemic agents |
AU6966696A (en) | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
WO1997021993A2 (en) | 1995-12-13 | 1997-06-19 | The Regents Of The University Of California | Nuclear receptor ligands and ligand binding domains |
IL117702A0 (en) | 1996-03-28 | 1996-07-23 | Tel Aviv Medical Center Resear | Drug for hyperlipoproteinemia |
US5770615A (en) * | 1996-04-04 | 1998-06-23 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
US5962440A (en) * | 1996-05-09 | 1999-10-05 | Bristol-Myers Squibb Company | Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method |
US5827875A (en) * | 1996-05-10 | 1998-10-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
US5885983A (en) * | 1996-05-10 | 1999-03-23 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
DE19622222A1 (de) | 1996-06-03 | 1997-12-04 | Hoechst Ag | Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikament zur Normalisierung der Serumlipide |
US6537987B1 (en) | 1996-06-20 | 2003-03-25 | Pfizer Inc. | 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors |
HRP970330B1 (en) | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
US5760246A (en) * | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
GB9713739D0 (en) | 1997-06-27 | 1997-09-03 | Karobio Ab | Thyroid receptor ligands |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
NZ503794A (en) | 1997-10-08 | 2002-09-27 | Sankyo Co | Benzimidazole and imidazopyridine derived heterocyclic compounds, pharmaceutical compositions and uses thereof |
EP2433623A1 (en) | 1998-02-02 | 2012-03-28 | Trustees Of Tufts College | Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism |
WO1999044609A1 (en) | 1998-03-03 | 1999-09-10 | Merck & Co., Inc. | FUSED PIPERIDINE SUBSTITUTED ARYLSULFONAMIDES AS β3-AGONISTS |
JP2002506075A (ja) | 1998-03-09 | 2002-02-26 | フォンダテッヒ・ベネルクス・ナムローゼ・フェンノートシャップ | セリンペプチダーゼ調節剤 |
WO1999045913A1 (en) | 1998-03-13 | 1999-09-16 | Merck & Co., Inc. | Combination therapy and composition for acute coronary ischemic syndrome and related conditions |
DE69904318D1 (de) | 1998-05-12 | 2003-01-16 | Wyeth Corp | Zur behandlung von insulin-resistenz und hyperglycemie geeignete biphenyl-oxo-essigsäuren |
CA2330555A1 (en) | 1998-05-12 | 1999-11-18 | Jay Edward Wrobel | Naphtho[2,3-b]heteroar-4-yl derivatives |
JP2002514638A (ja) | 1998-05-12 | 2002-05-21 | アメリカン・ホーム・プロダクツ・コーポレイション | インスリン抵抗性および高血糖症の治療に有用な11−アリール−ベンゾ[b]ナフト[2,3−d]フラン類および11−アリール−ベンゾ[b]ナフト[2,3−d]チオフェン類 |
US6506785B2 (en) | 1998-05-22 | 2003-01-14 | Pfizer, Inc. | Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in mammals using carprofen and derivatives |
DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
US6147089A (en) | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US6525203B1 (en) * | 1999-03-12 | 2003-02-25 | Bristol-Myers Squibb Company | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
US6548529B1 (en) * | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
US6218408B1 (en) * | 1999-06-30 | 2001-04-17 | Synaptic Pharmaceutical Corporation | Selective NPY (Y5) antagonists (bicyclics) |
US6515117B2 (en) * | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
PH12000002657B1 (en) * | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
US6750246B1 (en) * | 2000-02-03 | 2004-06-15 | Bristol-Myers Squibb Company | C-4 carbonate taxanes |
BR0108134A (pt) * | 2000-02-17 | 2003-09-30 | Bristol Myers Squibb Co | Ligantes derivados de anilina para o receptor tiróide |
US6395767B2 (en) * | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
DE60115227T2 (de) * | 2000-05-11 | 2006-08-24 | Bristol-Myers Squibb Co. | Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga |
US6573287B2 (en) * | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
-
2004
- 2004-09-21 US US10/946,055 patent/US7371759B2/en active Active
- 2004-09-22 WO PCT/US2004/031212 patent/WO2005030758A1/en active Application Filing
- 2004-09-22 EP EP04784885A patent/EP1667997A1/en not_active Withdrawn
- 2004-09-23 TW TW093128908A patent/TW200522950A/zh unknown
- 2004-09-24 AR ARP040103478A patent/AR045828A1/es unknown
- 2004-09-27 PE PE2004000935A patent/PE20050958A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AR045828A1 (es) | 2005-11-16 |
EP1667997A1 (en) | 2006-06-14 |
US7371759B2 (en) | 2008-05-13 |
PE20050958A1 (es) | 2005-11-17 |
WO2005030758A1 (en) | 2005-04-07 |
US20050085497A1 (en) | 2005-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200522950A (en) | Hmg-Coa reductase inhibitors and method | |
US7659281B2 (en) | HMG-CoA reductase inhibitors | |
US6620821B2 (en) | HMG-CoA reductase inhibitors and method | |
US6627636B2 (en) | HMG-CoA reductase inhibitors and method | |
US6670380B2 (en) | Pyridone inhibitors of fatty acid binding protein and method | |
US7420059B2 (en) | HMG-CoA reductase inhibitors and method | |
TWI810198B (zh) | Nlrp3發炎體之選擇性抑制劑 | |
US20020028826A1 (en) | HMG-CoA reductase inhibitors and method | |
US20020013334A1 (en) | HMG-CoA reductase inhibitors and method | |
KR20080019276A (ko) | 11-베타 히드록시스테로이드 데히드로게나제 ⅰ형의억제제로서의 이미다조- 및 트리아졸로피리딘 | |
KR20080026544A (ko) | 디펩티딜 펩티다아제 ⅳ의 피롤로피리딘계 억제제 및 방법 | |
CA2373999C (en) | Pyrazinone thrombin inhibitors | |
US6812345B2 (en) | HMG-CoA reductase inhibitors and method | |
US7226942B2 (en) | 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors | |
US7223786B2 (en) | 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors |